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 Phagocytosis by macrophages and neutrophils is an essential innate immune 
mechanism that involves temporal and spatial rearrangements of the actin cytoskeleton. 
The actin cytoskeleton is under the control of numerous actin regulators that modulate its 
polymerization kinetics. YopO, a serine/threonine kinase from the pathogenic bacterium 
Yersinia, disables the actin cytoskeletal machinery, impairing phagocytosis. YopO uses 
actin as a scaffold to recruit and phosphorylate various actin regulators. Substrates of 
YopO include gelsolin, mDia1, VASP, EVL and WASP, an array of proteins that 
regulate actin assembly and disassembly. However, the effects of phosphorylation by 
YopO on the function of these actin cytoskeleton regulators remain unknown. 
 In this work, phosphorylation sites on the substrates gelsolin, mDia1, VASP, EVL 
and WASP by YopO were identified via a proteomics approach, with in vitro mutational 
validation of the phosphorylation sites performed for gelsolin. Biochemical assays were 
designed and performed on each substrate to understand the effect of phosphorylation on 
actin dynamics. Gelsolin phosphorylated by YopO was shown to exhibit increased 
depolymerizing activity on actin filaments. Reduced nucleation activity was observed for 
phosphorylated mDia1. Phosphorylation of VASP/EVL by YopO appears to affect the 
actin polymerization machinery by a mechanism other than affecting its affinity for F-
actin. For the substrate WASP, phosphorylation by YopO does not effect direct activation 
of Arp2/3 but may affect its self-activation mechanism leading to misregulated Arp2/3 
nucleation activity. These findings lead to the conclusion that the net filamentous actin 
population is affected by phosphorylation of these substrates. Finally, a model was 
proposed which suggests that the phosphorylated actin regulators disable phagocytosis of 
the host macrophages via reduction of F-actin-rich filopodial protrusions and other actin 
derived structures. Thus, YopO utilizes its kinase activity as a means to help resist 
phagocytosis via disruption of the native cytoskeleton arrangements of the host.  The 
structure of YopO in complex with actin and active site co-factors, ADP and Mg
2+
, was 
elucidated. YopO binds actin at its pointed end, making contacts with subdomains 2 and 
4. In the catalytic cleft of the kinase domain, the strictly conserved catalytic residue 
Asp286 from the DFG motif co-ordinates the Mg
2+
 ion. Asp267 acts as a proton acceptor 
xiv 
 
and Lys269 helps in stabilizing of the transition state. The structure confirms that the 
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IQGAP1    Ras GTPase-activating-like protein 1 
LPA   Lysophosphatidic acid  
MAP   mitogen-activated protein 
MAPK    mitogen-activated protein kinase 
mDia1    mouse diaphanous 1 
Mena   Protein enabled homolog 
MSK   mitogen- and stress-activated protein kinase 
MST3    Mammalian STE20-like protein kinase 3 also known as 
   Serine/threonine-protein kinase 24 
Nck    NCK adaptor protein 1 
NPF    nucleation promoting factor 
NWASP    neural Wiskott Aldrich syndrome protein 
PAK    p21-activated kinase 
PDB    Protein Data Bank 
PEG    polyethylene glycol 
PIP2    phosphatidylinositol-4,5-bisphosphate 
PKA    cAMP-dependent protein kinase 
PKC    protein kinase C 
PKD1    protein kinase D1 
PKG    cGMP-dependent protein kinase 
P-loop    Loop within protein kinases that is involved in binding 
   phosphates of ATP 
PWA    proline-rich and VCA domains 
PYK2    proline-rich tyrosine kinase 2 
pYV   virulence plasmid 
SER    surface entropy reduction 
SH3    SRC Homology 3 Domain 
SILAC    stable isotope labeling by amino acids in cell culture 
SLAP    SLP-76-associated phosphoprotein 
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SLP-76    lymphocyte cytosolic protein 2 or SLP-76 tyrosine 
   Phosphoprotein 
SOK1   Sterile 20 (Ste20)-like oxidant stress response kinase-1 
SPR   Surface Plasma Resonance 
SRC    Proto-oncogene tyrosine-protein kinase Src 
TCR   T-cell receptor 
TIRF   Total internal reflection fluorescence microscope 
TMR    tetramethylrhodamine-5-maleimide 
Tris   trisaminomethane 
V    domain verprolin homology domain 
VASP    Vasodilator-stimulated phosphoprotein 
VCA   verprolin-central-acidic domain 
WAS    Wiskott-Aldrich syndrome 
WASP PWA   WASP construct contain poly-proline region and VCA   
   domains 
WASP    Wiskott Aldrich syndrome protein 
WH1    WASP homology domain 1 
WH2    Wiskott-Aldrich syndrome homology region 2 domain 
WIP    WAS/WASL-interacting protein 
WW    protein domain that contains two highly conserved    
   tryptophans 
Yop    Yersinia outer protein 
YopO   Yersinia outer protein O 
YopO SER  YopO (89-729) surface entropy reduction mutant (K205Y, 
   E206Y, E207Y, K440Y, K441Y) 
YopO KD   YopO (89-729) kinase dead mutant (D267A, K269A) 
YopO WT   YopO (89-729) wild type 






1.1 THE ACTIN CYTOSKELETON 
 The eukaryotic cytoskeleton is a network of filamentous proteins that provide the 
cell with an internal scaffold for maintaining cell shape and assist in generating 
movement. The cytoskeleton is involved in a variety of cellular processes including 
motility, cell division, adhesion, phagocytosis, apoptosis and signal transduction. The 
cytoskeleton scaffold is composed of three main components: microfilaments (actin), 
intermediate filaments and microtubules. The cytoskeleton forms a highly dynamic and 
flexible framework, which involves continuous cycles of polymerization and 
depolymerization.  
 Actin is a highly conserved intracellular protein that regulates a myriad of cellular 
processes in eukaryotic cells. It is one of the most abundant proteins comprising up to 20 
% of the total protein in muscle cells and 5-10 % in non-muscle cells. There are six 
isoforms of actin, two of which are ubiquitously expressed (β-cytoplasmic,                            
γ-cytoplasmic) while the rest are found in muscle (α-skeletal, α-cardiac, α-smooth,                 
γ-smooth). Actin can exist as a monomer (known as globular or G-actin), or upon 
polymerization, in the form of a filament (F-actin). This ability to transit between the 






1.1.1 The structure of monomeric actin (G-actin) 
 Rabbit skeletal muscle G-actin is composed of 375 amino acids and has a 
molecular weight of 42 kDa. In 1990, Wolfgang Kabsch and Kenneth C Holmes solved 
the first atomic resolution structure of rabbit skeletal muscle actin in complex with 
bovine pancreatic deoxyribonuclease I (DNase I) at 2.8 Å by X-ray crystallography [1,2]. 
The overall structure can be divided into two major domains or four subdomains, where 
each domain is comprised of a multi-stranded β sheet, a β meander, and a right-handed 
βαβ – unit (Fig. 1.1). The center of G-actin contains the nucleotide-binding cleft that can 
bind to ATP, ADP or ADP-Pi and a divalent cation (Ca2+ or Mg2+) [3,4]. Mg2+ is the 
predominant bound cation in vivo, but can be substituted for Ca2+ to reduce 
polymerization in vitro [5]. It has been hypothesized that the ATP is responsible for the 
“closed” conformation of actin by the interaction of its γ-phosphate with a network of 
side chains across the cleft [6]. However, in the ADP bound form, the absence of the γ-
phosphate and the corresponding side chain interactions is hypothesized to result in the 
major domains moving apart creating the “open” conformation [7,8]. Most of the actin-
binding proteins target the hydrophobic groove formed at the interface between 
subdomains 1 and 3, termed as the barbed end. The residues 39-51 of the subdomain 2 
are referred to as the DNase I binding loop (D loop) due to its interaction with DNase I. 
The D loop plays an important role in making intersubunit contacts with another actin 








Figure 1.1 The structure of G-actin. Actin subdomains are labeled 1, 2, 3 
and 4, with pointed and barbed ends as indicated. ATP is shown as sticks 
and calcium ions as red spheres. A. Structure of calcium-ATP-bound G-
actin. D-loop residues His40 to Gly48 in subdomain 2 are disordered. N- 
and C- termini are located near the barbed end as indicated (PDB: 3HBT 
[9]). B. Structure of calcium-ATP-bound actin in complex with 
deoxyribonuclease I (PDB: 1ATN [1]). D-loop becomes ordered upon 
DNase1 binding.  
 
 The structure of G-actin is well studied and many crystal structures have been 
elucidated in complex with proteins that inhibit actin polymerization. Similarly, 
complexes that include small molecules that inhibit polymerization, like latrunculin and 
tetramethylrhodamine (TMR), are also available in the PDB [10,11]. G-actin is generally 
represented with its “pointed” end directed at the top of the page and the “barbed” end 
towards the bottom (Fig. 1.1 A). Both the N- and C-termini of actin are located at the 








1.1.2  The structure of filamentous actin (F-actin)  
 Early in 1960’s, Jean Hanson and Jack Lowy described the helical nature of F-
actin, following which, several models of F-actin filament were described by different 
groups. The symmetry of an actin polymer is incompatible with most crystal space 
groups and its crystallization is further hampered by variable filament lengths. As a 
result, there is no atomic resolution structure for F-actin, and only models exist. Among 
the low resolution models, the Holmes’ F-actin model has been the most widely accepted 
[12]. This model was constructed by fitting the monomeric structure of G-actin into the 
X-ray fibre diffraction pattern obtained from oriented gels of F-actin. Here, the F-actin 
filament is represented as a two-stranded helix with 13 actin molecules per 6 turns, giving 
rise to 2.17 subunits per turn of a helix. However, the stabilizing interactions that occur 
during the G-actin to F-actin transition are not described in detail. 
 In 2009, Oda et al. described a higher resolution structure of F-actin from a well 
oriented sol of rabbit skeletal muscle actin by analyzing the X-ray fibre diffraction 
pattern [8]. They showed that the G- to F-actin conformational transition results from a 
simple relative rotation of the two major domains by about 20 degrees, which in turn 




















Figure 1.2 Transition from G-actin (PDB:3HBT [9]) conformation to F-
actin (PDB: 2ZWH [8]). 
 
 Actin filaments are polar in nature with two distinct ends called a pointed end 
(minus-end) and a barbed end (plus-end), terms that arise from myosin decorated F-actin 
[13]. This polarity is essential to actin’s function in cell motility. Thus, F-actin is 
considered as a dynamic entity that drives many biological processes cellular by 








1.2 PROTRUSIVE STRUCTURES OF ACTIN INVOLVED IN CELL 
 SHAPE, MOTILITY AND PHAGOCYTOSIS 
 The actin cytoskeleton plays a significant role in cell morphology. It offers 
structural and mechanical support to the plasma membrane and stabilizes interactions 
between cells and the extra cellular matrix (ECM). It is also essential for the 
establishment of specialized cell morphologies, such as those found in neurons and 
activated platelets. The dynamic nature of actin filaments allows cells to change their 
shape and to move. Phagocytosis has been shown to be an actin-dependent process where 
actin remodeling supports the extension of protrusive structures on the site of particle 
engulfment. Cells can arrange actin filaments into higher order cellular structures which 
includes sheet-like protrusive structures (such as lamellipodia and ruffles) and finger-like 
protrusions (such as filopodia and microvilli) [14]. These structures play pivotal roles in 
cell movement and phagocytic uptake. Lamellipodia and lamella are actin-rich structures 
in which the actin filaments are oriented with their barbed ends towards the plasma 
membrane at the leading edge [15]. The region immediately behind the leading edge and 
extending several micrometers into the cytoplasm is termed the lamellipodium, which is 
relatively thinner (< 200 nm) and is only weakly adherent to the substratum. 
Lamellipodia are rich in dendritically-branched filaments that disassemble abruptly in the 
transition into the lamella [16,17] The ARP2/3 complex is the primary actin nucleator of 
assembly in the lamellipodia [16]. In contrast to the lamellipodia, the lamellar filaments 
are less dense and less dendritically branched, with stronger adhesion to the substratum 
[17]. Ruffles are transient structures that are either peripheral or dorsal and contain 
dendritically branched filaments which do not attach to the substratum [18]. Membrane 
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ruffles promote binding of immune opsonized particles, a process which is required for 
efficient phagocytosis [19]. The ARP2/3 complex together with the formins mDia1 and 
mDia2 are involved in the assembly of actin filaments in the ruffles [14]. Filopodia are 
rod-like membrane protrusions comprised of bundled, parallel F-actin filaments. 
Filopodia dynamically extend and retract in a three step process that includes initiation, 
protrusion and retraction through the precisely regulated polymerization, convergence 
and crosslinking of actin filaments [20]. Filopodia have important roles in cell migration, 
chemotaxis, wound healing, neurite outgrowth and in the formation of adherens junctions 
between epithelial cells [21]. The parallel bundles of actin filaments in filopodia, which 
run along the length of the protrusion, have their barbed ends oriented towards the tip 
[22]. Filopodia are found embedded in, or protruding from, the lamellipodial actin 
network via elongation of actin filaments at filopodial tips by proteins such as Ena/VASP 
[23] or formins [24] which protect actin barbed ends from capping proteins. Fascin, an 
actin cross-linking protein is essential for maintaining the filopodial structures by 
bundling the actin filaments. Retraction of filopodia occurs by retrograde flow of the 
actin filament bundle [22]. Thus actin is the common force provider and dynamic 


















Figure 1.3 Actin based protrusive strutures involved in cell shape, motility 
and phagocytosis. Side view of a cell showing the different actin rich 
structures including ruffles, lamellipodia and filopodia. An enlarged view 
of the filopodia is shown which contains bundle of actin filaments oriented 
with their barbed end towards the filopodial tips. Figure modified from 
Chhabra et al. [14]. 
 
1.3 ACTIN DYNAMICS 
 Actin dynamics is the process of assembly and disassembly of actin monomers 
into higher order structures. Actin assembly can be divided into three phases: nucleation, 
elongation and steady state. It is a multi-step process that includes: 1) formation of the 
actin trimer referred to as “nucleus”; 2) elongation from the preformed actin trimer; 3) the 
steady state phase where the rate of monomer association equals disassociation. The rate 
limiting step of actin polymerization is the formation of the actin trimer [25]. Various 
parameters including salt concentration, ionic strength, temperature and pH have 
significant effects on actin polymerization kinetics [26,27].  
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 In vitro, actin polymerization attains a steady state where the rate of association of 
free ATP-actin at the barbed end is equal to the rate of disassociation at the pointed end 
in a process called treadmilling during which the filament lengths are constant [28]. At 
the steady state, the concentration of free G-actin monomers that is in equilibrium with 
the F-actin filaments is referred to as the critical concentration [29]. Under physiological 
buffer conditions, the critical concentration of actin at the barbed end is 12 to 15 times 
lower than at the pointed end, and hence, the actin monomer association occurs readily at 
the barbed end [30]. Actin polymerization is a process that turns on the ATPase activity 
of the actin protomer. The energy derived from ATP hydrolysis is subsequently used to 
dissociate the filaments. The sequence of steps in the actin transition from globular to 
filamentous form is given by the following schematic (Fig. 1.4). 
ATP-G-actin → ATP-F-actin → ADP-Pi-F-actin ↔ ADP-F-actin + Pi 
 
 
Figure 1.4 Conversion of ATP bound G-actin to ADP bound F-actin 
 
 
ATP bound G-actin associates with the barbed end of the filament. After association, the 
bound actin hydrolyzes its ATP to ADP + Pi, with the subsequent disassociation of Pi 
[31]. The ADP bound G-actin subunits have a higher Kd for the filament (they bind the 
filament less strongly) leading to their dissociation and filament turnover. 
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1.4 REGULATORS THAT MODULATE ACTIN DYNAMICS 
The dynamic process of actin polymerization and depolymerization is controlled 
by a horde of proteins called actin-binding proteins (ABPs). Several ABPs bind to actin 
monomers and/or filaments in order to direct the location and control the rate and timing 
of actin filament assembly and disassembly. More than three hundred actin-binding 
proteins are identified [32]. Many of these are not actin regulators rather they bind to 
actin for cellular location. Due to space limitations, only the most important actin 
regulators are discussed here. The fundamental roles played by actin-regulating proteins 
include monomer binding or sequestration, filament nucleation and elongation, filament 
end capping, filament cross-linking, filament severing and depolymerization. A 
schematic representation of these roles of actin regulators is shown in the figure 1.5. 
 
1.4.1 Monomer binding proteins  
Monomer-binding proteins sequester G-actin and prevent its polymerization. 
Some monomer-binding proteins are crucial for the nucleotide exchange from ADP-actin 
to ATP-actin. Profilins are small proteins of 13-19 kDa that bind the barbed end of G-
actin and facilitate nucleotide exchange from ADP-actin to ATP-actin [33,34,35,36]. 
Profilins can effectively prevent G-actin from self-nucleating or from associating with the 
pointed-end of actin filaments, while at the same time, permitting it to join the barbed-
end of actin filaments. Other monomer sequestering proteins include beta-thymosins 
[37,38,39,40] and DNase I [41,42,43]. β-thymosins helps to maintain a pool of G-actin in 
the mammalian cell and inhibit nucleotide exchange in actin [44]. DNase I is a 30 kDa 
protein that binds subdomain 2 of G-actin and prevents its polymerization. In vivo studies 
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hypothesize that the inhibition of DNase I by actin may serve as a self-protection 
mechanism against premature DNA degradation during cell damage [45]. 
 
1.4.2 Nucleators and Elongators 
 The formation of the actin nuclei is the pre-requisite for the formation of actin 
filaments. In cells, this is carried out by a group of actin regulators referred to as actin 
nucleators. They accelerate the formation of nuclei by binding to actin monomers from 
which filaments elongate. Nucleators include: ARP2/3, formins, Ena/VASP and tandem 
WH2 domain containing proteins like Cordon bleu. Ena/VASP are actin filament 
elongators that interact with the barbed ends of filaments and recruit monomeric actin for 
directly enhancing filament elongation, yet are not nucleators. VASP and formins are 
central proteins in this thesis that will be discussed later in more detail. 
 
1.4.3 Capping proteins 
These proteins cap the ends of filaments to prevent the exchange of monomers 
and to help the maintenance of filament lengths [46]. There are two kinds of capping 
proteins: barbed-end and pointed-end cappers. Barbed-end capping proteins cap the (+) 
end of the filaments and include CapZ [47], gelsolin [48]. Some formins also have 
barbed-end capping activity [47,49,50]. Pointed-end cappers bind and cap the (-) end of 
the filaments, and are represented by the tropomodulin family [51,52]. Gelsolin and 







1.4.4 Filament cross-linking proteins 
Cross-linkers are multimeric proteins with at least two actin-binding sites that 
bind two actin filaments and are critical for filament bundling at filopodial and 
lamellipodial protrusions. These proteins also help to maintain the viscoelastic properties 
of the cytoplasm and provide rigidity for the plasma membrane associated structures 
[53,54,55]. Cross-linkers or bundling proteins include: fascin [56,57,58], α-actinin 
[59,60,61,62], filamin [63,64,65] and members of the I-BAR family of proteins [66]. 
 
1.4.5 Filament severing proteins 
Severing proteins bind to the side of the actin filament and sever them into two 
fragments. Severing proteins help to regulate the in vivo actin polymerization cycle and 
are controlled by various factors such as calcium, pH and phosphatidylinositides. They 






Figure 1.5 Schematic representations of monomer sequestration, 
nucleation, and filament capping, cross-linking and severing by various 
































1.5 GELSOLIN - AN ACTIN SEVERING PROTEIN  
 The gelsolin superfamily consists of proteins that are highly conserved and occur 
in a wide range of vertebrates, plant cells and lower eukaryotes. In humans, they include 
eight different proteins: gelsolin, adseverin, CapG, villin, Villin-like protein, advillin, 
supervillin and flightless I. These are multi-domain proteins that consist of three, five or 
six homologous repeats of gelsolin-like domain (labeled G1, G2 etc). Gelsolin was first 
discovered and named in 1979 by Yin and Stossel based on its ability to transform the gel 
form of actin filaments to a sol form [77]. Gelsolin is a Ca2+ regulated actin filament 
severing and capping protein that is implicated in actin remodeling in many cell types 
including phagocytic cells [78]. Gelsolin can bind to actin directly in a Ca2+ dependent 
manner and has been shown in vitro to sever, cap and nucleate actin filaments 
contributing to actin assembly and filament remodeling [79]. Other modes of regulation 
include changes in pH [80], tyrosine phosphorylation and interaction with phospholipids 
such as phosphatidylinositol-4-5-bisphosphate (PIP2) [81]. 
 
1.5.1 Domain architecture of gelsolin  
 Gelsolin exists as two major forms: plasma and cytoplasmic. Human plasma (85 
kDa) and human cytoplasmic gelsolin (80 kDa) are identical in amino acid sequence, 
except that plasma gelsolin contains a 51-residue N-terminal extension, of which the first 
27 residues constitute a signal peptide [82]. Gelsolin has two compact halves where each 
half contains three gelsolin-like domains (G1-G3 and G4-G6). G1-G3 comprises the N-
terminal half of gelsolin that is Ca2+ insensitive, yet PIP2 sensitive and is involved in 
severing and capping (Fig. 1.6) [83]. The C-terminal region (G4-G6) is Ca2+ sensitive 
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and is involved mainly in capping [83]. Gelsolin exists as a globular protein in its inactive 
form in calcium-free conditions with its putative actin binding sites buried inside the 
compact arrangement of the six gelsolin domains [67]. In the presence of micromolar 
concentrations of calcium, gelsolin undergoes activation to adopt an extended structure 
exposing actin-binding surfaces on G1, G2 and G4 [68,84]. Structural studies show that 
each gelsolin domain can bind one calcium ion and the binding converts the globular 
form to an extended open structure that binds actin [68]. There are two types of calcium 
binding sites present in gelsolin: two type I sites that share coordination of Ca2+ with 






Figure 1.6 Schematic representation of the domain organization of full-
length human gelsolin. The functions of the C-terminal and N-terminal 
halves, linker region between G3-G4, C-terminal tail latch and the 
phosphorylation sites are indicated. The diagram is not drawn to scale. 
 
1.5.2  Physiological significance of gelsolin 
 Gelsolin has been implicated in various cellular processes including cell motility, 
actin remodeling, phagocytosis, signaling, apoptosis, cancer, platelet activation and 
Familial amyloidosis of the Finnish type (FAF) [85,86]. The role of gelsolin in actin 
remodeling during phagocytosis and apoptosis that are relevant to our study will be 
discussed further. Gelsolin-null mice have multiple defects in morphology and motility in 
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various cell types including neutrophils, platelets, osteoclasts, and dermal fibroblasts 
[87]. Gelsolin null fibroblasts have pronounced actin stress fibers and migrate slower 
than the wild type which indicates that these cells, which are devoid of gelsolin, are 
unable to sever and remodel the actin filaments with their usual efficiency [83,87]. 
Gelsolin is involved in Fc-gamma receptor (FcγR) and integrin-mediated phagocytosis, 
but not in complement-mediated phagocytosis [88]. Gelsolin null neutrophils are 
impaired in FcγR-mediated phagocytosis while gelsolin-null fibroblasts exhibit defective 
binding and phagocytosis [88].  
 Gelsolin also acts as a substrate for caspase-3 which is an executioner caspase that 
is activated during apoptosis [89]. Caspase-3 cleaves murine gelsolin at the linker region 
between G3 and G4 at D352 of the DQTD352G sequence, generating two fragments of 
gelsolin of which the N-terminal fragment severs actin filaments in a Ca2+ independent 
manner [90,91]. Microinjection of the N-terminal fragment triggers rapid 
depolymerization of the actin cytoskeleton causing bleb formation and DNA 
fragmentation, an onset of apoptosis [91]. In cancer cells, gelsolin expression levels can 
be significantly down regulated [92] to circumvent the onset of apoptotic pathways. 
Gelsolin has multiple inputs to apoptosis since it is reported to not only promote 
apoptosis but also acts as an inhibitor of apoptosis. Gelsolin forms a complex with PIP2 
and caspase-3 to inhibit caspase-3 activity thereby preventing apoptosis [93]. Other 
studies hypothesize that the inhibitory action of gelsolin on apoptosis could involve its 
activity at the level of mitochondrial membrane potential [94]. Given this seemingly 
contradictory evidence, the overall assessment of the effects of gelsolin on apoptosis 
remains in question. 
17 
 
1.5.3 Structural studies on gelsolin 
 The structure of human gelsolin is well studied both in its active and inactive 
form. The crystal structure of active gelsolin in complex with monomeric actin has been 
determined in two parts, G1-G3 in complex with actin and G4-G6 in complex with actin 
as shown in Fig. 1.7. The inactive structure is globular in nature where three latches: C-
terminal tail latch, G1-G3 latch and G4-G6 latch hold gelsolin in a compact arrangement 
[48]. At submicromolar concentrations of calcium, salt bridges between G2 and G6 are 
broken, enabling the release of the C-terminal tail latch to expose the F-actin binding site 
on G2 that binds the side of the filament (Fig. 1.8B). The G1-G2 interface dissociates 
enabling the extension of the G1-G2 linker, which in turn directs G1 for insertion 
between two actins in the longitudinal axis. These structural rearrangements trigger the 
linker between G3-G4 to adopt an extended conformation that enables G4-G6 to reach 
































Figure 1.7 Crystal structures of inactive and active forms of gelsolin. A. 
Crystal structure of inactive gelsolin in calcium-free conditions 
(PDB:3FFN [95]). B. Crystal structure of calcium-activated N-terminal 
half of gelsolin (G1-G3) in complex with actin (PDB:1RGI [96]) C. 
Crystal structure of calcium-activated C-terminal half of gelsolin with 
actin (PDB: 1H1V [84]). ATP is represented as red stick, calcium ions as 
grey spheres and actin is indicated in marine. The gelsolin domains are 





 At micromolar concentrations of calcium, gelsolin severs and caps the preexisting 
actin filaments at their barbed ends preventing any monomer addition [48]. The barbed-
end capping by gelsolin is highly stable which can be displaced by interactions with 
regulatory phospholipids such as PIP2 [81]. PIP2 can also inhibit the interaction between 
free gelsolin and actin [81]. Gelsolin-capped filaments are marked for rapid 
depolymerization by cofilin, possibly due to a change of twist of the filaments [97]. 
Gelsolin also exhibits nucleation activity and stimulates actin filament formation by 
forming actin nuclei by binding two actin monomers [98]. However the physiological 
relevance of the nucleation function of gelsolin remains in question, since it can only 
support pointed-end elongation, something that is unlikely in the presence of profilin. 
Gelsolin is also reported to be activated at low pH [80] and this involves a different 











Figure 1.8 Model of F-actin binding and severing by gelsolin. A. 
Sequential steps involved in the calcium activation of inactive gelsolin. B. 
Model of the active gelsolin bound to F-actin followed by severing and 
capping at the barbed end. The linker region between G3 and G4 adopts an 
A B 
Filament severing and capping 
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extended conformation to intertwine the filament. Figure was modified 
from Nag et al. [48]. 
 
1.5.4 Regulation of gelsolin by phosphorylation  
 Very few studies have highlighted the phosphorylation effects on gelsolin. 
Gelsolin is phosphorylated by tyrosine kinase c-Src primarily at Tyr438 in the domain G4 
[99]. In vitro, this phosphorylation is inhibited when gelsolin is bound to actin and greatly 
enhanced in the presence of PIP2 [100]. Kingo et al. demonstrated that artificial 
phosphorylation of plasma gelsolin at the N-terminus removes its dependence on calcium 
activation [101]. A single phosphorylation site was identified at the N-terminus of 
gelsolin by α-chymotrypsin digestion and it was hypothesized that the electrostatic 
interactions between N- and C-terminal ends are important for the Ca2+ independent 
activity of gelsolin [101]. In osteoclasts, proline-rich tyrosine kinase 2 (PYK2) directly 
interacts with gelsolin, phosphorylating it at tyrosine residues, reducing gelsolin-actin 
interactions and increasing the association of gelsolin with PIP2 [102]. 
 
1.6 mDia1 – AN ACTIN NUCLEATOR 
1.6.1 Formins – an overview 
 Formins are large multidomain proteins that perform de novo nucleation as well 
as elongation of existing filaments, assembling unbranched actin filaments. Based on the 
phylogenetic analysis of the highly conserved Formin Homology domain (FH2), 15 
mammalian formin genes are classified into seven groups which includes, the diaphanous 
formins (mDia1, mDia2 and mDia3), the formin related proteins (FRLs), the disheveled-
associated activators of morphogenesis (DAAM), delphilin, the inverted formins (INF1, 
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INF2), the formin homology domain containing proteins (FHOD1, FHOD2) and the 
original ‘namesake’ formins (FMN1, FMN2) [103]. Formins: diaphanous, DAAM and 
FRLs constitute the family diaphanous-related formins (DRFs) and serve as the direct 
effectors of Rho-family GTPases [104]. Mouse diaphanous-formin1 (mDia1), which 
belongs to the DRF family is the main focus of this research and will be discussed in 
detail.  
 
1.6.2  Domain organization of mDia1 
  mDia1 can be divided into two halves: the C-terminal region which consists of 
three formin homology domains (a) the profilin binding - FH1, (b) the actin-binding FH2 
and (c) diaphanous auto-regulatory domain (DAD), of which FH2 is the highly conserved 
signature domain of all the formins and is responsible for the nucleating activity. The 
FH2 domain forms a dimer which remains attached to the barbed end of an actin 
filament, processively capping the filament ends as it moves in a stair stepping fashion as 
the filament elongates [49] while the adjacent FH1 domain which is proline rich binds 
profilin-actin and delivers actin to the barbed end of the elongating filament [105]. The 
N-terminal half of formin comprises of four distinct regions: (a) the GTPase-binding 
domain (GBD) that binds Rho-family GTPases; (b) the diaphanous inhibitory domain 
(DID) that serves to maintain formin in its autoinhibited form via intermolecular 
interactions with DAD region at the C-terminus [103]; (c) the dimerization domain (DD); 
and (d) the coiled coil domain (CC). The region comprising the DID and DD domains are 
often referred to as the FH3 domain. A schematic representation of the comparison of the 












     
 
Figure 1.9 Domain organizations of various formins. Schematics of the 
domain compositions, with one member from each of the seven formin 
families depicted. The domain nomenclature denotes the GTPase binding 
domain (GBD), formin homology domain 1 (FH1) and domain 2 (FH2), 
diaphanous inhibitory domain (DID) and diaphanous auto-regulatory 
domain (DAD), dimerization domain (DD), coiled coil domain (CC), Spir 
interacting domain (SBD) and WH2 domain binding motif. The figure was 
modified from Schonichen et al. [106]. 
 
1.6.3  Structural studies on mDia1 
  mDia1 is the most intensely studied formin and a number of crystal structures of 
discrete domains are available. These structures provide insights into the formin-
mediated actin assembly. The crystal structure of the core FH2 domain of mDia1 reveals 
an elongated, crescent shaped molecule of size 100 Å by 25 Å consisting of the three-
helix bundle subdomain and the FH2 motif (Fig. 1.11A). Further biochemical analysis 
performed on mDia1 show that the FH2 domain inhibits actin polymerization at a 1:1 
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ratio of mDia1 to actin. However the addition of a 72 residue linker between FH1 and 
FH2 induces oligomerization of mDia1 and this construct induces actin polymerization 
[107]. Rho proteins relieve the auto-inhibition of formins by disrupting the DAD and 
DID interactions [108]. The crystal structure of GBD/FH3 region of mDia1 in complex 
with Rho C has been solved in the presence of GMPPNP (Fig. 1.11B). The auto-
inhibitory interaction of DAD with DID gets released mainly due to the Rho-induced 
restructuring of the adjacent GBD, which in turn, interferes with binding of DAD to the 
neighboring DID domain [109,110]. Another crystal structure of the auto-inhibited form 
of the mDia1 C-terminal FH2-DAD region in complex with N-terminal DID region has 
been solved (Fig. 1.12). This complex represents a formin dimer due to the ability of the 
FH2 domains to form the dimers, which resulted in recruiting two FH2-DAD constructs 







Figure 1.10 Schematic of the domain organization for mDia1. The domain 
nomenclature denotes the GTPase binding domain (GBD), formin 
homology domain 1 (FH1), domain 2 (FH2), domain 3 (FH3), diaphanous 
inhibitory domain (DID) and diaphanous auto-regulatory domain (DAD). 
Individual domains with their residue numbers, interacting partners and 













Figure 1.11 Schematics of the three dimensional structure of mDia1. A. 
Crystal structure of the FH2 domain of mDia1 with two dimers present in 
an asymmetric unit (PDB:1V9D [107]). B. Crystal structure of the mDia1 
GBD-FH3 domain in complex with Rho C in the presence of GMPPNP 



































Figure 1.12 Crystal structure of the auto-inhibited form of mDia1. A. The 
crystal structure of dimeric mDia1 with its C-terminal FH2-DAD region 
complexed with N-terminal DID region. Two domains of DID and two 
copies of FH2-DAD of the dimeric structure are shown with domains 
marked in their corresponding colours. (PDB: 3OBV [113]) B. The crystal 
structure of mDia1 C-terminus DAD region only in complex with N-
terminus DID. (PDB: 2F31 [111]). 
 
 Although there are no crystal structures of mDia1 in complex with actin available, 
crystal structures of homologous formins, yeast formin Bni1p FH2 and mammalian 
formin FMNL3 in complex with actin serve as good models for understanding mDia1 
induced actin filament assembly due to the high degree of sequence similarity between 





























Figure 1.13 Sequence alignments of the FH2 domains of mDia1, Bni1p 
and FMNL3 showing the sequence similarity. Created using ESPript. 
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The three dimensional structure of the yeast Bni1p FH2 domain with 
tetramethylrhodamine (TMR) - actin showed that each of structural unit in the FH2 dimer 
binds two actins in an orientation similar to that in an F-actin filament, suggesting that 












Figure 1.14 Crystal structure of FH2 domain of Bni1p with TMR 
conjugated actin monomer; two actin monomers are shown in this view. 
The Bni1p FH2 domain binds the barbed end of actin between subdomains 
1 and 3. TMR is a fluorescent molecule that binds actin at Cys374 and 
prevents actin polymerization. TMR is not shown in the crystal structure 
due to the lack of electron density for Cys374 residue. The two actin 
molecules are shown in marine, the FH2 domain of Bni1p in green, ATP 
as red sticks, and the calcium ions as grey spheres (PDB: 1Y64 [109]). 
 
 Very recently, the crystal structure of dimeric FH2 domain of FMNL3 with two 
actins has been solved [114]. The structure provides a clear picture of the interactions 
between the lasso, linker, post, coiled coil and knob subdomains of FH2 domain with 
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subdomains 1 and 3 of actin as shown in the Fig. 1.15. The structure contains an actin-
FH2 tetramer in which the two FH2 domains interact in a head-to-tail orientation 
encircling the barbed end of two actin monomers.  
 
Figure 1.15 Crystal structure of the dimeric FH2 domain of mammalian 
formin FMNL3 in complex with actin (PDB:4EAH [114]). The lasso-post, 
knob and coiled coil domains of the FH2 domain are marked with blue 
boxes. The residues involved in interaction are shown as red spheres in the 
FH2 domain of FMNL3 and as yellow spheres in actin. Two molecules of 
the FH2 domain and two molecules of actin are shown with domains 
marked in their corresponding colours.  
 
1.6.4 Physiological significance of mDia1 
 Diaphanous formins play an indispensable role in major biological processes like 
cytokinesis, filopodial formation, microtubule stabilization, axon elongation, stress fibre 
formation, cell adhesion and motility and phagocytosis [112]. mDia1 is activated by 
members of Rho-family GTPases, RhoA-C, and perform functions that are mainly 
dependent on its subcellular localization. mDia1 work co-operatively with ROCK during 
the Rho-induced actin stress fibre formation [115]. Diaphanous formins are enriched at 
the filopodial structures that have been implicated in cellular processes like cell-substrate 
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adhesion, phagocytosis and in the formation of the immunological synapse between T-
cells and antigen presenting cells [24,116,117,118]. Both mDia1 and mDia2 play a 
critical role in complement receptor-mediated phagocytosis in macrophages [119]. 
Microtubule-binding CLIP-170 is involved in the recruitment of formin mDia1 to 
phagocytic cups during CR3-mediated phagocytosis [120]. The cytoskeletal scaffold 
protein IQGAP1 directly binds and recruits Rho-activated mDia1 via the DAD domain to 
phagocytic cups during phagocytosis [121]. mDia1 has been shown to co-localize with 
active RhoA and profilin in membrane ruffles of highly motile fibrosarcoma cells [122] 
and with RhoA alone in migrating fibroblasts, further supporting their significance in 
directed cell locomotion [123]. Upon lysophosphatidic acid (LPA) stimulation, mDia1 
captures and stabilizes microtubules by acting as a scaffold protein for EB1 and APC 
[124].  
 
1.6.5  Regulation of mDia1 by phosphorylation  
 mDia1 was shown to be phosphorylated at Thr759 upon dibutyryl cAMP 
stimulation via an ERK dependent pathway [125]. The phosphorylation site lies in the 
FH2 domain and nonphosphorylatable mutant T759A is more stable and attenuates the 
interaction between mDia1 and its partners kinesin and (OSBP)–related protein 2 (ORP2) 
but not with RhoA and β-tubulin [125]. The activity of mDia2, a homologue of mDia1, is 
enhanced by Rho-kinase (ROCK) phosphorylation at two conserved residues Thr1061 
and Ser1070 which lie C-terminal to the DAD region, a region involved in the auto-
inhibitory mechanism of formins [126]. Biochemical analysis indicate that the 
phosphomimetic mutants T1061E/S1070E significantly reduced the interaction between 
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DAD and DID and enhanced mDia2 activation by RhoA, resulting in increased actin 
polymerization [126]. A third homologue mDia3 was shown to be regulated by aurora B 
kinase phosphorylation for stable kinetochore microtubule attachment [127]. 
Phosphorylated mDia3 has reduced ability to bind and stabilize the microtubules and the 
phosphomimetic mutant does not form stable kinetochore microtubule fibres [127]. 
 
1.7  ENA/VASP – ACTIN FILAMENT ELONGATORS 
 Ena/VASP proteins are a conserved family of multi-functional actin regulators, 
which include vasodilator-stimulated phosphoprotein VASP, drosophila protein enabled 
(Ena), its mammalian orthologue Mena, and the Ena/VASP-like protein EVL. Ena/VASP 
bind to the barbed ends of actin filaments and prevent filament capping by capping 
protein (CapZ) [128]. Ena/VASP proteins are abundant at the filopodial tip complexes 
where they promote clustering of filaments at their polymerizing ends and perform 
filament elongation [129]. The structural organization, physiological functions and 
regulation of Ena/VASP proteins by phosphorylation will be discussed in the following 
sections.  
 
1.7.1 Domain architecture of Ena/VASP proteins 
 Ena/VASP is comprised of three major domains: an amino terminal Ena/VASP 
homology domain 1 (EVH1), a carboxy terminal EVH2 and a central proline rich region 
connecting EVH1 and EVH2 (Fig. 1.16A). The EVH1 domain binds to proline-rich 
ligands [130] such as lamellipodia/filopodia protein lamellipodin [131], axon guidance 
receptor Robo [132], semaphorin 6A-1 [133], focal adhesion proteins zyxin and vinculin 
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and Listeria surface protein ActA [134]. The central proline rich region binds to the 
actin-monomer binding protein profilin, the profilin-actin complex, as well as to SH3 and 
WW domain containing proteins [135,136]. The C-terminal EVH2 is a highly conserved 
motif, which can be further subdivided into three sequential blocks: a G-actin binding 
region, an F-actin binding region and a coiled-coil motif that is responsible for 
oligomerization. The G-actin binding site binds an actin monomer and confers nucleation 
activity to VASP at low salt concentrations, in vitro [137]. The F-actin binding region of 
EVH2 can bundle and co-sediment F-actin filaments at low salt conditions [138]. The 
coiled coil motif helps in tetramerization of Ena/VASP that is required for F-actin cross-
linking and enhanced F-actin binding [139]. Homo/hetero tetramerization states of 
Ena/VASP are observed in vivo as indicated by co-immunoprecipitation and yeast two-
hybrid analysis [130,140]. 
 
1.7.2 Structural studies on Ena/VASP 
 A number of domains of Ena/VASP proteins have been solved by X-ray 
crystallography. The crystal structure of EVH1 domain from murine EVL has been 
solved in complex with poly-proline rich ActA peptide (Fig. 1.16C) [141]. The structure 
reveals that the EVH1 domain is composed of an incomplete seven-stranded anti-parallel 
barrel that is closed by a helix which runs parallel to the barrel axis [141]. The crystal 
structure of the ternary complex of the proline-rich region and the G-actin-binding region 
of VASP in interaction with actin and profilin has also been solved (Fig. 1.16B). ITC and 
tryptophan fluorescence measurement binding studies have provided evidence for the 
structural basis of the recruitment of the profilin-actin complex by the central poly-
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proline region of Ena/VASP and the subsequent incorporation of actin into the growing 
barbed end of the filament using G-actin binding site, leaving behind profilin [142]. The 
crystal structure of the tetramerization domain of VASP at 1.3 Å resolution reveals that 
the domain forms a right-handed alpha-helical coiled coil structure which is stabilized by 

































        
 
 
Figure 1.16 Schematic of the domain organization for vasodilator-
stimulated phosphoprotein VASP and Ena/VASP-like (EVL) and crystal 
structures of the different domains of VASP A. The domain nomenclature 
denotes Ena/VASP homology domain 1 (EVH1), proline-rich region (PR) 
and Ena/VASP homology domain 2 (EVH2) that contains a G-actin-
binding site (G), an F-actin-binding site (F) and a tetramerization (TET) 
domain. Relevant binding partners are shown below each domain and the 
reported phosphorylation sites are indicated. The crystal structures of the 
domains available in the PDB database are also marked. The schematic is 
not drawn to scale. B. Crystal structure of complex of profilin, actin with a 
construct of VASP containing a part of the proline-rich region and G-
actin-binding site. Actin is shown in marine, profilin in green, VASP in 
magenta, the calcium ion as a grey sphere and ATP as red sticks (PDB: 
2PBD [142]). C. Crystal structure of the EVH1 domain of murine VASP 
(PDB:1QC6 [141]). D. Crystal structure of the tetramerization domain of 






1.7.3  Physiological functions of Ena/VASP proteins 
 Ena/VASP proteins are localized at the actin-rich structures at the leading edge of 
cells, filopodial tip complexes, focal adhesions and actin stress fibres and are involved in 
the developmental and physiological processes of T cell activation [144], epithelial 
morphogenesis [145], phagocytosis [146] and in the migration of neutrophils, fibroblasts 
and neurons [147]. VASP was originally discovered as a protein that is phosphorylated in 
platelets where it is widely expressed [148,149]. Ena/Mena participates in the 
downstream pathways of axon guidance receptors and is highly expressed in brain cells 
[132] whereas EVL is abundant in haematopoietic cells [150]. In mice, deletion of Mena 
causes defects in the formation of nerve fiber tracts in the brain [151], while deletion of 
VASP causes defects in the actin-dependent process of platelet aggregation [152]. A 
dose-dependent decrease in the movement of fibroblast cells was observed upon over 
expression of Ena/VASP proteins, indicating their negative regulatory effect on fibroblast 
motility [153]. In phagocytic pathways, upon Fcϒ receptor activation, Ena/VASP are 
recruited to the phagocytic cups of macrophages to engulf the opsonized particles, a 
process that involves remodeling of the actin cytoskeleton, filopodial extension and 
particle internalization [146]. Ena/VASP proteins in conjunction with the ARP2/3 
complex and Fyn- and SLP-76-associated protein Fyb/SLAP play key roles in linking      
T-cell signaling to the actin cytoskeleton remodeling [144]. 
 
1.7.4 Regulation of Ena/VASP by phosphorylation 
 Ena/VASP proteins serve as substrates for a number of kinases, which include c-
AMP dependent protein kinase (PKA), and c-GMP dependent protein kinase (PKG), 
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protein kinase C (PKC), AMP-activated protein kinase (AMPK) and protein kinase D1 
(PKD1). VASP is phosphorylated at three sites Ser157, Ser239 and Thr278 by PKA and 
PKG [154] while Mena contains the first two phosphorylation sites [155], and EVL only 
the first site, Ser157 [135]. AMPK phosphorylates Thr278 [156]; PKC phosphorylates 
Ser157 [157] and PKD1 mediates phosphorylation of Ser157 and Ser322. Thus, Ser157 
of VASP is the most common phosphorylation site for PKA, PKG, PKC and PKD1 and 
this phosphorylation event is very evident from the large gel-shift of the phosphorylated 
protein band in SDS-PAGE [149]. A VASP knock-out mice study revealed that VASP is 
required for the PKA-mediated inhibition of platelet aggregation [152] and Ser157 may 
be the key residue involved in the regulation. Phosphorylation of VASP at Ser239, 
present at the EVH2 domain, greatly reduced its interaction with G-actin [137]. Ser/Thr 
phosphorylation of EVL by PKA in the EVH1 domain disrupts its binding to the SH3 
domain of c-Abl and Src [135]. PKD1 directly phosphorylates VASP at two serine 
residues, Ser157 and Ser322, and mediates VASP re-localization from focal adhesions to 
the leading edge, inducing an increase in F-actin polymerization, lamellipodia and 
filopodia formation [158]. 
 
1.8 WISKOTT–ALDRICH SYNDROME PROTEIN (WASP) 
 WASP is a nucleation-promoting factor (NPF) for ARP2/3, the seven-subunit 
protein complex that is involved in the formation of branched actin filaments. It is an 
important regulator of the cytoskeletal machinery that is required to carry out various 
haematopoietic and immune cell related functions. While WASP expression is restricted 
to haematopoietic cells, N-WASP (neuronal WASP) and the related verprolin 
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homologous proteins WAVE1, WAVE2 and WAVE 3 are more widely expressed [159]. 
They act as adaptors or scaffolding proteins that bring together various downstream 
mediators to facilitate ARP2/3 mediated actin polymerization.  
 
1.8.1 Domain architecture of WASP 
 WASP is a 502 amino acid long, proline-rich protein (>15 % of its sequence) that 
is encoded by the gene WAS [160]. Members of the WASP family have a common 
modular structure. WASP consists of an N-terminal WASP homology domain 1(WH1) 
that is homologous to EVH1, a central GBD (GTPase binding) domain, poly-proline 
region (PR) and a C-terminal VCA region. The carboxy terminal region VCA (verprolin 
homology (V) also known as WH2; cofilin homology/central region(C) and an acidic 
region (A)) is highly conserved among the WASP family of proteins. WASP exists in the 
auto-inhibited form in its normal state, by interaction of its VCA region with the GBD 
domain [161]. The Rho GTPases Cdc42/Rac relieve the auto-inhibition by binding the 
CRIB (Cdc42/Rac Interactive Binding) motif that is found in the GBD region[162]. The 
VCA region of WASP in the auto-inhibited state cannot bind ARP2/3 or monomeric 
actin. Binding of the WH1 region to the WASP interacting protein (WIP) is thought to 
stabilize the auto-inhibited form of WASP [163]. Via the proline-rich regions, WASP 













Figure 1.17 Domain architecture of WASP. The domain nomenclature 
denotes WASP homology domain 1 (WH1), GBD (GTPase binding 
domain), CRIB (Cdc42/Rac Interactive Binding) motif, proline-rich region 
(PR), WASP homology domain 2 (WH2) or verprolin homology (V), the 
central region (C) and an acidic region (A). The interacting partners of the 
different domains are indicated with blue arrows. Reported 
phosphorylation sites are also indicated.  
  
1.8.2 Physiological significance of WASP 
 WASP is an important regulator of the actin cytoskeleton and is essential for 
various actin-dependent cellular functions including migration, phagocytosis and immune 
synapse formation [159]. WASP plays an important role in the formation of the actin-rich 
phagocytic cup [166]. Myeloid lineage cells that are deficient in human WASP exhibit 
impaired phagocytosis [167]. Cells derived from patients with WAS exhibit defects in the 
formation of filopodia, lamellipodia and podosomes with reduction in the migration of 
macrophages and dendritic cells [168,169]. The absence of WASP affects the localized 
assembly of actin filaments induced by TCR stimulation at immunological synapses 
[170,171]. WASP is widely expressed in haematopoietic cells and WASP deficient 
peripheral blood monocytes exhibit impaired FcγR-mediated phagocytosis [172]. 




1.8.3 Structural studies on WASP 
 Three-dimensional structures of the various domains of WASP with its distinct 
interacting partners are available in the PDB (Protein Data Bank). The interaction of the 
verprolin homology (V) domain, also known as the WH2 domain of WASP, with 
monomeric actin has been elucidated [173]. The structure reveals that WH2 binds the 
barbed end of the actin monomer between the subdomains 1 and 3 (Fig. 1.18A). WASP is 
activated by the RhoGTPase Cdc42 and the interaction between the GBD domain of 
WASP with human Cdc42 has been solved by NMR, shedding light on residues of GBD 
involved in the activation [162] (Fig. 1.18B). The auto-inhibited form of the C-terminal 
region of WASP has been solved by NMR [161]. The auto-inhibited structure shows that 
the interactions between the GBD domain and VCA region, occludes the binding site of 
ARP2/3 to the VCA region, leaving WASP in its inactive conformation. The solution 
structure for the complex of the WH1 domain of N-WASP with WIP peptide has also 





















Figure 1.18 The three-dimensional structures of the WH2 and GBD 
domains of WASP with their interacting partners. A. Crystal structure of 
WH2 domain of WASP complexed with actin and DNase I (PDB: 2A3Z 
[173]). Actin is shown in marine, DNase I in orange, WH2 domain in 
green, a calcium ion as a grey sphere and ATP as red sticks. B. Solution 
structure of the GDB domain of WASP in complex with the RhoGTPase 
Cdc42 (PDB:1CEE [162]). Cdc42 is shown in green and GBD of WASP 
in magenta.  
 
1.8.4 Regulation of WASP by phosphorylation 
 Phosphorylation of WASP seems to enhance its activity for actin polymerization 
in various cellular functions including phagocytosis, proliferation and chemotaxis. It has 
also been suggested to mark WASP for degradation [174] or influence its subcellular 
localization [175]. WASP and N-WASP are regulated by phosphorylation by different 
kinases including tyrosine kinases Btk, FAK, Ser/Thr kinase CK2 and the dual specificity 
kinase ACK1. Phosphorylation of WASP at Tyr291 in the GBD domain by Btk kinase 
either activates WASP or stabilizes its active conformation [176]. Mutations in this 
region disrupt auto-inhibition of WASP and results in constitutive activation. This results 
B 




in enhanced ARP2/3 mediated actin polymerization as the affinity of the GBD domain 
for VCA region of WASP is greatly reduced thus favoring the VCA-ARP2/3 interaction 
[177]. Casein kinase 2 (CK2) phosphorylates WASP in its VCA domain at the junction of 
C and A domains, on Ser483 and Ser484. The resultant CK2-phosphorylated VCA 
domain has an increased affinity for the ARP2/3 complex and enhances actin 
polymerization [178]. Phosphorylation at Tyr256 slightly enhances the ability of N-
WASP to activate ARP2/3 and inhibits nuclear translocation of N-WASP by reducing its 
interaction with nuclear importin NPI-1 [175]. Cdc42-associated kinase ACK1 displays 
dual specificity in phosphorylating WASP on both Ser242 and Tyr256, in which 
phosphorylation on Ser242 enhances the ability of WASP to stimulate ARP2/3 mediated 
actin polymerization [179]. 
 In summary, phosphorylation of the various actin regulators by native kinases has 
a range of effects on actin dynamics. Gelsolin is phosphorylated at Tyr residues at its 
COOH-terminus which decreases its affinity for actin monomer resulting in growth of the 
actin filaments. Phosphorylation of mDia1 has been shown to either upregulate or 
downregualte its activity, leading to increase or decrease in net F-actin respectively. 
Phosphorylation of VASP at S157 and S322 by PKD1 mediates VASP re-localization 
from focal adhesions to the leading edge, inducing an increase in F-actin polymerization, 
lamellipodia and filopodia formation. Likewise, phosphorylation of WASP by CK2 at 
junction of C and A domains, on Ser483 and Ser484, leads to an increased affinity for the 
ARP2/3 complex and enhances actin polymerization. Therefore, the overall effect of 
phosphorylation of the actin regulators by native kinases helps in regulating the actin 
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assembly and disassembly process that is essential for various cellular functions 
including phagocytosis.  
 
1.9  YERISINIA OUTER PROTEINS 
 Pathogenic Yersinia species - Yersinia enterocolitica, Yersinia pseudotuberculosis 
and Yersinia pestis carry a 70 kb virulence plasmid pYV that encodes: (a) A type III 
secretion system (TTSS); (b) Effector proteins/Yersinia Outer proteins (Yops); and (c) 
Regulators for gene expression and Yop-secretion/translocation [180,181,182]. Yersinia 
spp. uses the TTSS to inject its effector proteins Yops, a group of six proteins 
YopO/YpkA, YopH, YopM, YopE, YopT and YopJ that target host macrophages and 
collectively inhibit phagocytosis by distinct mechanisms to reorient the host immune 
responses [183]. Of the three pathogenic species within the genus Yersinia: Yersinia 
pestis causes the plague, whereas its homologues Yersinia enterocolitica and Yersinia 
pseudotuberculosis causes acute/chronic gastrointestinal syndromes and Far East scarlet-
like fever, respectively [182]. Yops interfere with the regulators of various signaling 
pathways that are essential for important cellular functions including cytoskeletal 
regulation, control of apoptosis, immune signaling and phagocytosis [184]. Among the 
six effector proteins, four Yops, YopO/YpkA, YopT, YopE and YopH are involved in 
phagocytic resistance and in disrupting the regulation of the actin cytoskeleton 
[185,186,187]. While YopJ inhibits NF-κB and MAP kinase signal transduction 
pathways, YopM acts as a scaffold protein for kinases that are involved in proliferation, 
apoptosis and translation pathways [188,189]. Of particular interest to actin remodeling 
are YopO/YpkA, YopE and YopT, which affect the Rho-GTPase cycle. The Rho-GTPase 
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pathway controls a diverse range of cellular functions including regulation of the actin 
cytoskeleton. YopT is a cysteine protease that cleaves the isoprenoid lipid group from 
Rho GTPases RhoA, Rac and Cdc42, resulting in the release of the Rho GTPase from the 
membrane [190]. YopE, a GTPase-activating protein, which binds to RhoA, Rac1 and 
Cdc42 in vitro, stimulating their GTPase activity, terminating their capacity for signaling 
[191]. YopO is a serine/threonine kinase that harbors an actin-binding domain and a GDI-
like activity domain. The GDI domain inhibits nucleotide exchange in Rac1 and RhoA 
[192,193]. YopH causes the inhibition of the β1 integrin phagocytic pathway and the 
activation of signal transduction in early stages of the immune response [194]. Yersinia 
effector protein YopO, the focus of our research will be discussed in greater detail in the 
following sections. 
Table 1.1 Summary of the activities of various classes of Yops 
Class Action on host cells 
YopO 
Ser/Thr kinase that inhibits nucleotide exchange in Rac1 and RhoA. 
YopE 
Binds to RhoA, Rac1 and Cdc42 in vitro, stimulating their GTPase 
activity, terminating their capacity for signaling. 
 
YopT 
Cysteine protease that cleaves the isoprenoid lipid group from Rho 
GTPases resulting in their release from the membrane. 
 
YopH 
Inhibition of the β1 integrin-mediated phagocytosis. 
YopJ 
Inhibits NF-κB and MAP kinase signal transduction pathways 
YopM Acts as a scaffold protein for kinases that are involved in proliferation, 
apoptosis and translation pathways 
 
1.9.1 Domain structure of YopO/YpkA 
 Yersinia protein kinase A, known as YopO in enterocolitica and YpkA in pestis 
and pseudotuberculosis, is the only Yop which contains a kinase domain. The primary 
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sequence identity is greater than 96% amongst YpkA/YopO homologues. YopO from 
Yersinia enterocolitica is an 80 kDa protein. YopO contains an N-terminal membrane 
anchoring domain, a central catalytic domain and at the C-terminus a GTPase binding 
domain (GBD) (Fig. 1.19A) [195]. The membrane anchoring domain targets the protein 
to the host cell plasma membrane and is involved in bacterial secretion/translocation 
[196]. Following the membrane anchoring domain in sequence is the kinase domain (89-
435) which imparts serine/threonine kinase activity to YopO upon activation by the 
eukaryotic host factor, actin [197]. In vitro studies have shown that actin acts as the co-
factor for YopO and its kinase activity is completely dependent on G-actin [197]. YopO 
binds G-actin with an affinity of Kd = 1.9 µM [197]. The C-terminal region of YopO 
(436-729) is functionally similar to Rho GDIs (Rho-GDP disassociation inhibitor) and 
constitutes a GDI-like domain that binds to Rac1 [193]. The GDI domain of YopO 
inhibits nucleotide exchange of bound Rho-GTPases, similar to eukaryotic Rho GDIs. At 
the very C-terminal end of YopO is a stretch of 21 amino acids (711-721) that share 
homology with the coiled-coil domain of actin-bundling protein coronin [185]. Deletion 
of this stretch of 21 amino acids results in a complete loss of kinase activity, and 













          
Figure 1.19 Domain organization of YpkA and crystal structures of the GDI 
domain of YpkA A. Schematic representation of the domain structure of YpkA B. 
Structure of the GDI domain crystallized alone (PDB: 2H7O [193]). C. Structure 
of the GDI domain crystallized in complex with Rac1 (PDB: 2H7V [193]) with 
YpkA. Rac1 is shown in red, the GDI domain is shown in magenta and the actin-
binding region is shown in yellow. 
 
  YopO becomes autophosphorylated upon the activation of its kinase activity, 
which is essential for the phosphorylation of external substrates [197]. YopO is activated 







actin binding sites, one within the kinase domain (89-435) and another within the GDI 
domain (436-729). The binding of actin triggers autophosphorylation of YopO on serine-
90 and serine-95 [197]. In addition to autophosphorylation, the YopO 1:1 complex with 
G-actin and prevents its polymerization [197]. YopO is differentially activated by 
different isoforms of actin, with the muscle isoform being about ten-fold weaker in 
activating the autophosphorylation of YpkA as compared to non-muscle isoforms [197]. 
 
1.9.2  Regulators of the actin cytoskeleton in phagocytosis 
 The Rho GTPases Rac, RhoA, RhoG and Cdc42 are key regulators in modulation 
of the actin polymerization machinery and are involved in spatial and temporal control of 
actin dynamics. Rho GTPase members Rac, RhoA and Cdc42 either directly affect 
polymerization through activation of actin nucleators and elongators, or indirectly 
through activation of kinases, while RhoG affects polymerization through the activation 
of Rac and Cdc42 [198]. Via yeast two-hybrid and co-immunoprecipitation experiments, 
YpkA has been identified to bind RhoA and Rac1 but not to Cdc42, which reorients the 
downstream pathways leading to cytoskeletal rearrangements [199,200,201]. Cytoskeletal 
rearrangement is central to the function of phagocytosis in phagocytes (i.e. macrophages, 
dendritic cells and neutrophils), that provide innate immunity [202]. The major 
phagocytic receptors involved during infection are opsonin receptors Fcγ receptors 
(FcγR) and complement receptors (CR3), which recognize particles that have been 
opsonized with IgG and complement proteins C3bi, respectively. The rearrangements 
necessary for FcγR-mediated phagocytosis are mediated by Rac and Cdc42, whereas 
CR3-mediated uptake is mediated by RhoA [203]. RhoG is involved in both FcγR- and 
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CR3-mediated phagocytosis [204]. During FcγR-mediated internalization, active Cdc42 
accumulates at the tips of extending pseudopodia while active Rac1 localizes throughout 
the phagocytic cup. Knockout studies of Rac1 and Cdc42 in macrophages reveal that 
phagocytosis is inhibited by the prevention of F-actin accumulation in the phagocytic cup 
[205].  
 Actin filament regulating machineries that are implicated in the phagocytic 
processes include gelsolin, mDia1/2, WASP, ARP2/3 and VASP. Gelsolin is enriched at 
phagosomes and gelsolin-null neutrophils are aberrant in FcγR-mediated phagocytosis 
but not in complement-mediated phagocytosis [88]. Diaphanous is recruited at the start of 
CR3-mediated phagocytosis and colocalizes with actin in the phagocytic cup. Reduction 
of Dia activity significantly reduces CR3-mediated phagocytosis but not FcγR mediated 
phagocytosis [119]. The cytoskeletal scaffold protein IQGAP1 is involved in recruiting 
Rho-activated mDia1 via the DAD domain to phagocytic cups [121]. ARP2/3 is 
important in mediating actin polymerization for phagocytic cup formation and particle 
engulfment in both FcγR mediated and CR3-mediated phagocytosis, localizing to 
phagosomes in both phagocytic pathways while VASP is linked to FcγR-mediated 
phagocytosis. VASP accumulates with F-actin at nascent FcγR-induced phagosomes 
together with other proteins including Fyb/SLAP, Nck, Vav, SLP-76 and WASP [146]. In 
summary, the modulation of actin dynamics by Rho GTPase members Cdc42, Rac, RhoA 
and RhoG and their effectors ARP2/3, VASP, WASP, gelsolin and diaphanous are 
indispensable to the process of phagocytosis. Bacterial pathogens have evolved a large 
array of mechanisms to combat the phagocytic pathways of host cell machinery, some of 
which directly modify the actin cytoskeleton in host cell cytosol [206]. 
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1.9.3  In vivo studies on YopO/YpkA  
 YopO/YpkA target Rho GTPases, with the resulting phenotypes of disruption of 
stress fibres and cell rounding, accompanied by inhibition of phagocytosis. Mutant 
Yersinia spp. lacking the Yop effector proteins are more prone to being phagocytosed in 
both opsonin receptor-dependent and independent pathways [187]. YopO significantly 
inhibits the uptake of both IgG-opsonized and C3bi-opsonised particles, with a greater 
inhibitory effect on the FcγR pathway [200]. In mouse models, pathogenic Yersinia 
strains that have deletion mutations in the YpkA gene are no longer lethal [192]. YpkA 
expression enhances resistance to killing by macrophages [207]. In HeLa cells, over 
expression of YpkA leads to extensive actin cytoskeletal disruption with cell rounding 
and retraction of fibres [185] and cells are observed to retract around their edges but 
maintain focal adhesions [185,208]. In yeast, YpkA expression disrupts the normal 
distribution of actin [209].   
 
1.9.4  Structural studies on YopO/YpkA 
 The structure of the GTPase binding domain of YpkA has been solved on its own 
and in complex with Rac1. The free crystal structure of YpkA (436-729) reveals an 
elongated molecule made up of helices consisting of two subdomains connected by a 65 
Å long linker helix (Fig. 1.19B) [193]. The N-terminal subdomain has ACC fingerlike 
repeats that are required for small GTPase binding, while the C-terminal subdomain 
contains a binding site for actin [193]. The co-crystal structure of the C-terminal domain 
of YpkA and Rac1 reveals that the GDI-like domain of YpkA mimics the crystal 
structure of the host Rho-family GDI proteins in its binding to the Rac1, a GTPase 
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member (Fig. 1.19C). The YpkA C-terminal domain was determined to be a potent 
inhibitor of nucleotide exchange in Rac1 and RhoA in vitro via nucleotide disassociation 
assays [193]. Introduction of loss-of-contact mutations into the GDI domain, for binding 
Rac1 and RhoA, greatly reduces the cytoskeletal disruption induced by this domain. 
Studies in mice have shown that these mutations also reduce Yersinia virulence [193]. 
Thus, the YpkA GDI domain mimics host GDI proteins by acting as an ‘‘off switch’’ to 
modulate the Rac1 and RhoA-associated signaling pathways that regulate host 
cytoskeletal dynamics [193].  
 Very recently, Lee et al. solved the crystal structure of YopO encompassing the 
kinase and GDI domains in complex with actin [210]. The structure reveals that, the GDI 
domain and the kinase domain sandwich subdomain 4 and part of subdomain 2 of actin, 
with the GDI domain contacting the front face of actin with a total surface area of 812 Å2 
and the kinase domain contacting the rear face with 1218 Å (Fig. 1.20). The domain 
structure of the GDI domain is very similar to the previously reported structures of GDI 
domain in isolation (PDB: 2H7O, Fig. 1.19B) and in complex with Rac1 (PDB: 2H7V, 
Fig. 1.19C). The kinase domain is similar to other eukaryotic kinases comprising of an N-
lobe made up of β-sheets and one single α-helix (αC helix) and a C-lobe comprising an α-
helical bundle (Fig. 1.21). The kinase domain interacts extensively with actin through the 
C-lobe of the kinase domain while the N-lobe and the catalytic cleft do not interact with 
actin. These interactions appear to allosterically position the catalytic loop and the 
activation segment of the kinase domain for kinase activity in such a way that it can only 
phosphorylate substrates that are inserted between the kinase domain and the GDI 
domain. The kinase and GDI domains are 31.5-33.0 Å apart and substrates presumably 
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will have to insert into this gap for phosphorylation to take place (Fig. 1.21). The glycine-
rich sequence immediately C-terminal to the APE motif is partially disordered and is a 
candidate region for substrate binding. Poor density was observed for the P-loop of the 
kinase domain, which requires Mg-ATP binding for stabilization (Fig. 1.22). The kinase 
domain becomes active on binding actin. The structure also suggests that YopO could be 
using actin as a scaffold for means of substrate selection and as bait for recruitment of 
substrates due to positioning of the catalytic cleft above the bound actin. The interaction 
of the GDI domain with actin is separate and distinct from the Rac1-interaction site and 









Figure 1.20 The crystal structure of the complex of YopO (89-729) with 
actin. Actin is shown in blue, the kinase domain in green and the GDI 
domain in magenta. A calcium ion is shown as a grey sphere and ATP as 




                              
Figure 1.21 Kinase substrate binding groove on YopO. Crystal structure 
of the YopO-actin complex showing the substrate binding cleft between 
the kinase and the GDI regions of YopO. Substrates are likely to be 
accommodated in the space between the kinase and the GDI domain. The 











Figure 1.22 Crystal structure of the kinase domain of YopO showing the 
disordered P-loop region near the catalytic site. Lee et al. [210]. 
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 It was hypothesized by Lee et al. [210] that the binding of YopO on the pointed 
end of actin would inhibit actin nucleation and the YopO-bound actin monomer would 
not be added to the barbed end of an actin filament due to steric hindrance of YopO. This 
was validated using a pyrene actin assay, which showed that YopO retards actin 
polymerization, with near complete retardation when YopO is at an equimolar ratio to 
actin. Thus, YopO sterically blocks the pointed end of the actin monomer, providing 
structural basis for the sequestration of actin monomers and the inhibition of actin 
polymerization by YopO [197]. Pointed end binding by YopO leaves the barbed end ‘hot 
spot’ of actin between subdomains 1 and 3, free to bind other actin regulators [211]. The 
20 residues to the C-terminus of YopO form multiple salt bridges with actin, in 
accordance with literature that the C-terminal 20 residues of YopO are important for 
binding actin [185,197]. The putative phosphorylation sites Ser90 and Ser95 are located 
outside of the catalytic site of YopO, suggesting that YopO is auto-inhibited in the 
inactive state [197]. 
 The crystal structure also provided a structural basis for the differential ability of 
muscle and non-muscle actin isoforms to activate YopO. Muscle α-actin contains a valine 
at position 203 while non-muscle actin contains threonine in the corresponding position 
202. Muscle actin is weaker at activating YopO due to the inability of the α-actin isoform 
to mediate a hydrogen bond with Lys245 of YopO and this interaction appears to be 
important for stabilizing the catalytic loop.  
  The interaction of YopO with actin stabilizes the closed conformation of the 
nucleotide-binding cleft of actin by masking the cleft between the subdomains 2 and 4, 
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while leaving the barbed end free. This likely causes YopO to inhibit nucleotide 
exchange in a bound actin monomer and in a bound actin-profilin complex.  
 
1.9.5  Identified substrates of YopO 
  Almost a decade ago Juris et al. identified ovarian tumor domain ubiquitin 
aldehyde binding 1 (otubain-1) as a novel substrate for YopO. However, the role of 
otubain-1 in the cytoskeletal regulation remains elusive [212]. Very recently, studies by 
Lee et al. have identified the novel substrates of YopO kinase by proteomics approach 
[210]. The interaction of YopO and actin in the presence of other actin-binding proteins 
was investigated via a proteomics approach, to understand the mechanism of actin 
cytoskeleton interference by YopO and to identify substrates of the kinase activity of 
YopO. SILAC MS, an in vivo labeling strategy that enables characterization of protein–
protein interactions, was used to identify proteins that were bound to YopO via actin in 
macrophage cell lines, as macrophages are the key targets for Yersinia pathogenesis. In 
this study, YopO-actin and YopO-actin-profilin complexes were employed to 
demonstrate that YopO uses either actin or actin-profilin as baits to enrich for the binding 
partners that are directly recruited by actin, or by binding profilin-actin via their proline-
rich regions. The proteins that are enriched in the pull downs included various actin 
binding proteins: gelsolin family proteins (gelsolin and CapG); Formins (Dia1, INF2, 
FMNL1); VASP family proteins (VASP, EVL); WASP and twinfilin. The GDI domain 
of YopO also pulled down Rho GTPases, including Rac2, RhoA and RhoG, which were 
further validated by another experiment involving YopO nRac mutant that did not pull 
down any Rho GTPases. Further in vitro phosphorylation assays on actin binders 
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gelsolin, Dia1, VASP, EVL, WASP, twinfilin and CapG were performed to test if these 
binding partners serve as potential substrates for YopO kinase (Fig.1.23). The 
phosphorylation assays were carried out in the presence of either the gelsolin G1 domain 
to compete for the binding partners that target the barbed end of actin like gelsolin, 
CapG, WASP and twinfilin or in the presence of profilin that recruits proteins like Dia1, 
VASP and EVL via their proline-rich regions to bind actin and form ternary complexes. 
Of the targets tested in the phosphorylation assays, gelsolin, Dia1, WASP, VASP and 
EVL were shown to be phosphorylated by YopO, representing the novel substrates of 











Figure 1.23 In vitro phosphorylation assays for potential substrates of 
YopO. YopO WT (4.7 µM) incubated with Sf9 actin (4.7 µM) and various 
substrates (4.7 µM), in the presence or absence of either profilin (14 µM) 
or gelsolin domain 1 (14 µM) as indicated, supplemented with [γ-32P] 
ATP. Substrates are marked with red arrows. Dried gels were exposed to 
X-ray film (upper panel). Proteins were separated by SDS-PAGE and 
visualized by Coomassie Blue staining (lower panel). Adapted by 
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permission from Macmillan Publishers Ltd: Nat Struct Mol Biol.  Lee et 




 YopO did not phosphorylate CapG, twinfilin, profilin and G1. The reason being 
the length of these proteins is insufficient to reach between the catalytic cleft between 
GDI and kinase domain of YopO, which lies above the bound actin. In summary, YopO 
can phosphorylate proteins that can simultaneously bind to actin and reach the catalytic 
cleft. Thus, the YopO-actin crystal structure in combination with SILAC MS results 
suggests that YopO uses actin for recruitment into the actin machineries and that actin is 
used as a scaffold for the selection and binding of substrates for phosphorylation.  
 Collectively, Lee et al. suggest that YopO adopts a three pronged approach to 
hijack the actin cytoskeletal machinery: 1) sequestration and inhibition of Rac and RhoA 
by the GDI domain impairing their downstream pathways controlling the cytoskeletal 
dynamics; 2) sequestration of actin monomers and inhibition of nucleotide-exchange of 
profilin-actin that prevents actin polymerization; and 3) modulation of actin 
polymerization machineries by phosphorylation of actin regulators that serve as 
substrates for YopO [210].  
 The YopO substrates gelsolin, mDia1 and VASP/EVL and WASP are the focus of 
the research in this thesis and were introduced in the sections 1.5, 1.6, 1.7 and 1.8, 
respectively.   
 
1.10 MECHANISM OF DISRUPTION OF PHAGOCYTOSIS BY YopO  
 Phagocytic cells are sentinels that form the first line of defense against infections 
caused by bacterial pathogens. Pathogens have evolved numerous mechanisms to 
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interfere with the host immune signaling pathways. Pathogens prevent being engulfed by 
macrophages by interfering with antigen processing/presentation, or perturbing the 
signaling pathways that are required for the production of soluble cytokines to recruit 
cells to the site of infection [213]. Pathogenic Yersinia utilizes its T3SS to avoid being 
engulfed by macrophages. Pathogenic Yersinia spp. deliver its effector proteins into the 
macrophages to interrupt the signaling required for phagocytosis [187,200,207]. 
YpkA/YopO is one such effector protein of Yersinia enterocolitica that resists 
phagocytosis. In both opsonin receptor-dependent and -independent pathways, Yersinia 
bacteria lacking YopO were phagocytosed to a greater extent by leukocytes and 
macrophages than wild type Yersinia [187]. The GDI domain of YopO mimics the host 
GDI function to inhibit GDP-GTP exchange of G-proteins, which facilitates YopO to 
repress the Rho activity, which in turn limits the downstream signaling pathways 
involving actin remodeling. The kinase domain of YopO has also been reported to 
phosphorylate G-protein subunit Gαq, impairing guanine nucleotide binding and its 
activation [214]. Both the Rho proteins and Gαq play roles in actin stress fibre formation 
[215]. Actin remodeling is central to the function of phagocytosis [216]. Various actin 
regulators are either directly or indirectly controlled by Rho proteins. These include 
gelsolin, mDia1/2/3, VASP, WASP, ARP2/3, CapG and cofilin. VASP and gelsolin are 
involved in FcγR-mediated phagocytosis [88,146]. Diaphanous is involved in CR3- 
mediated phagocytosis [119]. While YopO does not seem to phosphorylate ARP2/3, it 
may exert effects on ARP2/3 via the phosphorylation of WASP. WASP is important for 




1.11  ROLE OF THE ACTIN REGULATORS THAT ARE SUBSTRATES 
 OF YopO AT THE LEADING EDGE OF MACROPHAGES 
 Particle internalization is an actin-dependent process. During phagocytosis, actin 
remodeling within the protrusive structures may occur through various mechanisms [217] 
(i) an increase in the number of actin filaments by de novo nucleation (ii) an increase in 
the average filament length of the preformed filaments by uncapping which allows the 
addition of monomers to filament barbed ends (iii) a reduction in the length or number of 
filaments by actin depolymerization machineries and (iv) stabilization of the filaments by 
actin cross-linking or bundling proteins, with no change in net F-actin. Among the 
protrusive structures, filopodial extensions are indispensable to macrophages where they 
act as phagocytic tentacles and pull bound objects towards the cell for phagocytosis 
[218]. Filopodial formation occurs in a three step process that includes initiation, 
protrusion and retraction, which are precisely regulated by polymerization, convergence 
and crosslinking of actin filaments by several actin regulators [20]. The importance of the 
actin regulators gelsolin, mDia1, VASP and WASP which are identified as the novel 
substrates of YopO at the filopodial protrusions will be discussed in detail. 
  Diaphanous has been shown to perform de novo nucleation at the plasma 
membrane leading to an increase in the linear filaments that make the filopodial 
protrusions [219]. Dia proteins remain attached to the barbed end of the filaments 
protecting them from capping proteins, and perform filament elongation by processive 
movement along the filaments [220]. The processive movement of formins along the 
filament generates a force in the range of around 1.3 pN per actin filament, while the sum 
of the forces from the bundle of filaments present at the filopodia significantly 
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contributes to the membrane deformation [221]. In vivo studies show that, the 
overexpression of formin Dia2 induces filopodia in mammalian cells and its depletion 
results in defects in filopodia formation [20]. Thus, diaphanous plays an indispensable 
role in the initiation and elongation phases of filopodia formation.  
 Gelsolin null mice are reported to exhibit delayed filopodial retraction [222]. The 
elongation phase was not affected, however impaired retraction phase was observed, 
strongly suggesting the importance of the severing function of gelsolin in the initiation of 
filopodial retraction of neuronal cells. With alternating currents of Ca2+/PIP2, gelsolin 
helps to sever the actin filaments leading to filopodial retraction.  
 Electron microscopy analysis of filopodial tips revealed the presence of 
Ena/VASP proteins at the barbed end of actin filaments. Biochemical and TIRF 
microscopy experiments demonstrated that Ena/VASP do not uncap the barbed ends of 
the filaments but remain attached and by its anti-capping activity protect filament barbed 
ends from capping proteins [222,223,224]. Ena/VASP-null cortical neurons fail to initiate 
the neurite formation due to the lack of filopodia. However, this phenotype could be 
rescued in cell culture by the expression of other filopodia-inducing proteins suggesting 
that Ena/VASP proteins are important but not essential for filopodial formation in 
mammalian cells [225]. Taken together, it is clear that Ena/VASP proteins help to 






















Figure 1.24 Substrates of YopO in filopodia formation. Schematic 
representation of the process of filopodial formation showing the 
molecular activities of the various substrates of YopO in the formation, 
protrusion and retraction of filopodia. Formins are involved in the 
filopodial tip complex formation via de novo nucleation and help in 
filament elongation. WASP and VASP/EVL proteins promote the fast 
filament elongation and are concentrated at the tips of filopodia. Cross-
linking proteins help to stabilize the filaments by the formation of actin 
bundles. Retraction of the filaments is performed by the filament 
depolymerization/severing proteins like gelsolin. Figure modified from 
Faix et al. [20]. 
 
 ARP2/3 complex is considered the major nucleator of the lamellipodial network 
that forms branched filaments. These branched filaments converge into parallel bundles 
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to give rise to filopodia [226]. The ARP2/3 complex is activated by the WASP family of 
proteins. WASP is recruited to FcγR phagosomes in macrophages [172]. The 
macrophages from WAS patients who express little or no WASP, exhibit defective 
phagocytosis [172]. WASP was also found to co-localize with VASP proteins at the 
phagosomes [227]. 
 
1.12  STRUCTURE AND FUNCTION OF PROTEIN KINASES 
 Protein kinases are key regulators of cellular functions that constitute one of the 
largest families of proteins. They perform the covalent transfer of a phosphate group from 
a phosphate donor ATP molecule onto amino acids with a free hydroxyl group, namely 
serine, threonine or tyrosine, in a process termed phosphorylation. Protein 
phosphorylation is a reversible post-translational modification that plays a very important 
role in most eukaryotic cellular processes and cell signaling pathways and is often 
misregulated in pathological conditions [228,229]. Protein phosphorylation leads to 
structural changes that can affect the native function of a protein or induce changes in 
interaction partners or subcellular localization [228]. Despite low sequence homology, 
the structure of the catalytic domain of kinases is strongly conserved across kingdoms 
[230,231,232]. Specific motifs and residues which are involved in the catalysis or 
positioning of the phosphate donor ATP molecule and the protein substrate are highly 
conserved [230]. 
 Protein kinases consists of a characteristic bilobal fold that includes an N-terminal 
lobe (N-lobe) made up of β-sheets and a universally conserved α-helix (αC helix) and a 
C-terminal lobe which is mostly helical [230,233]. The deep cleft formed between the N- 
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and C-lobes constitutes the catalytic cleft, also known as the active site that binds ATP. 
The N-lobe contains a P-loop region that is comprised of a highly conserved glycine-rich 
sequence motif GXGXφG (where φ is usually tyrosine or phenylalanine) of which the 
glycine residues coordinate the phosphates of bound ATP via backbone interactions. The 
C-terminal lobe contains the activation segment of about 20–35 residues, demarcated by 
a conserved Asp-Phe-Gly (DFG) motif and an Ala-Pro-Glu (APE) motif; and the 
catalytic loop which contains the Asp-X-Lys residues in which Asp is directly involved 
in catalysis [230,233] and Lys binds to the phosphate before and after transfer.  
 Kinases act like molecular switches that exist either in “ON” or “OFF” states i.e. 
active or inactive. The transition from inactive to active state is tightly controlled by 
factors such as binding to allosteric effectors [234], subcellular localization [235], 
phosphorylation of the activation segment [236] and activation segment exchange [237]. 
During activation, the N-lobe undergoes extensive conformational changes whereby the 
glycine-rich P-loop and αC helix move towards the activation segment of C-lobe, 
allowing multiple interactions between the two lobes, leading to the correct positioning of 
phosphate donor ATP, catalytic aspartate and protein substrate within the catalytic cleft 
for transfer of the γ- phosphoryl group of ATP [229,238,239]. The activation segment is 
partially disordered in inactive kinases. However, the activation segment is stabilized 
upon activation, which is a crucial constituent of the substrate-binding site (Fig. 1.25). 
 Kinases are generally specific and their specificity is determined by two factors: 
peptide specificity of the kinase for the substrate, and the frequency of encounter between 
the kinase and substrate, known as the recruitment [240]. Various mechanisms have 
evolved that confer the exquisite peptide specificity to kinases which includes the 
61 
 
structure of the catalytic site and the local and distal interactions between the kinase and 
substrate [235]. The active site of the kinase possesses specific features including depth 
and charge/hydrophobicity of the binding pocket: (i) depth, which differentiates between 
Ser/Thr or Tyr residue phosphorylation, and (ii) charge, such that substrates with 
complementary characteristics are preferentially bound. Although Ser/Thr and Tyr 
kinases have similar catalytic domain structures, Tyr kinases have a deeper catalytic cleft 
such that a Tyr residue can reach the catalytic residues while the smaller side chains of 
Ser and Thr cannot approach sufficiently closely [235]. Thus, the protein kinases share a 
common fold and conserved catalytic cleft, yet charge and hydrophobicity of surface 
residues differ, conferring substrate specificity.  
 The consensus sequence of the kinase substrates is often determined using peptide 
variants or random library approaches [241]. The phosphorylation site of the substrate is 
referred to as the P-site and the stretch of amino acids that are situated immediately N-
terminal and C-terminal to the P-site of the substrate peptide constitutes the consensus 
sequence. The consensus sequence substantially influences kinase–substrate recognition. 
Table 1.2 shows the consensus sequence of a number of eukaryotic kinases with amino 
acids N- and C-terminal to the P-sites indicated. Regions of the substrate 50-100 residues 
away from the P-site may also contribute to the substrate recognition mechanism by 
binding to distal docking sites on the kinase [242]. Some kinases utilize modular binding 






Table 1.2 Consensus phosphorylation sites of some of the important 
eukaryotic kinases. The consensus sequences were obtained from 
www.kinexus.ca. pS/pT at the residue position 0 represents the P-site. The 
residues N- and C-terminal of the P-site (denoted in single letter AA code) 









 Localization of the kinases also contributes to their substrate specificity. Kinases 
may be targeted to specific substrates that are confined to distinct subcellular 
compartments or structures, reducing the complexity of substrate selection. The 
recruitment of the substrates by kinases can also be controlled via complex formation 
with scaffolding or adaptor proteins that regulate the kinase [243,244]. 
 In bacterial pathogenesis, eukaryotic-like bacterial serine or threonine kinases 
(eSTPK) play an important roles where they mimic the eukaryotic host kinases and hijack 
the host signaling pathways to perturb their normal cellular functions [245]. These 
kinases are potential virulence factors that modify the global host response to infection. 
eSTPKs are structurally homologous to eukaryotic kinases as catalytic site of kinases are 
highly conserved across kingdoms, which allows them to mimic the eukaryotic host 
kinases.  Examples of eSTPKs include YopO from Yersinia, Stk1 from Staphylococcus, 
SteC from Salmonella and LegK1 from Legionella, which act through phosphorylation of 
Protein 
Kinase 
-4 -3 -2 -1 0 1 2 3 
PAK  KR R  pSpT    
MSK  R   pSpT    
MAPK  G P QM pS P I  
PKA KR KR KR RN pSpT FILVY I F 
        N-terminus         P-site       C-terminus 
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host proteins. The sequence homology between eSTPK YopO and its closely related 

























Figure 1.25 Structure of protein kinases in the active and inactive states. 
Mammalian STE20-like protein kinase 3 (MST3/STK24) inactive (green, 
PDB: 3CKW) [Crystal structure of sterile 20-like kinase 3 (MST3, 
STK24). Antonysamy, S.S.,  Burley, S.K.,  Buchanan, S.,  Chau, F.,  Feil, 
I.,  Wu, L.,  Sauder, J.M.] and active (splitpea, PDB: 3A7H [246]) 
structures. The catalytic loop (blue) contains catalytic residues Asp-X-Lys 
of which Asp144 and Lys146 are shown in sticks. Conserved residues 
Lys53, Glu70 and Asp160, which coordinate ADP (yellow and orange 
sticks), and Mg2+ (grey spheres) are shown. The activation segment 
(magenta) is partially disordered in the inactive structure but fully ordered 
in the active structure. The glycine rich loop (orange) coordinates the 
phosphates of ADP. Phosphorylated threonine in the activation segment of 
active MST3 is shown as sticks. An enlarged view of the catalytic cleft is 
























Figure 1.26 Sequence alignment of the kinase domain of YopO with 
structurally similar kinases as identified by FFAS (Fold Function 
Assignment Server) within the Protein Data Bank. Alignment was 
performed using Clustal Omega. The image was created in ESPript. The 
conserved domains are indicated with thick blue lines. The catalytic Asp 
residue is marked with a green asterisk. 
65 
 
1.13  RATIONALE AND SIGNIFICANCE OF WORK 
 YopO is the only kinase effector protein of Yersinia whose activity is dependent 
on binding to actin and is implicated in host pathogenesis by disrupting the cytoskeletal 
architecture. It was reported by Lee et al. that YopO uses a three-pronged attack to hijack 
host macrophage cells, causing misregulation of the actin cytoskeleton [210]. A number 
of key actin polymerization players have been reported to be substrates of YopO as 
identified by SILAC MS and were validated in vitro. YopO uses actin as a bait to recruit 
and phosphorylate actin regulators including gelsolin, mDia1, WASP, VASP and EVL. 
However, the effects of phosphorylation of these proteins on regulation of actin dynamics 
remain unknown. The goal of this work is: (1) to obtain the crystal structure of the 
catalytically active form of YopO-actin in complex with Mg-ATP, to shed light on active 
site architecture (2) to identify YopO’s phosphorylation sites on gelsolin, mDia1, VASP, 
EVL and WASP using mass spectrometry (3) to validate the identified phosphorylation 
sites by in vitro phosphorylation assays (4) to determine the effect of phosphorylation of 
these proteins with respect to actin dynamics by biochemical assays and (5) to obtain a 
global overview of how phagocytosis may be impaired through the collective 












2.1  MOLECULAR CLONING 
2.1.1 Constructs, vectors and E. coli strains 
 The following vectors were used for cloning: pSY5 contains an N-terminal His-
tag followed by a human rhinovirus 3C protease cleavage site; pOPINE which contains a 
noncleavable C-terminal His-tag; a modified pGEX-4T1 which contains an N-terminal 
GST tag cleavable by thrombin, with a non-cleavable C-terminal His-tag; and pToomy, 
modified from pGEX-6P1 to contain an N-terminal GST followed by a human rhinovirus 
3C protease cleavage site, and a His-tag followed by a thrombin cleavage site N-terminal 
to the protein of interest [247]. Table 2.1 details the list of genes, plasmids and expression 
systems employed for the various constructs. DH5α cells were used for plasmid selection 
and propagation following molecular cloning. E. coli strains BL21 Star (DE3) or Rosetta 
2 (DE3) were used for recombinant expression of proteins in bacteria. 
 
2.1.2 Site directed mutagenesis 
Mutants of gelsolin and YopO were made by QuikChange site-directed 
mutagenesis (Stratagene) following manufacturer’s instructions. All mutations were 






Table 2.1 List of constructs used for the recombinant expression of proteins 




Construct Residues Mutations Vector 
Expression 
system 
NP_783721 YopO WT 89-729 - pOPINF 
Bl21 Star 
(DE3) 






PO63961.1 Gelsolin 1-782 - pSY5 
Bl21 Rosetta 
(DE3) 































 Gelsolin PM2 1-782 S381D pSY5 
Bl21 Rosetta 
(DE3) 







* The vector was modified to include a 6×-histidine tag at the C-terminus of gene of 
interest to complement the GST-tag at the N-terminus of the gene of interest. 
 
# The vector was modified to include an 8×-histidine tag followed by a thrombin cleavage 
















































1-463 - pSY5 
Bl21 Star 
(DE3) 
NP_003361 VASP 1-380 - pSY5 
Bl21 Star 
(DE3) 
NP_057421 EVL 1-416 - pSY5 
Bl21 Star 
(DE3) 












2.2  EXPRESSION AND PURIFICATION OF RECOMBINANT  PROTEINS 
2.2.1  Purification of native Sf9 actin from insect cells 
 Sf9 cells were allowed to grow to a cell density of 0.8 – 1x107 cells per ml prior 
to harvesting. Harvested Sf9 cells were resuspended in 10 mM Na Hepes, 5 mM CaCl2, 1 
mM ATP, 50 mM KCl and protease inhibitor (Roche, 1 tablet per 50 ml) and lysed using 
a Potter-Elvehjem homogenizer. The lysate was incubated with purified protein gelsolin 
(G4-G6) overnight, followed by clarification via centrifugation at 30,000 × g for 1 hour. 
Imidazole was added to the lysate to a final concentration of 20 mM prior to applying the 
lysate to equilibrated Ni2+ sepharose beads. After incubation for 1 hour at 4 ˚C, beads 
were then washed with 10 mM Na Hepes (pH 7.6), 50 mM KCl, 1 mM ATP, 20 mM 
Imidazole followed by a second wash step with 10 mM Na Hepes (pH 7.6), 50 mM KCl, 
1 mM ATP. Actin was eluted from G4-G6 via the chelation of CaCl2, using buffer 50 
mM KCl, 10 mM Na Hepes (pH 7.6), 0.1 mM EGTA, 7 mM β-mercaptoethanol. The 
purified actin was then polymerized by the addition of 2 mM MgCl2 and 0.2 mM ATP 
and incubated for 2 hours at 4˚C followed by centrifugation at 80,000 × g for 2 hours at 4 
˚C. The supernatant was discarded and the actin pellet was allowed to depolymerize via 
dialysis into 2 mM Tris-HCl (pH 7.6), 0.2 mM ATP, 0.5 mM DTT, 0.2 mM CaCl2 over 
three days with daily buffer changes. The protein solution was then clarified via 
centrifugation for 2 hours at 16,000 × g at 4 ˚C. The yield of actin is approximately 4 






2.2.2 Expression and purification of YopO and gelsolin constructs 
Constructs of YopO, YopO mutants, gelsolin, and gelsolin mutants were 
transformed into E. coli Rosetta 2 (DE3) cells (Novagen) for gelsolin; and E.coli Bl21 
Star (DE3) for YopO, for expression according to the manufacturer’s instructions. 
Overnight cultures were prepared by growing Rosetta 2 (DE3) cells in LB media 
supplemented with 100 µg/ml ampicillin and 100 µg/ml chloramphenicol; 100 µg/ml 
ampicillin only for Bl21 Star (DE3) cells, at 37 ˚C. Fresh LB media was inoculated with 
10 ml of overnight culture per litre, and incubated with shaking at 250 rpm at 37 ˚C until 
cell density reached OD600 0.7. Protein expression was induced with 0.2 mM IPTG at 15 
oC for 16 hours for YopO constructs and 1 mM IPTG at 15 ˚C for 16 hours for gelsolin. 
The cells were harvested by centrifugation at 4900 × g at 4 ˚C for 1 hour and resuspended 
in His-binding buffer (50 mM Tris-HCl (pH 7.6), 0.5 M NaCl, 20 mM imidazole) 
supplemented with EDTA-free protease inhibitor cocktail tablet (Roche), 0.1% Triton-X 
and 0.5 mg/ml lysozyme and lysed using a French press. The cell lysate was clarified by 
centrifugation at 30 000 × g in SS-34 rotor in a RC 5C Plus centrifuge (Sorvall) at 4 °C 
followed by filtration through 0.45 µm syringe filters prior to purification. 
YopO and YopO mutants were purified using Ni-NTA affinity chromatography 
followed by tag cleavage using home-made 3C protease and subjected to size-exclusion 
chromatography. Briefly, the filtered supernatant was loaded on a HisTrap FF 1 ml (GE 
healthcare) equilibrated with 50 mM Tris-HCl (pH 7.6), 500 mM NaCl, 20 mM 
imidazole and then cleaved on-column with 3C protease overnight. The protein was then 
subjected to size exclusion chromatography (Superdex 200pg, GE Healthcare) using 10 
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mM Na Hepes (pH 7.6), 100 mM NaCl. The same procedure was followed for gelsolin 
and gelsolin mutants without the tag cleavage step.  
 
2.2.3 Expression and purification of mDia1 (FH1-FH2-DAD), mDia1 (DID-
 DD/FH3), VASP, EVL, WASP and profilin 
 The following protocol was used for the expression and purification of mDia1 
(DID-DD), VASP, EVL and profilin. These constructs were in the pSY5 vector, which 
includes an N-terminal His-tag followed by a 3C protease cleavage site. Cells were 
induced for recombinant protein expression at OD600 0.7 with    1 mM IPTG at 15 ˚C for 
16 hours for mDia1 (DID-DD); 0.2 mM IPTG at 15 ˚C for 16 hours for VASP; 1 mM 
IPTG at 15 ˚C for 16 hours for EVL; and 0.5 mM IPTG at 18 ˚C for 16 hours for profilin. 
Cells were then harvested via centrifugation at 4900 × g at 4 ˚C for 1 hr. Cell pellets were 
then resuspended in 50 mM Tris-HCl (pH 7.6), 500 mM NaCl, 20 mM imidazole, 5% 
glycerol, 0.1% Triton-X, 0.5 mg/ml lysozyme and EDTA-free protease inhibitor cocktail 
tablet (Roche). The cells were lysed via sonication and the cell lysate was clarified via 
centrifugation at 30,000 × g for 30 min and passed through a 0.45 µm syringe filter. The 
filtered supernatant was loaded on a HisTrap FF 1 ml (GE healthcare) equilibrated with 
50 mM Tris-HCl (pH 7.6), 500 mM NaCl, 20 mM imidazole and then cleaved on-column 
with 3C protease overnight. The protein was then subjected to size exclusion 
chromatography (Superdex 200pg, GE Healthcare) in 10 mM Na Hepes (pH 7.6), 100 
mM NaCl. 
 mDia1 FH1-FH2-DAD and WASP PWA, gifts from Laurent Blanchoin, were in a 
pGEX4T1-modified vector, which includes an N-terminal GST-tag followed by a 
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thrombin cleavage site. The vector was modified to include a His-tag at the C-terminus of 
the protein of interest. The following protocol was used for expression and purification of 
mDia1 FH1-FH2-DAD and WASP PWA. Cells were induced for recombinant protein 
expression at OD600 0.7 with 0.2 mM IPTG at 15 ˚C for 16 hours and harvested via 
centrifugation at 4900 × g at 4 ˚C for 1 hr. Cell pellet was then resuspended in 50 mM 
Tris-HCl (pH 7.6), 200 mM NaCl, 5% (v/v) glycerol, 0.1% Triton-X, 0.5mg/ml lysozyme 
and EDTA-free protease inhibitor cocktail tablet (Roche). The cells were lysed via 
sonication and the lysate was clarified via centrifugation at 30,000 × g for 30 min and 
passed through a 0.45 µm syringe filter. The filtered supernatant was loaded on a GSTrap 
FF 5 ml (GE healthcare) equilibrated with 50 mM Tris-HCl (pH 7.6), 200 mM NaCl, and 
then eluted with 50 mM Tris-HCl (pH 7.6), 200 mM NaCl, 100 mM reduced glutathione 
and then dialyzed into 50 mM Tris-HCl (pH 7.6), 200 mM NaCl overnight. The protein 
was then applied to HisTrap FF 1 ml (GE healthcare) equilibrated with 50 mM Tris-HCl 
(pH 7.6), 500 mM NaCl, 20 mM Imidazole and eluted with 50 mM Tris-HCl (pH 7.6), 
500 mM NaCl, 500 mM imidazole and then dialyzed into 10 mM Na Hepes (pH 7.6), 100 
mM NaCl overnight. The proteins were kept with their GST tags intact as cleavage 
removal of the GST tags prompted precipitation of mDia1 FH1-FH2-DAD and WASP 
PWA. 
 
2.3  IN VITRO [γ32P] PHOSPHORYLATION ASSAY 
 YopO WT (2 µM) was incubated with different gelsolin mutants (6 µM) and 
adjusted to a final volume of 10  µl with HBOA buffer containing 2 mM Na Hepes, pH 
7.6, 0.2 mM ATP, 0.5 mM DTT, 0.1 mM CaCl2, 1 mM NaN3. The kinase reaction was 
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initiated by the addition of an equal volume of kinase buffer containing 40 mM Na 
Hepes, pH 7.6, 2.0 mM ATP, 2 mM DTT, 20 mM MgCl2, 4 mM MnCl2, supplemented 
with 5 µCi of [γ-32P] ATP. The phosphorylation reactions were carried out for 30 min at 
30 ˚C and terminated by the addition of SDS-PAGE buffer. The samples were heated for 
5 min at 95 ˚C and subjected to SDS-PAGE followed by Coomassie Blue staining. Gels 
were destained and radioactivity in the dried SDS-PAGE gels was visualized by exposure 
to X-ray film. 
 
2.4  IN VITRO PHOSPHORYLATION OF SUBSTRATES OF YopO FOR 
 PHOSPHORYLATON SITE IDENTIFICATION BY MASS 
 SPECTROMETRY 
 Each mDia1, VASP, EVL and WASP were incubated with YopO WT, profilin 
and Sf9 actin in the molar ratio of (5:1:1:1 – substrate:YopO WT:Sf9 actin:profilin) in 
separate reactions for 30 min at 30 ˚C in 20 mM Na Hepes, pH 7.6, 1.0 mM ATP, 1 mM 
DTT, 10 mM MgCl2, 2 mM MnCl2 for the phosphorylation reaction to take place. The 
same experimental setup was followed for gelsolin, without profilin. The phosphorylated 
samples were sent to the Quantitative Proteomics Facility at IMCB, Singapore, to identify 
the phosphorylation sites.  
 
2.5  MASS SPECTROMETRY 
2.5.1  SDS-PAGE and in-gel digestion 
 The phosphorylated substrates of YopO were run on a NuPAGE 4-12% Bis-Tris 
Gel (Invitrogen). The protein bands corresponding to the phosphorylated substrates were 
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excised, and then subjected to reduction, alkylation and in-gel digestion via the following 
protocol. Gel pieces were washed with 50 µl of 50 mM ammonium bicarbonate and 
destained with 50 µl of 50% acetonitrile/25 mM ammonium bicarbonate for 10 min. 
Reduction was carried out by covering the gel pieces with 10 mM DTT for 30 min at 56 
˚C; alkylation was carried out with 55 mM iodoacetamide for 15 min in the dark at room 
temperature. 50 µl of 50 mM ammonium bicarbonate was used for washing and 50 µl of 
100% acetonitrile was used for shrinking twice for 10 min. 30 µl of 13 ng/µl sequencing-
grade trypsin (Promega) was added to each well for 30 min at 4 ˚C before 25 mM 
ammonium bicarbonate was added to cover the gel pieces. Samples were incubated for 3 
h at 37 ˚C. Supernatants containing peptides were cleared by centrifugation. 20 µl of 5% 
formic acid was added to each well followed by 20 µl of 100% acetonitrile for peptide 
extraction. Both steps were repeated. 
 
2.5.2 LC/MS analysis 
 The vacuum dried sample was reconstituted in 0.1% formic acid and analyzed 
using a nano-HPLC coupled to an LTQ Orbitrap classic (Thermo Fisher Scientific). 
Peptides were trapped onto a C18 pre-column and separated on an analytical column 
using a 4 h gradient ranging from 2 to 40% acetonitrile and 0.1% formic acid, followed 
by a 5 min gradient ranging from 40 to 80% acetonitrile and 0.1% formic acid. Survey 
full scan MS spectra (m/z 310–1400) were acquired with a resolution of r = 60,000 at m/z 
400, an AGC target of 106, and a maximum injection time of 1000 ms. The ten most 
intense peptide ions in each survey scan with an ion intensity of >2000 counts and a 
charge state ≥2 were isolated sequentially to a target value of 5000 and fragmented in the 
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linear ion trap by collision-induced dissociation using a normalized collision energy of 
35%. A dynamic exclusion was applied using a maximum exclusion list of 500 with one 
repeat count, repeat duration of 45 s and exclusion duration of 30 s.  
 
2.5.3 Data processing and database search 
 Data were processed using MaxQuant (Version 1.3.0.5) against Uniprot 2014-07 
human or mouse databases containing 262 commonly observed contaminants. Database 
searches were performed with tryptic specificity allowing a maximum of two missed 
cleavages and two labeled amino acids as well as an initial mass tolerance of 6 ppm for 
precursor ions and 0.5 Da for fragment ions. Cysteine carbamidomethylation was 
searched as a fixed modification, and N-acetylation, oxidized methionine, phosphorylated 
serine/threonine/tyrosine were searched as variable modifications. Maximum false 
discovery rates were set to 0.01 for both protein and peptide. Proteins were considered 
identified when supported by at least one unique peptide with a minimum length of seven 
amino acids. 
 
2.6  SEQUENCE ALIGNMENTS AND STRUCTURAL ANALYSIS 
 Images of protein models were generated by PYMOL 
(http://pymol.sourceforget.net). Amino acid sequence analysis between homologous 
proteins was performed using Clustal Omega (www.ebi.ac.uk/Tools/msa/clustalo/). 
Selected sequence alignments were presented using BOXSHADE server. Secondary 
structures of the protein were generated using ESPript 
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(http://espript.ibcp.fr/ESPript/ESPript/). Kinase consensus site analysis was performed 
using Phosphologo (http://helixweb.nih.gov/PhosphoLogo/). 
 
2.7  FUNCTIONAL ASSAYS ON GELSOLIN 
2.7.1 Actin depolymerization assay 
 The actin depolymerization assay was performed as described in [248]. 10% 
pyrene-labeled G-actin (12 µM) was incubated with Buffer F (50 mM KCl, 0.2 mM ATP, 
2 mM MgCl2, 0.5 mM DTT, 1 mM EGTA, and 50 mM Na Hepes, pH 7.5) in 96-well, 
flat-bottomed plates (Corning, NUNC) for 30 min to allow the formation of F-actin. 
Reactions were equilibrated for 1 h with the required calcium concentrations before 6 µM 
of the gelsolin WT or mutant proteins were added. The final volume of the reaction was 
set to 100 µl. Fluorescence intensities were measured kinetically with excitation and 
emission wavelengths of 365 nm and 407 nm respectively using a Safire2 fluorimeter 
(TECAN). 
 
2.7.2  Actin nucleation assay 
10% pyrene-labeled G-actin (2 µM) was incubated with 50 nM of respective 
gelsolin proteins for 30 min in 2 mM Na Hepes, pH 7.5, 0.2 mM ATP, 0.5 mM DTT, 0.2 
mM CaCl2 in a final volume of 90 µl in 96-well black flat-bottomed plates (Corning, 
NUNC). 10 µl of 10 Χ KMEI (500 mM KCl, 10 mM MgCl2, 10 mM EGTA, 100 mM 
imidazole-HCl, pH 7.0) was added to each reaction before measurement of the 




2.7.3  Actin co-sedimentation assay 
F-actin and gelsolin, at various molar ratios, were incubated in 50 µl of Buffer F 
(50 mM KCl, 0.2 mM ATP, 2 mM MgCl2, 0.5 mM DTT, 1 mM EGTA, and 50 mM Na 
Hepes, pH 7.5) for 30 min on ice before centrifugation for 30 min at      100,000 × g 
using a TLA120.1 rotor in Beckman Optima Max ultracentrifuge. The supernatant was 
removed and analyzed as the soluble fraction (S). The pellet was washed by addition of 
50 µl of buffer F followed by centrifugation for 30 min at 100,000 × g. The supernatant 
of the second run was discarded and the pellet resuspended in 50 µl of buffer F for 
analysis of the pellet (P) fraction. 15 µl each of the supernatant and resuspended pellet 
was analyzed by SDS-PAGE to determine if the protein of interest binds actin filaments.  
 
2.8 FUNCTIONAL ASSAYS INVOLVING IN VITRO 
 PHOSPHORYLATED PROTEINS mDia1, VASP and WASP 
2.8.1 Nucleation assay – mDia1 
 mDia1 (0.5 µM) was incubated with YopO WT or KD (0.25 µM) in the presence 
of Sf9 actin (0.25 µM) and profilin (0.5 µM) for 30 min at 30 ˚C in    20 mM Na Hepes, 
pH 7.6, 1.0 mM ATP, 1 mM DTT, 10 mM MgCl2, 2 mM MnCl2 for the phosphorylation 
reaction to take place. Phosphorylated mDia1 was added to the actin polymerization 
reaction containing 2 µM α-actin (10% pyrene-labeled) and 2.8 µM profilin. mDia1, 
YopO WT and YopO KD are present in the reaction at final concentrations of 0.05 µM, 
0.025 µM and 0.025 µM, respectively. The same experimental setup was followed for 
testing mDia1 (FH1-FH2-DAD) – (DID-DD) interactions with an addition of 60 nM DID 
that inhibits the nucleation activity of WT mDia1 (FH1-FH2-DAD). 
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2.8.2 Co-sedimentation assay - VASP 
VASP (10 µM) was mixed with YopO WT or YopO KD (5 µM) in the presence 
of Sf9 actin (5 µM) and incubated for 30 min at 30 ˚C in 20 mM Na Hepes, pH 7.6, 1.0 
mM ATP, 1 mM DTT, 10 mM MgCl2, 2 mM MnCl2 to allow phosphorylation to take 
place. The YopO-phosphorylated VASP was then added to 4 µM of pre-formed F-actin in 
a 100 µl reaction and incubated for 1 h prior to centrifugation at 100,000 × g using a 
TLA120.1 rotor in Beckman Optima Max ultracentrifuge. The supernatant was removed 
and analyzed as the soluble fraction (S). The pellet was washed by addition of 50 µl of 
buffer F followed by centrifugation for 30 min at 100,000 × g. The supernatant of the 
second run was discarded and the pellet resuspended in 50 µl of buffer F for analysis of 
the pellet (P). 15 µl each of the supernatant and resuspended pellet was analyzed by SDS-
PAGE to determine whether the protein of interest binds to actin filaments. VASP, YopO 
WT and YopO KD are present at final concentrations of 1 µM, 0.5 µM and 0.5 µM, 
respectively. 
 
2.8.3  ARP2/3 activation assay - WASP 
WASP (40 µM) was mixed with YopO WT or YopO KD (15 µM) in the presence 
of Sf9 actin (15 µM) and incubated for 30 min at 30 ˚C in 20 mM Na Hepes, pH 7.6, 1.0 
mM ATP, 1 mM DTT, 10 mM MgCl2, 2 mM MnCl2 to allow phosphorylation to take 
place. Phosphorylated WASP was added to the actin polymerization reaction containing 1 
µM α-actin (10% pyrene-labeled), 1.4 µM profilin and 10 nM ARP2/3. 10 µl of 10 Χ 
KMEI was added to each reaction before measurement of the fluorescence intensity at 
407 nm with a Safire2 fluorimeter (TECAN). WASP, YopO WT and YopO KD were 
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present in the reaction at final concentrations of 0.4 µM, 0.15 µM and 0.15 µM, 
respectively. 
2.9  PREPARATION OF THE YopO-ACTIN COMPLEX 
 A Surface Entropy Reduction (SER) version of YopO, YopO SER mutant 
(K205Y, E206Y, E207Y, K440Y, and K441Y), was used for the crystals, as wild type 
crystals had poor crystal diffraction (Lee et al. [210]). YopO SER mutant was mixed with 
Sf9 actin at a molar ratio of 1:1.5 then purified by size exclusion chromatography 
(Superdex 200pg) at 4 ˚C in 10 mM Na Hepes (pH 7.6), 50 mM NaCl. Column fractions 
containing YopO-actin complex as analyzed by SDS-PAGE were pooled and dialyzed 
into 2 mM Tris-HCl (pH 7.6), 0.2 mM ATP, 0.5 mM DTT, 0.2 mM CaCl2 at 4 ˚C 
overnight and then concentrated to 10 mg/ml.  
 
2.10  CRYSTALLIZATION OF YopO-ACTIN IN COMPLEX WITH Mg2+ AND 
 ATP 
 Crystallization plates were set up using the sitting-drop vapor-diffusion method 
by mixing 500 nl of YopO-actin complex (10 mg/ml) with 500 nl of the reservoir 
solution containing 0.1 M Na Hepes (pH 7.5), 30% PEG 400, 0.2 M NaCl and incubated 
at 4 ˚C. YopO-actin crystals appeared in one week. Harvested crystals were soaked in 0.1 
M Na Hepes, pH 7.5, 30% PEG 400, 0.2 M NaCl, 5 mM MgCl2, 5 mM ATP, 25 % 





2.11 X-RAY DATA COLLECTION OF CRYSTALS SOAKED IN Mg2+ AND 
 ATP 
 X-ray diffraction data for YopO-actin: MgATP crystals were collected at the 
National Synchrotron Radiation Research Center, Taiwan (NSRRC). At the NSRRC, data 
were recorded using an Area Detection Systems Corporation Quantum 315 CCD detector 
ADSC Q315 3x3 CCD detector on beamline BL13B1. The wavelength was set to 1 Å 
and the data collected with the crystal maitained at 105 K. Each image covered an 
oscillation of 1˚ and exposure times were 45 seconds. 
  
2.12 STRUCTURE DETERMINATION, MODEL BUILDING AND 
 REFINEMENT OF YopO - ACTIN: MgATP 
  The YopO-actin complex structure (Lee et al. [210]) without the solvent 
molecules was used as the starting model to refine against the diffraction data obtained 
from the crystals of YopO-actin complexed with Mg2+ and ATP. Various crystallographic 
software were employed in the structure determination process that include HKL 2000 
suite [249], CCP4 program [250], PHENIX [251] and COOT [252]. Crystallographic data 
were indexed, integrated and scaled using     the HKL-2000 suite of software [249]. Free 
R flags were copied from the Yopo-actin apo dataset (Lee et al. [210]) using program 
Freerflags as part of CCP4 suite of crystallographic programs [250]. Solvent content 
analysis suggests 63.1% solvent and a Matthew’s coefficient (Vm) of 3.33 Å
3/Da. This is 
consistent with the presence of two complexes in the asymmetric unit. Molecular 
replacement was performed using Phaser as part of the PHENIX suite of crystallographic 
programs [251], using the Yopo-actin apo dataset as a search model for molecular 
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replacement. Restrained positional and B-factor refinement were performed using 
Phenix.refine [253] with the apo structure of YopO:actin as a reference model. Loops 
were built with the use of Phenix fit_loops [254]. Manual building was performed using 
graphics program COOT [252]. MolProbity present in PHENIX and validation tools in 
COOT were used to assess the quality of the model in the refinement of the structure. The 
metal-binding sites were assessed with CheckMyMetal web server [255]. After several 
rounds of refinement by the program Phaser [256] of the PHENIX suite, the final 
structure was obtained with Rwork/Rfree of 0.019/0.024,  in which MgADP was modeled 
in using LigandFit within PHENIX suite and the CheckMyMetal server [255]. 
 
2.13 MOLECULAR DYNAMICS SIMULATION 
 We carried out 0.3 microsecond long MD simulations of WT and pho-gelsolin. In 
case of pho-gelsolin, S381, S384 and S385 were phosphorylated. Before starting the MD 
simulation, gelsolin was centered and solvated in (7 nm) 3 cubic box using TIP3P water 
model, and with 150 mM KCl to simulate the cytosol environment. Sufficient numbers of 
potassium ions was added to neutralize the system. Then energy minimization was 
performed in Gromacs 4.6 [257] using the all-atom CHARMM 36 force field [258] 
utilizing steepest descent algorithm which allows fast convergence to the local energy 
minima. Next the equilibration of the system was performed in two steps: 100 ps 
canonical ensemble (NVT) and 100 ps isothermal-isobaric ensemble (NPT) simulation 
with harmonic restraints (force constant: 1 kJmol-1K-1) applied to the backbone atoms of 
the protein. Further the production MD runs were carried out for 0.3 µs with the NPT 
ensemble without any restraints. 
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 During all simulations a 2 fs integration time step was used. The temperature was 
maintained at 310 K with the V-rescale algorithm [259] and the pressure was coupled at 1 
bar by isotropic pressure coupling utilizing the Parrinello-Rahman algorithm (time 
constant 2 ps, isothermal compressibility of water: 4.5 x 10-5 bar-1) [260]. Long-range 
electrostatics was calculated by fourth order particle mesh Ewald (PME) algorithm [261]. 
All bonds were constrained using a fourth order P-LINCS algorithm [262]. Electrostatic 
and van der Waal's interactions were cut-off at 1 nm and a dispersion correction was 
applied to account for it. Periodic boundary conditions were implemented in three 
dimensions. Initial atomic velocities, prior to NVT equilibration, were obtained from 
Maxwell's distribution at 310 K. Water molecules were constrained by SETTLE [263]. 
Neighbor lists for nonbonded interactions were updated at every 20th step using Verlet 
cut-off scheme utilizing NVIDIA 970 GPU. 
 Trajectories were analyzed by Gromacs tools, Pymol, VMD [264]. In-house bash 













STRUCTURE OF THE YopO-ACTIN IN COMPLEX WITH  
Mg2+ AND ATP 
 
3.1  PREPARATION AND CRYSTALLIZATION OF YopO SER  MUTANT: 
 Sf9 ACTIN COMPLEX  
 Given that constructs of YopO are more soluble in the absence of the membrane 
localization domain (1-88) [197] and the actin-binding sites are located within both the 
kinase domain (89-440) and the GDI domain (441-729), residues 89-729, encompassing 
the kinase domain and the GDI domain represents the standard construct used in this 
study. YopO SER mutant (89-729), from Yersinia enterocolitica, was recombinantly 
expressed with an N-terminal His-tag in E. coli and purified via Ni2+ affinity resin with 
on-column tag cleavage by 3C protease, followed by size exclusion chromatography, as 
described in section 2.2.2. Sf9 actin from Sf9 cells was purified using gelsolin domains 4-
6 following a published protocol [265], described in section 2.2.1. The complex of YopO 
and actin was prepared by mixing YopO with Sf9 actin at a molar ratio of 1:1.5 followed 
























Figure 3.1 Preparation of the YopO-actin complex. A. The elution profile 
(A280) from size exclusion chromatography using a Superdex 200pg 
column with the peaks corresponding to fractions containing the YopO-
actin complex and excess actin. B. SDS-PAGE gel of selected fractions, 
named according to the elution profile in (A). 
 
3.2  CRYSTALLIZATION TRIALS AND DATA COLLECTION OF THE 
 YopO-ACTIN COMPLEX 
 YopO SER mutant – Sf9 actin complexes were prepared and crystallized 
according to Lee et al. [210] as described in section 3.1. The YopO-actin complex was 





˚C overnight and then concentrated to approximately 10 mg/ml and 
crystallization trials were set up as sitting drops, consisting of a 1:1 (v/v) mixture of 
protein solution with 0.1 M Na Hepes (pH 7.5), 30% PEG 400 and 0.2 M NaCl well 
solution. Microseeding was used to improve crystal size and morphology [266]. Crystals 









Figure 3.2 Crystal hits obtained for YopO SER mutant with Sf9 actin. 
 
 The diffraction measurements were carried out at Diamond Light Source, UK. 
The datasets were collected on I03 beam at a wavelength of 0.97626 Å using an Pilatus3 
6M detector. The X-ray beam was collimated with beam slits to 10 X 10 µm. Each 
dataset was collected with an exposure time of 0.010s and 2700 frames were recorded 
with an oscillation of 0.1˚. 
 
 
0.1 M Na Hepes, pH 7.5, 30 % PEG 400, 0.2 M 
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3.3  STRUCTURE OF THE YopO-ACTIN IN COMPLEX WITH Mg2+ AND 
 ATP 
 The YopO-actin MgATP structure was solved by molecular replacement using 
Phaser [256] using the apo Yopo-actin structure as a search model. The obtained solution 
was subjected to restrained refinement using Phenix.refine and yielded an Rfree of 0.245. 
Inspection of the resultant electron density map revealed that YopO residues 135-138, 
143-144, 151-155, 162-167 and 313-314 which were previously disordered in the apo 
structure, are now ordered. Phenix fit_loops program was used to build loops into the 
density to connect the existing chain ends. Multiple rounds of refinement using 
Phenix.refine and manual rebuilding using COOT were performed to improve the 
structure of the P-loop. Restrained positional and B-factor refinement were performed 
with the apo structure as a reference model using Phenix [253]. 
 A positive electron density was also observed at the kinase active site where the 
ligand ATP was expected to bind. The program Phenix LigandFit was used to fit in the 
ATP at the active site of the kinase. The resultant model was subjected to refinement and 
the third phosphate group of ATP was found to have an exceptionally high B factor of 
123 Å2 as compared to that of the first and second phosphate groups with B factors of 50 
Å2  and 55 Å2 respectively. The presence of an ATP would leave no space in the electron 
density for coordination of a Mg2+. ADP was then used to fit in the electron density map. 
Scores from LigandFit were lower for ADP; however, ADP with Mg2+ gave a better fit to 





Table 3.1 Correlation coefficient and scores obtained through LigandFit 
  









Figure 3.3 Difference map with Fourier coefficients Fo-Fc and phases 
from refined model where ADP and Mg2+ have been omitted from 
calculation. The mesh map object was created using PyMol, where the 
map was contoured at 3.0 sigma and within 3 Å of the Mg-ADP molecule. 
The magnesium ion is represented as a sphere in lime and ADP is 
represented as sticks. The residues of the YopO’s kinase domain involved 
in interaction with ADP/Mg are shown as sticks. 
 
 After fitting in one ADP and one Mg2+ per complex of the asymmetric unit, the 
model was again subjected to several rounds of refinement. Lastly, water molecules were 
added to the active site where positive density was present. The model was then subjected 
to further rounds of refinement. The metal-binding sites were assessed with the 
CheckMyMetal web server [255] and the results are tabulated in Table 3.2. Two 
molecules of YopO-actin: Mg-ADP complexes are found in the asymmetric unit. 
 ATP ADP 
Score 111.13 100.78 
Overall CC 0.904 0.871 
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However, the electron density for the ligand and co-ordinated waters are clearer for one 
complex and thus statistics differ between the two Mg2+ ions. 
 
Table 3.2 Assessment of Mg2+ ion binding in the YopO-actin:MgADP 
complex by the CheckMyMetal server 
 
Metal Occupancy B factor Ligands Valence Geometry Vacancy gRMSD(°) 
Mg2+ 1 63.2(49.1) O6 2.2 Octahedral 0 10.1° 
Mg2+ 1 41.2(57.2) O4 1.1 Octahedral 33% 14.7° 
 
 Valence - Accounts for metal-ligand distances 
 Vacancy - Percentage of unoccupied sites in the coordination sphere 
gRMSD(°) - R.M.S. Deviation of observed geometry angles (L-M-L angles) 











Figure 3.4 Metal binding site of YopO kinase showing the metal-ligand 
distances for the Mg2+ ion that co-ordinates six oxygens, as generated by 
CheckMyMetal server. Oxygen atoms of N272 and β- phosphate group of 
ADP represent the apical O.  Rest of the interactions occur on the 
equatorial plane. Mg2+ is represented as a sphere in lime. ADP is shown as 
orange and red sticks. The water molecules and other residues of YopO 




 Table 3.3 Unit cell and space group for apo and YopO-actin: 
 MgADP structures 
 
 Apo MgADP 
Space group P21 P21 
Unit cell 
 (a,b,c)(Å) 
(α, β, γ) (o) 
 




α=90.00, β=104.88, γ=90 





1 complex with 63.5% 
solvent 
2 complexes with 63.1% 
solvent 
 
The structure was refined to an overall Rwork of 0.196 and Rfree value of 0.240 and the 

















Table 3.4 Data collection, processing and refinement statistics for  
 the YopO-actin:MgADP complex 
 
Unit-cell parameters  
a, b, c (Å) 
β (°) 
108.73, 121.75, 118.58 
104.9 
Space group  P21 
Molecules in the asymmetric unit 2 
Data collection  
Wavelength (Å) 0.9763 
Resolution (Å) 114.60-2.93 (2.97-2.93) a 
Rmerge 0.125 (0.778) 
I/σ(I) 11.9 (2.7) 
Completeness (%) 99.9 (99.8) 
Unique reflections 64,212 
Redundancy 6.8 (6.6) 
Refinement  
No. of atoms: (protein/ligand/water) 14992/120/9 
Rwork / Rfree (%) 19.6/24.0 
Average B-factors (Å2) 69.3 
RMSD bond lengths (Å) 0.006 
RMSD bond angles (o) 1.272 
Ramachandran plot  
Most preferred regions (%) 97.3 
Allowed regions (%) 2.59 












3.4  DISCUSSION 
3.4.1 Kinase domain is more ordered in the YopO-actin:MgADP structure upon 
Mg2+ and ADP binding 
 The YopO-actin: MgADP structure obtained shares high similarity with the 
structure of the YopO: actin complex on its own as shown in the Fig. 3.5A. Briefly, the 
structure reveals that, the GDI domain and the kinase domain sandwich subdomain 4 and 
part of subdomain 2 of actin (Fig. 3.5A). The kinase domain is very similar to other 
eukaryotic kinases with a N-lobe consisting of β-sheets and one single α-helix (αC helix) 
and a C-lobe comprising an α-helical bundle. The catalytic cleft bound to ADP lies in 
between the kinase domain and GDI domain (Fig. 3.5A). The C-lobe of the kinase 
domain interacts extensively with actin, while the N-lobe and the catalytic cleft do not 
interact with actin. These interactions place the catalytic loop and the activation segment 
for kinase activity in such a way that it can only phosphorylate substrates that are inserted 
between the kinase domain and the GDI domain.  
The P-loop of the kinase domain (135-144) is disordered in the apo structure. 
However, the residues 135-138 and 143-144 of the P-loop interact with the phosphate 
groups of ADP and attain an ordered conformation in YopO-actin: MgADP structure 
(Fig. 3.5B, C). The other residues of the kinase domain 151-155, 162-167, 313-314 
which were previously reported to be disordered in the apo structure were also structured 
upon MgADP binding. The ordered residues 313-314 lie in close proximity to the 
activation segment. Thus, ADP binding helps to allosterically stabilize the catalytic cleft 
of YopO kinase via its interactions with P-loop and its surrounding residues. However, 
residues 510-529 of the GDI domain remain disordered in both the active and inactive 
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structures. This is consistent with the previously reported structure for GDI domain in 
complex with Rac (PDB: 2H7V [193]) where this region was also shown to be 
disordered. A close up view of the active site of the kinase domain of YopO in its apo 
and MgADP-bound forms is shown in the figure 3.6. The secondary structure alignment 
of the apo and MgADP YopO: actin structures and the sequence alignment of Yops from 
different Yersinia spp. are shown in the figure 3.7. 
  The crystals of YopO: actin were soaked in ATP, however the resultant crystal 
structure had electron density to accommodate ADP, instead of ATP. This resulted from 





































Figure 3.5 Crystal structure of the complex of the YopO-actin:Mg-ADP. 
A. The superimposed crystal structures of the apo and MgADP bound 
YopO:actin complexes. The domains are labeled according to their 
respective colors. B. The crystal structure of the kinase domain of the apo 
form of the YopO-actin complex. The disordered loops are indicated with 





YopO-actin: MgADP complex showing the bound ADP and Mg ion. The 
loops, which were disordered in the apo form and were ordered in the 






























Figure 3.6 Structure of the kinase domain of YopO in the apo and 
MgADP-bound states. YopO kinase domain – Apo (green) and Mg-ADP 
(grey). The catalytic loop (blue) contains catalytic residues Asp-X-Lys of 
which Asp267 and Lys269 are shown in sticks. Conserved residues 
Lys160 and Glu173 that coordinate ADP are shown. The P-loop (orange) 
in the MgADP bound form coordinates the phosphates of ADP. An 
























Figure 3.7 Secondary structure alignments of the apo and MgADP bound 
structures of the YopO-actin complex shown alongside the sequence 
alignment of the kinase and GDI domains of YopO from different species 
of Yersinia. The P-loop region showing the secondary structural 
differences between the apo and Mg-ADP bound forms is marked with a 
rectangular box. Residues marked with solid blue and yellow squares are 






3.4.2  Analysis of the active site of YopO kinase 
 Protein kinases are ATP-dependent enzymes that transfer the γ- phosphoryl group 
from ATP to the hydroxyls of Ser/Thr/Tyr. They require a divalent cation, usually Mg2+, 
which facilitates the phosphate transfer. The phosphoryl transfer mechanism involves a 
series of conformational changes at the active site of kinases. The amino acids present at 
the active sites of kinases are highly conserved across kingdoms and are responsible for 
catalysis. Although, our crystal structure accommodates ADP instead of ATP due to 
hydrolysis, the active site of the kinase domain of YopO with ATP is described here, that 
is physiologically relevant and will help in understanding the catalytic mechanism behind 
the phosphorylation of its substrates. ATP promotes the phosphotransfer to the hydroxyl 
group of the serine by an in-line attack of the lone pair of electrons of the serine on the 
phosphate group of ATP. In the catalytic cleft, the strictly conserved catalytic residue 
Asp286 from the DFG motif co-ordinates the Mg2+ ion, Asp267 acts as a proton acceptor 
and Lys269 helps in stabilizing of the transition state. In the YopO KD mutant, the 
replacement of Asp267 and Lys269 with alanine completely abolishes the kinase activity 
of YopO indicating the importance of these residues in the stabilization of the substrate 

























Figure 3.8 Schematic representation of the mechanism of phosphate 
transfer to the substrate at the active site of the kinase domain of YopO 
with bound ATP. Asp286 co-ordinates Mg2+ ions and stabilizes the ATP 
molecule in position by interactions with the phosphate molecules of ATP. 
Asp267 and Lys269 in the catalytic site helps in stabilization of the 






3.4.3  Structural comparison of kinase domains of YopO and PAK1 and their 
 interactions with ATP/ADP 
 In order to obtain structural understanding of the catalytic cleft of YopO kinase, a 
structural comparison was made between YopO and PAK1 kinase. Human p21 activated 
kinase 1 (PAK1) was identified as the closest homolog of YopO in a DALI search with a 
high z score of 23.6 (Fig. 3.9). The catalytic cleft of these kinases reveal that the 
adenosine moiety of ADP/ATP is buried in a hydrophobic pocket (Met211, Val214, 
Val274, Val283, Ile285 in YopO and Met344, Tyr346, Leu347, Leu396, Val328 in 
PAK1) while the phosphate groups of ADP/ATP are oriented outwards that make 
interactions with the conserved Asp of the DFG motif, Asp286 in YopO and Asp407 in 
PAK1 (Fig 3.10). In PAK1, the interaction between Arg299 and Glu355 serves as a 
switch between the active and inactive states of the kinase. In the inactive state, Glu355 
of PAK1 forms an ion-pair with Arg299, which is disturbed upon ADP binding leading to 
activation of the kinase. However, in YopO, Glu173 and Lys160 lie at equidistant 
positions in both the active and inactive forms suggesting that the electrostatic interaction 






Figure 3.9 Structure similarity search using DALI server for YopO kinase showing 




















Figure 3.10 Structural comparison of the catalytic clefts of YopO and 
PAK1. ADP in top panel (A) and ATP in bottom panel (B) are represented 
as sticks. The residues of YopO and PAK1 that co-ordinate ADP/ATP 
respectively are also represented as sticks. Mg ions are shown as spheres 







3.4.4  Electrostatic surface potential varies greatly among the closely related 
 kinases - a determinant for substrate selection 
 Although thousands of kinases possess conserved catalytic residues, they 
generally have very specific substrate specificities. This characteristic property is 
conferred by residues around the active site of the kinases that assist in recognizing their 
true substrates. The substrate specificity of kinases is conferred by factors like the charge, 
hydrophobicity and contours of the surface residues. Surface residues target substrates for 
phosphorylation by charge complementarities and increase the local substrate 
concentration available for phosphorylation. The distribution of these surface residues 
can be visualized by representing the electrostatic surface potential with the negatively 
charged residues shown in red and the positively charged in blue. 
  A comparison of the electrostatic surface potentials of YopO with homologous 
kinases is shown in the figure 3.11. Analysis of the region around the catalytic cleft 
shows a vast difference in the charge distribution of the surface residues that determines 



























Figure 3.11 Electrostatic surface representations of YopO and its closely 
related kinases. The electrostatic surface representations of YopO, PAK1 
(PDB: 3Q53 [267]), MAPK11 (PDB: 3GP0 Filippakopoulos et al. 
(unpublished)) and SOK1 (PDB: 3GGF [268]) generated using ABPS 
tools.The surface electrostatic potential is represented as a color ramp, 
ranging from -5 kcal/e.u. (red) to +5 kcal/e.u. (blue). The positive charge 
is represented as blue and negative charge in red. The ATP binding cleft is 









3.5  CONCLUSION 
 In this chapter, the YopO-actin complex was successfully crystallized and the 
crystals were soaked with MgATP to obtain the structure of YopO bound to active site 
cofactors. The ATP molecule was hydrolyzed during the course of crystallization, which 
resulted in the structure bound to ADP. The asymmetric unit contained 2 molecules of the 
complex in comparison with the apo form, which possesses one.  Structural analysis 
reveals that the YopO-actin: MgADP structure is similar to the apo form in its binding to 
actin. However the kinase domain, which was previously reported to be disordered at 
many regions including the P-loop, became relatively ordered upon Mg2+ and ADP 
binding. The roles of the catalytic residue Asp284, Asp267 and Lys269 found at the 
active site of the kinase are consistent with the standard mechanism for phosphorylation 
by native eukaryotic kinases. Therefore, the structure confirms that the catalytic 














PHOSPHORYLATION OF GELSOLIN BY YopO 
 
4.1  PREPARATION OF PHOSPHORYLATED GELSOLIN FOR MASS 
 SPECTROMETRY 
 Lee et al. [210] had identified gelsolin as a novel substrate of YopO. The full-
length human cytoplasmic gelsolin was recombinantly expressed with an N-terminal His-
tag in Rosetta DE3 cells and purified via Ni2+ affinity chromatography followed by size 
exclusion chromatography. The gel filtration profile of the full length human cytoplasmic 
gelsolin (1-755) on a Superdex 200pg column shows that gelsolin elutes as a monomer 
corresponding to a molecular weight of ~ 80 kDa as a symmetric peak as shown in the 
figure 4.1A. 
            







Figure 4.1 Preparation of phosphorylated gelsolin for mass spectrometry. 
A. The elution profile (A280) of the full length human cytoplasmic 
gelsolin from size exclusion chromatography using a Superdex 200pg 
column showing a symmetric peak indicating the homogeneity of the 




recombinantly purified gelsolin, YopO and Sf9 actin. The band 
corresponding to gelsolin is marked with black box and was excised from 
SDS-PAGE for MS analysis.  
 
 In an attempt to identify phosphorylation sites of YopO on gelsolin, purified 
gelsolin was phosphorylated in vitro in the presence of YopO and actin. The 
phosphorylation mix containing YopO, gelsolin and actin were further separated by SDS-
PAGE (Fig. 4.1B).  
 
4.2  IDENTIFICATION OF THE PHOSPHORYLATED SITES BY MASS 
 SPECTROMETRY 
 Phosphorylated gelsolin was analyzed using mass spectrometry by the 
Quantitative Proteomics Facility at IMCB. Briefly, the gelsolin band marked with a 
rectangular box in Fig. 4.1B was excised from SDS-PAGE followed by in gel digestion, 
reduction, alkylation and peptide extraction. The vacuum dried samples were analyzed on 
nano-HPLC and data were processed using MaxQuant.  
 The phosphorylation sites identified include Ser381, Ser384 and Ser385, which 
were detected in phosphopeptides with spectral counts of 4, 9 and 2 respectively. Two 
other phosphorylation sites Ser403 and Thr404 were detected in phosphopeptides with a 
spectral count of 1. 
  Among the phosphorylation sites detected by mass spectrometry, biological 
validation was carried out for phosphorylation sites located on phosphopeptides with 
spectral count greater than 1 as this indicates high abundance of the identified 
phosphopeptides, and hence more likely a true substrate of YopO. The results obtained 
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from MaxQuant showing the various phosphopeptides with their respective 
phosphorylation sites and spectral counts are tabulated in Table 4.1. 
 
Table 4.1 Mass spectrometry results for the phosphorylated gelsolin 
   




















Modified Sequence window Spectral 
count 
Gelsolin 381 1 _DPDQTDGLGL(pS)YLSSHIANVER_ 4 
Gelsolin 384 1 _DPDQTDGLGLSYL(pS)SSHIANVER_ 9 
Gelsolin 385 1 _DPDQTDGLGLSYLS(pS)HIANVER_ 2 













































Figure 4.2 ESI-MS spectrum of the phosphorylated gelsolin peptides. 
ESI-MS spectrum of the phosphorylated gelsolin peptides with 
phosphorylation sites identified at Ser381, Ser384 and Ser385 as indicated 







4.3  VALIDATION OF THE PHOSPHORYLATED SITES BY IN 
 VITRO [γ32P] PHOSPHORYLATION ASSAY  
Mass spectrometry identified peptides with phosphorylated serine residues at 
positions 381 or 384 or 385. These identified phosphorylation sites S381, S384 and S385 
lie in the linker region between G3 and G4 of gelsolin (Fig. 4.3). Since the three serine 
residues lie in close proximity to each other in the linker region S381YLS384S385, 
proteomics data could not differentiate the level of phosphorylation at each site. Thus, the 
phosphorylated sites were validated in vitro by a radioactive [γ32P] assay using phospho-
deletion mutants in which serine residues were mutated to alanine by site directed 
mutagenesis. 
 Four mutants were generated, three of which, DM1, DM2 and DM3 each contain 
a double mutation where two of the putative phosphorylation sites were mutated to 
alanine, and the fourth, TM which has all three putative phosphorylation sites mutated to 
alanine. All of these mutants were expressed and purified. The list of the phosphor-






Figure 4.3 Domain architecture of human cytoplasmic gelsolin with 
identified phosphorylation sites. The linker region between gelsolin 





Table 4.2 List of gelsolin phosphor-deletion mutants used in the 
radioactive assays and their corresponding band intensities upon 








Relative density of 
the phosphorylated 
protein band 
measured by  
Image J 
DM1 AYLAS 72.2 
DM2 SYLAA 59.5 
DM3 AYLSA 53.8 
TM AYLAA 51.6 
WT 
S381YLS384S385 
No mutation 72.6 
 
 In the presence of Sf9 actin, YopO phosphorylates wild type gelsolin (WT) and 
this phosphorylation is remarkably reduced for the mutants TM and DM3, followed by 
DM2 and only a slight attenuation was observed for the mutant DM1 compared to the 









Figure 4.4 In vitro phosphorylation assays for gelsolin mutants by YopO 
kinase. YopO WT (2 µM) was incubated with different gelsolin mutants 
(12 µM) in the presence of [γ32P] ATP and kinase buffer. Proteins were 
separated on SDS-PAGE and visualized by Coomassie Blue staining 




The gelsolin deletion mutants were ranked according to the reduction in the amount 
of [γ32P] incorporation. Among the mutants, TM (A381YLA384A385), the triple mutant had 
the least phosphorylation with band density of 51.6 and is comparable to DM3 
(A381YLS384A385), which has a band density of 53.8. Both possess mutations at positions 
381 and 385, indicating that YopO readily phosphorylates these residues in WT gelsolin. 
The mutant DM2 (S381YLA384A385) showed a significant reduction in phosphorylation 
(band density: 59.5), while DM1 (A381YLA384S385) had only a slight attenuation (band 
density: 72.2). Thus, it can be concluded that Ser385 is the most important residue, 
followed by Ser381, with Ser384 being the least important. Collectively, the results show 
that Ser385 is the most favoured phosphorylation site as compared to Ser381 and Ser384, 
which is evident from the reduction in incorporation of radioactivity observed for the 
mutants TM and DM3.  
 
4.4  EFFECT OF PHOSPHORYLATED GELSOLIN ON ACTIN  DYNAMICS 
 The phosphorylation sites identified in gelsolin were present in the linker region 
connecting gelsolin domains G3 and G4. Upon Ca2+ activation, a series of 
rearrangements of gelsolin domains take place, which in turn trigger the linker between 
G3-G4 to adopt an extended conformation that enables G4-G6 to reach across the 
filament to bind to the other strand to G1-G3, resulting in two actins bound per one 
molecule of gelsolin (Fig. 1.8B). This leads to the hypothesis that phosphorylation at the 
linker region could affect the interaction of gelsolin with actin. Various aspects of the 
interaction of gelsolin with actin were investigated, namely: nucleation of F-actin, 
depolymerization of F-actin and F-actin binding activity of gelsolin with the use of 
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phosphomimetic mutants of gelsolin. Phosphomimetic mutants of gelsolin used in the 
assays include PM1, PM2, PM3, PM4 and PM5 where the serine residues on the linker 
region that undergo phosphorylation were mutated to aspartic acids to mimic the 
phosphorylated state. These mutants were designed based on the degree of 
phosphorylation of the three serine residues validated in the radioactive [γ32P] assay. The 
list of phosphomimetic mutants and their corresponding mutations are given in Table 4.3. 
 




4.4.1 Phosphomimetic mutant mimics gelsolin wild type at high calcium 
 concentrations 
 The behavior of the phosphomimetic mutants and WT gelsolin at high Ca2+ levels 
were assessed by depolymerization and co-sedimentation assays in the presence of 1.0 
mM CaCl2. In the depolymerization assay, the polymerized pyrene-labeled actin 
filaments give a higher fluorescence output compared to the pyrene-labeled monomeric 
G-actin. Therefore during severing/depolymerization, the conversion of filamentous F-










actin into monomeric G-actin results in a loss of fluorescence of the pyrene-labeled actin 
filaments. The results of the depolymerization assay show that both WT and 
phosphomimetic mutants of gelsolin exhibit the same depolymerizing kinetics (Fig. 4.5), 












Figure 4.5 Actin depolymerization assay on gelsolin phosphomimetic 
mutants at high Ca2+ concentrations. Polymerized F-actin (12 µM) was 
incubated with different gelsolin mutants (6 µM) in the molar ratio of 2:1 
at a calcium concentration of 1.0 mM. Phosphomimetic mutants and WT 
depolymerize actin filaments to a similar extent. 
 
 This was further confirmed by the co-sedimentation assay, in which F-actin was 
incubated with the gelsolin phosphomimetic mutant PM5 and WT for 1 h followed by 
high speed centrifugation to separate G-actin from F-actin. The relative proportions of G- 
and F-actin provide readout for the severing activity of gelsolin. In other words, this 
assay helps to estimate the amount of pelletable actin present in the reaction that 
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correlates with the actin filament depolymerizing activity of gelsolin. The results agreed 
with those obtained for the depolymerization assay at high Ca2+ levels, confirming the 
identical behavior of the mutant PM5 (S381D/S384D/S385D) with WT, suggesting that 
these mutations do not confer any difference to the activity of gelsolin at saturating 
calcium levels (> 1µM) (Fig. 4.7B). 
 
4.4.2 Phosphorylated gelsolin is more active at severing actin filaments in 
 calcium free conditions 
 The F-actin binding and severing activity of the phosphomimetic mutants in Ca2+-
free conditions i.e. in the presence of EGTA was studied by depolymerization and co-
sedimentation assays respectively. 
 In the depolymerization assay, depolymerization of F-actin in the   presence of 1.5 
mM EGTA was monitored by the loss of fluorescence of pyrene labeled F-actin in the 
presence of wild type and phosphomimetic mutants (Fig. 4.6). Single mutants PM2 
(S381D), PM3 (S385D) and PM4 (S384D) and the double mutant PM1 (S381D/S385D) 
showed slightly more depolymerization than gelsolin WT, whereas the triple 
phosphomimetic mutant PM5 (S381D/S384D/S385D) was significantly more active at 
depolymerization compared to the wild type. These data suggest that mutation of the 
















Figure 4.6 Actin depolymerization assay on gelsolin phosphomimetic 
mutants in EGTA conditions. Polymerized F-actin (12 µM) was incubated 
with different gelsolin mutants (6 µM) in 1.5 mM EGTA. The loss of 
pyrenyl fluorescence was measured. In this condition, mutant the triple 
mutant PM5 is more active in severing the actin filaments compared to 
WT and the other mutants. 
 
 The activity of the phosphomimetic mutants of gelsolin in EGTA conditions was 
further validated using the co-sedimentation assay. The assay was performed using the 
WT and the triple phosphomimetic mutant (PM5) with increasing concentrations of 
gelsolin from 0.1 to 0.3 µM against a constant concentration of preformed F-actin (4 
µM). 
 In the presence of 1.5 mM EGTA, WT gelsolin did not significantly co-sediment 
with actin, however a slight decrease in proportion of F-actin was detected, due to the 
residual activity of gelsolin (Fig. 4.7A). A remarkable decrease in the pelletable actin 
fraction (P) and a corresponding increase of G-actin in the supernatant (S) was observed 
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for the mutant PM5 (S381D/S384D/S385D) compared to the wild type across the tested 
concentrations of gelsolin (Fig. 4.7A). 
 
Figure 4.7 Co-sedimentation assays on gelsolin and the phosphomimetic 
mutant PM5. 4 µM F-actin was incubated with different concentrations of 
gelsolin or PM5 (0-0.3 µM) for 1 h at room temperature and subjected to 
ultracentrifugation (352,000 × g, 1 h), and the supernatants (S) and the 
pellets (P) were analyzed by SDS-PAGE. A. EGTA condition - 1.5 mM B. 
Calcium condition - 1 mM). The SDS-PAGE band densities were 
quantified using IMAGE J and the results were represented as graphs. C. 
The percentages of actin in the pellet fractions were plotted as a function 
of the total concentration of gelsolin in the presence and absence of 
EGTA. D. The percentages of actin in the supernatant fractions were 
plotted as a function of the total concentration of gelsolin in the presence 
and absence of EGTA. Data represented were average ± S.D. of three 
experiments. PM5 severs actin filaments more rapidly compared to WT in 
EGTA conditions. However, at high calcium levels, both WT and PM5 




 In a second experiment involving phosphomimetic mutants at a higher gelsolin (2 
µM) to F-actin (4 µM) ratio, in EGTA conditions, it was evident that mutants PM1 
(S381D /S385D) and PM5 (S381D/S384D/S385D) were more active at depolymerizing 
F-actin (indicated with red asterisk), showing less pellet-able actin, compared to PM2 








Figure 4.8 Co-sedimentation assay on gelsolin phosphomimetic mutants. 
4 µM F-actin was incubated with different gelsolin mutants (2 µM) for 1 h 
at room temperature and subjected to ultracentrifugation (352,000 × g, 1 
h), and the supernatants (S) and the pellets (P) were analyzed by SDS-
PAGE. The pelletable actin fraction was very low for the mutants PM1 
and PM5 indicative of their high severing capability compared to the other 
mutants in 1.5 mM EGTA conditions.  
 
 Taken together, the phosphomimetic mutants behave similarly to WT at high Ca2+ 
concentrations (1.0 mM) in the depolymerization and co-sedimentation assays as 
described in section 4.4.1. In EGTA conditions (1.5 mM), the single phosphomimetic 
mutants (PM2, PM3 and PM4) did not influence the effect of gelsolin on actin 
dynamics. However, the triple mutant PM5 was more active compared to the WT. These 
findings prompted us to further investigate calcium requirements for activation of the 
phosphomimetic mutants by a steady-state pyrene actin depolymerization assay. This 
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assay was carried out with calcium concentration titrations and the pyrene fluorescence 
measured only after steady state was achieved.  
 
4.4.3 Phosphorylated gelsolin has lower calcium requirements to sever actin 
 filaments compared to non phosphorylated gelsolin  
 The phosphomimetic mutants were tested for the calcium concentrations required 
for activation in a steady state pyrene-actin depolymerization assay. In this assay, gelsolin 
mutants were incubated with F-actin in the presence of different Ca2+ concentrations and 
the pyrenyl fluorescence was measured after 3 hours of incubation, upon attaining steady 
state. The results show that PM5 (S381D/S384D/S385D) and PM1 (S381D/S385D) are 
more active at depolymerizing F-actin at lower (0.001 – 0.1 µM) calcium levels 
compared to WT. However, no difference was observed among the single mutants and 
WT, which is consistent with our previous results described in sections 4.4.1 and 4.4.2. 
Also, at high Ca2+ concentrations (>1 µM), the depolymerization curves of the mutants 
were similar to the WT suggesting that these mutations were unaltered at saturating Ca2+ 


















Figure 4.9 Actin depolymerization assay on gelsolin phosphomimetic 
mutants at different Ca2+ concentrations. Polymerized F-actin (12 µM) 
was incubated with different gelsolin mutants (6 µM) in a molar ratio of 
2:1 and depolymerization was observed by titrating against EGTA-
buffered calcium levels. PM1 and PM5 require lower calcium levels to 
sever the filaments and sever at a faster rate as opposed to the other 
mutants and WT.  
 
 
4.4.4 Phosphomimetic gelsolin shows reduced nucleation activity  
 Gelsolin acts as a nucleator and stimulates actin filament formation by binding 
two actin monomers to form actin nuclei [79]. The actin filament nucleation properties of 
the WT and gelsolin mutants were examined by the pyrene-actin polymerization assay at 
a lower gelsolin to actin ratio (1:40) in the presence of Ca2+ (0.1 mM). Gelsolin has 
higher Ca2+ requirements (> 1 µM) to bind two actin monomers via its subdomains G1-
G3 and G4-G6 to form a stable actin nucleus. As expected, WT gelsolin eliminated the 
lag phase and increased the initial rate of polymerization compared to the actin control, 
through the formation of actin filament nuclei. In contrast, PM5 did not eliminate the lag 
phase and the polymerization kinetics was very similar to the actin control. Mutants PM1 
and PM3 showed intermediate effects in attenuating the nucleation activity of gelsolin, 
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whereas PM2 exhibited only a slight attenuation. PM4 had little effect and its activity 











Figure 4.10 Actin nucleation assay on gelsolin phosphomimetic mutants. 
G-actin was incubated with different gelsolin mutants in the molar ratio of 
40:1 for 1 hour followed by polymerization with Buffer F. PM5 did not 
efficiently nucleate actin filaments as compared to WT. 
 
 Collectively, the data suggest that the PM5 (S381D/S384D/S385D) mutant, where 
all three serine residues in the linker region of gelsolin have been mutated to aspartate, 
had very little or almost negligible nucleation activity compared to the WT, followed by 
the mutant PM1 (S381D/S385D) that holds double mutation and PM3 (S385D). This 
suggests that the YopO phosphomimetic gelsolin lacks the ability to nucleate actin 
filaments. The actin nucleus is a prerequisite for the formation of F-actin filaments and 




 To summarize, the biochemical assays on the phosphomimetic forms of gelsolin 
show that phosphorylation of gelsolin by YopO leads to its activation in the absence of 
Ca2+, whereas Ca2+ is essential for the activation of WT gelsolin. The depolymerization 
and co-sedimentation data suggest that a significant reduction of proportion of F-actin is 
observed for the phosphomimetic mutants [PM1 (S381D/S385D) and PM5 
(S381D/S384D/S385D)] as compared to the WT. Results of the nucleation assay also 
support the conclusion that the mutants were deficient in nucleating the filaments, which 
would affect filament formation. However, the mutants behave similarly to WT at higher 
Ca2+ concentrations suggesting that the mutations were insensitive to saturating Ca2+ 
levels (>1 µM).  
  Taken together, the biochemical analysis on the phosphomimetic form of gelsolin 
by YopO reveals that the phosphorylation event on gelsolin is likely to lead to activation 
of the molecule and result in a reduction of F-actin levels. We expect that the true 
phosphorylated gelsolin will have more pronounced effects, since the phosphate is larger 
and more highly charged than the aspartic acid residues used to mimic. Filamentous actin 
formation is crucial in phagocytosis for phagocytic cup formation in particle engulfment. 
YopO from Yersinia impairs phagocytosis of host macrophages by cytoskeletal 
disruption and phosphorylation of gelsolin may be one of the mechanisms adopted by 







4.5 CRYSTALLIZATION TRIALS OF THE PHOSPHOMIMETIC 
 MUTANTS OF GELSOLIN AND DATA COLLECTION 
 In an attempt to discover the structural changes associated with the differential 
behavior of the mutants, crystallization trials were set up for phosphomimetic mutants 
PM1 and PM5, the behavior of which were different from WT gelsolin based on the 
functional assays as described in section 4.4. Crystals were also set up for the mutant 
PM3 (SYLSD), since S385 was identified as the major phosphorylation target in the [γ-
32P] radioactive assay as shown in the figure 4.4. The wild type gelsolin crystals were 
obtained following the crystallization conditions and protein concentrations as described 
in the literature [95]. WT crystals appeared after 5 days, whereas the mutants did not 
yield any crystals in the same time frame. In an attempt to trigger the crystal nucleation 
process for the mutants, cross-seeding was employed as described [269]. Seeds were 
obtained by crushing the WT crystal in mother liquor using plastic beads by vortexing 
and were diluted to a concentration of 10-4 with mother liquor. Seeds were then streaked 

































Figure 4.11 Crystal hits obtained for the various phosphomimetic mutants 
of gelsolin and their corresponding crystallization conditions. 
PM3 (SYLSD), Cuboid 
1.6 M ammonium sulfate, 12 % glycerol 
100 mM Tris-HCl pH 8.0 
WT, Cuboid 
1.5 M ammonium sulfate, 15 % glycerol, 
100 mM Tris-HCl pH 8.5 
PM3 (SYLSD), Plates 
1.6 M ammonium sulfate, 18% glycerol 100 
mM Tris-HCl pH 8.5 
PM3 (SYLSD), Plates 
1.5 M ammonium sulfate, 12 % glycerol, 
100 mM Tris-HCl pH 8.0 
PM5 (DYLDD), Plates 
1.5 M ammonium sulfate, 21% glycerol 
100 mM Tris-HCl pH 8.0 
122 
 
a cat’s-whisker tool. Streak seeding was successful and crystals appeared one week after 
the seeding. The crystals were allowed to grow bigger at 25 ˚C for 3 weeks. 
 The crystals for PM3, which has a single mutation (S385D), appeared first 
compared to PM1 (S381D/S385D) and PM5 (S381D/S384D/S385D) which took a 
slightly longer time (about 12 days) for crystals to be visible. The reason could be that the 
conformational changes introduced by the mutations may hamper crystal growth.  
 The crystals obtained for the mutants were exposed to X-rays in an in-house 
diffraction facility. The crystals diffracted poorly and this could either be due to the small 
size of the crystals or poor crystal ordering. Thus, these crystals might require longer time 
to grow to the desired size due to the conformational changes. Therefore, optimization of 
the crystallization trials is still required at this stage in order to derive any structural data 
for the mutants. Attempts are in progress to get larger crystals via macro-seeding 
technique [270] in which selected crystals are transferred to a fresh crystallization drop 
containing the protein and the precipitant and incubated under similar crystallization 
conditions to allow the crystal to grow to the desired size.  
 
4.6 DISCUSSION  
4.6.1 Correlation between the structural changes on gelsolin and its effect on 
 actin dynamics upon phosphorylation by YopO 
 Lee et al. [210] human cytoplasmic gelsolin as a novel substrate of YopO. In 
this work, the phosphorylation sites on gelsolin were studied by MS and the effects of the 
phosphorylated gelsolin on actin dynamics were studied through biochemical assays. The 
identified phosphorylation sites S381, S384 and S385 were validated in vitro using 
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phosphor-deletion mutants.  S385 was identified as the major phosphorylation site, 
followed by S381, and S384 was identified as the site that undergoes the least 
phosphorylation. Various phosphomimetic mutants were prepared with the aim of 
understanding the effect of phosphorylation of gelsolin by YopO on actin dynamics. The 
biochemical assays clearly showed a difference in the behavior of some of the mutants 
compared to the WT. In an attempt to understand the differential behavior of these 
mutants, crystallization trials were setup to obtain the structural bases for the observed 
differences. However, deriving structural data for the mutants was hampered by poor 
crystal diffraction. Thus, we do not know the structural basis of the phosphorylation 
activation. 
 Nevertheless, analysis of existing gelsolin structures aids in understanding the 
role of the G3-G4 linker and the effects of phosphorylation of S381, S384 and S385 on 
the activity of gelsolin. Structural models were derived from the crystal structure of full-
length inactive gelsolin (PDB: 3FFN [95]) in which the three serine residues S381, S384 
and S385 were mutated into phosphoserines corresponding to phosphomimetic mutant 
PM5 (S381D/S384D/S385D), to obtain insight on structural changes that could arise 
from these mutations.  
 Residues that lie in the vicinity of the serines as derived from the inactive 
structure of full-length human cytoplasmic gelsolin (PDB: 3FFN) are tabulated in Table 
4.3. For any non-covalent bonding to occur the bond length between the two oppositely 
charged residues should not be more than 5 Å for electrostatic interactions and 1.5 to 2.6 
Å for hydrogen bonding (measured from the hydrogen atom) [271]. Likewise, a repulsive 
force is likely to be experienced when two similar charged residues were placed at these 
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bond distances. From the table 4.4,  it is clear that the Ser381 lies in close proximity to 
the negatively charged residues Asp371 and Glu358 with bond distances of 2.9 Å and 3.8 
Å respectively, whereas Ser385 lies close to the negatively charged residue Asp84 with a 
bond distance of 6.3 Å. These distances were measured from the unphosphorylated 
serines in the native crystal structure of the full length inactive human cytoplasmic 
gelsolin (PDB: 3FFN [95]). Therefore, addition of phosphate groups at Ser 381 and 
Ser385 would lead to further reduction in the bond distances in case of the 
phosphorylated protein as shown in the figure 4.12B (model). The phosphate group is 
relatively bulkier which might also result in steric clashes with the residues that lie close 
to the phosphorylation site. Thus we hypothesize that, the repulsive electrostatic 
interactions between the similarly charged residues and the steric hindrance introduced 
by the phosphate group addition could potentially  
 
Table 4.4 List of the residues present in the vicinity of serines in the 
crystal structure of the full-length human cytoplasmic gelsolin  
  































Figure 4.12 Modeling of the phosphorylated serine residues onto the 
inactive structure of the full-length human cytoplasmic gelsolin (PDB: 
3FFN [95]) A. Domain structure of the full length human cytoplasmic 
gelsolin with phosphorylation sites as indicated. B. Structural model 
showing the phosphorylated Ser residues and its interacting partners 
represented as sticks.  
 
 
destabilize the inactive conformation of gelsolin, resulting in the extension of the linker 
region between G3 and G4, which in turn would partially activate gelsolin. YopO 
phosphorylates gelsolin in its active conformation, as only the active form of gelsolin can 
bind the YopO-bound actin. Thus, gelsolin phosphorylated by YopO might not be able to 





would become constitutively active upon phosphorylation by YopO. This deduction is 
based on the observation that the phosphomimetic mutants PM1 and PM5 were found to 
be active in depolymerization, in the absence of Ca2+, as shown by the co-sedimentation 
assays (Fig. 4.7). 
 Hypothesis drawn from the structural models were further reinforced by 
performing Molecular Dynamic Simulations on the inactive full length human gelsolin 
(PDB: 3FFN). MD simulation was performed on WT gelsolin and its phosphorylated 
form (where the serines identified to be phosphorylated by YopO (S381, S384 & S385) 
on the linker region were modelled as phosphoserines) over a 0.3 µs timespan following 
the procedures mentioned in the section 2.13. Gelsolin is a ~ 80 kDa protein and due to 
the limitation of the computational resources, only short time frame could be probed by 
MD.   After 0.3 µs, WT gelsolin remained in the closed state.  In the case of pho-gelsolin, 
G4-G6 domain (pale green) showed repulsion from G1-G3 domain (pale red) due to the 
displacement and extension of the linker region (pale cyan) from its native position (WT - 
cyan) (Fig. 4.13A). The radius of gyration of the phosphorylated gelsolin increases with 
respect to time as compared to the WT, indicating opening of the gelsolin structure which 
is the hallmark of its activation (Fig 4.13B). All these observations reinforce our 
hypothesis of extension of the linker region between G1-G3 and G4-G6 domains upon 
phosphorylation, leading to the activation of the inactive gelsolin.  
 The hypotheses drawn from the structural models and MD simulations are 
consistent with the results obtained from the biochemical assays performed to test the 
effect of phosphorylation on gelsolin with respect to actin dynamics. Altered 
polymerization kinetics was observed for the phosphomimetic mutants that mimic the 
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phosphorylated state of gelsolin. WT gelsolin remains inactive in EGTA conditions due 
to the absence of divalent calcium ions in the reaction to activate the protein. Whereas, 










Figure 4.13 Molecular dynamics simulation on full-length human gelsolin (PDB: 
3FFN). A. WT and phosphorylated gelsolin after MD simulations were 
superimposed in PYMOL. WT gelsolin [G1-G3 (red), G4-G6 (green)]; 
phosphorylated gelsolin (Pho) [G1-G3 (pale red); G4-G6 (pale green)]. 
Phosphorylated serines (pS) pS381, pS384 and pS385 in the linker region (WT – 
cyan; Pho – pale cyan) are represented as sticks. G4-G6 domain and the linker 
region are zoomed in for visual clarity. B. A plot of Radius of Gyration (nm) vs 
Time (ns). Change in radius of gyration of WT and phosphorylated gelsolin 
during the MD simulation. In case of WT, it remains stable but in phophorylated 
gelsolin it keeps increasing throught the simulation indicating opening of the 
gelsolin structure which is the hallmark of its activation. 
 
 
mutated to Asp within the linker region was found to be partially active in severing the 
actin filaments in both depolymerization and co-sedimentation assays in EGTA 
conditions. This characteristic activity of PM5 in the absence of Ca2+ perhaps results 
from the repulsive electrostatic interactions and steric clashes between the Asp residues at 




environs, which facilitate the activation of the protein by inducing structural changes at 
the linker region. This is consistent with the modeling that indicates that the 
phosphoserines introduce repulsive electrostatic interactions and steric hindrance that 
destabilize the conformation of inactive gelsolin (Fig. 4.12).  
 Gelsolin is activated in a three-step latch release process that includes the release 
of C-terminal tail latch followed by the G1-G3 latch and finally the G4-G6 latch as 
described in section 1.5.3 (Fig. 1.8). Upon complete activation, the linker region between 
G3 and G4 attains the fully extended conformation and becomes available for binding 
actin monomers and at this state, gelsolin is hypothesized to display maximum severing 
activity.  
 The phosphomimetic mutant PM1 (S381D/S385D) was also found to be more 
active in contrast to WT, as identified by co-sedimentation (Fig. 4.8) and 
depolymerization (Fig. 4.9) assays, hence expected to follow the same phenomena as 
described earlier for PM5 activity. The phosphomimetic mutants PM1/PM5 also has 
lower calcium requirements for activity due to the partially active state of these proteins. 
However, the nucleation effect was reversed, where PM5, the most active mutant 
amongst the other mutants as validated by co-sedimentation (Fig. 4.7 & 4.8) and 
depolymerization (Fig. 4.6 & 4.9) assays, does not nucleate the actin filaments. PM1 and 
PM3 displayed intermediate effect in nucleating the filaments. PM4 and PM2 did not 
have any effect on the nucleation property of gelsolin.  
 To summarize, full-length human cytoplasmic gelsolin was phosphorylated by 
YopO in the presence of Sf9 actin and was analyzed by mass spectrometry for 
identification of its phosphorylation sites. Mass spectrometry identified the peptides 
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corresponding to the linker region of gelsolin with high spectral counts and the serines: 
S381, S384 and S385 of the linker were found to be phosphorylated by YopO. The 
peptides were detected in such a way that, a single phosphorylation was identified within 
each peptide corresponding to the linker region, however the MS could not quantify the 
degree of phosphorylation at each site. As such the in vitro validation assay was 
performed to identify the major serine phosphorylation site.  
  The phosphorylation sites were validated in vitro using double and triple 
phosphor-deletion mutants – DM1, DM2, DM3 and TM by [γ-32P] radioactive assay. The 
radioactive assay confirmed that S385 is the major phosphorylation site, followed by 
S381. DM2 mutant with mutations at S381A and S384A had only a slight attenuation of 
[γ-32P] incorporation, suggesting that S384 is not a major phosphorylation site. In 
conclusion, S385 was identified as the major phosphorylation site followed by S381 and 
S384.  
 So far, only a small number of phosphorylation sites have been identified and 
validated in literature for gelsolin. Gelsolin can be phosphorylated at Tyr438 by Src-
kinase in the presence of PIP2, yet the downstream effect of which remains elusive [99]. 
In this study, three novel phosphorylation sites have been identified on the linker region 
of gelsolin. This linker region plays an important role in the activation of gelsolin.  
 Biochemical assays show that the phosphomimetic mutants PM1 and PM5 of 
gelsolin are partially active in EGTA conditions and have lower calcium requirements for 
actin filament severing or depolymerizing activity. It was also shown that triple 
phosphomimetic mutation abolishes the nucleation activity of the protein to a large 
extent. All these observations lead to the conclusion that the phosphorylation event on 
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gelsolin by YopO results in activating gelsolin with the possible consequence of 




 In conclusion, the overall effect of the phosphorylation event on gelsolin, could 
lead to a decrease in F-actin population by enhanced depolymerization/severing of the 
actin filaments. Inhibiting the nucleation event for the formation of nascent filaments is 
unlikely to have a physiological role in vivo, since pointed end elongation does not occur 
in the presence of profilin. Thus, YopO phosphorylates gelsolin and misregulates the 
actin cytoskeleton via significant reduction of the F-actin population. Disruption of the 
formation of F- actin rich cytoskeletal structures might contribute to the disabling of 
phagocytosis by YopO.  
 The effect of YopO phosphorylation on formin mDia1 with respect to actin 












PHOSPHORYLATION OF mDia1 BY YopO 
 
5.1 PREPARATION OF PHOSPHORYLATED mDia1 FOR MASS 
 SPECTROMETRY 
 Lee et al. [210] had identified mDia1 as a novel substrate of YopO, using a 
construct of mDia1 containing the FH1-FH2-DAD domains (residues 586-1255). The 
FH1-FH2-DAD region of mDia1 was recombinantly expressed with an N-terminal GST 
tag and a C-terminal His-tag and purified via sequential GST affinity chromatography 
and Ni2+ affinity. The protein yield was too low to perform gel filtration and hence the 
protein from the sequential affinity chromatographies was dialyzed overnight into GF 
buffer containing 10 mM Na Hepes (pH 7.6), 100 mM NaCl. The affinity purification 























Figure 5.1 Preparation of phosphorylated mDia1 for mass spectrometry. 
A. The elution profile (A280) from GST affinity chromatography of FH1-
FH2-DAD region of mDia1 B. SDS-PAGE of the phosphorylated mixture 
containing the recombinantly purified mDia1, YopO, Sf9 actin and 
profilin. The band corresponding to mDia1 is marked with black box and 
was excised from SDS-PAGE for MS analysis. 
 
 In an attempt to identify the phosphorylation sites of YopO on mDia1, purified 
mDia1 was phosphorylated in vitro in the presence of YopO. The phosphorylation mix 
containing YopO, mDia1, profilin and Sf9 actin were separated by SDS-PAGE (Fig. 
5.1B) and the band corresponding to mDia1 was analyzed by mass spectrometry for 
phosphorylation site identification. The experiment was carried out in the presence of 
profilin, as profilin delivers actin to mDia’s FH2 domain in the nucleation process via 
binding to the polyproline region also known as the FH1 domain. Moreover, the profilin-




within the cells [272]. Thus, mDia1 phosphorylation was carried out in the presence of 
profilin to mimic physiological conditions.  
 
5.2 IDENTIFICATION OF THE PHOSPHORYLATED SITES BY MASS 
 SPECTROMETRY 
 Phosphorylated mDia1 was analyzed using mass spectrometry by Quantitative 
Proteomics Facility at IMCB, Singapore. Briefly, the mDia1 band marked with a 
rectangular box in Fig. 5.1B was excised from SDS-PAGE followed by procedures 
mentioned in the section 2.5. Unlike phosphorylated gelsolin where three major 
phosphorylation sites were identified by MS as described in Chapter 4, the mass 
spectrometry analysis of phosphorylated mDia1 yielded many phosphopeptides with 
multiple phosphorylation sites. Phosphopeptides with spectral counts greater than 1 were 
chosen and tabulated in Table 5.1. 
 In total, seven phosphorylation sites were identified with high confidence of 
which two of them (S844 and S942) fall under the FH2 region, whereas the rest were 
mapped onto the region C-terminal to the DAD region (T1213, S1214, S1218, S1237 and 














Figure 5.2 Schematic of the domain organization for mDia1 with the 
identified phosphorylation sites. The domain nomenclature denotes the 
GTPase binding domain (GBD), formin homology domain 1 (FH1), 
domain 2 (FH2), domain 3 (FH3), diaphanous inhibitory domain (DID) 
and diaphanous auto-regulatory domain (DAD). The phosphorylation sites 
were identified at the FH2 domain and the region C-terminus to DAD as 
indicated with a black box.  
 
 The sequence alignment of the FH2-DAD region of mDia1 with its close 
homologues Bni1 and FMNL3 with the identified phosphorylation sites on mDia1 










Modified sequence window 
Spectral 
count 
mDia1 S844 1 TAQNLS(ph)IFLGSFR 2 
mDia1 S942 1 LQFSEQVENIKPEIVS(ph)VTAACEELR 2 
mDia1 T1213 1 AGCAVT(ph)SLLASELTK 2 
mDia1 S1214 1 AGCAVTS(ph)LLASELTK 4 
mDia1 S1218 1 AGCAVTSLLAS(ph)ELTK 3 
mDia1 S1237 1 KS(ph)EGVPTILEEAK 2 


















Figure 5.3 Sequence alignment of the FH2-DAD region of formins 
mDia1, FMNL3 and BNI1. The FH2 region of mDia1 is colored as cyan 
and DAD as magenta. The phosphorylation sites identified in mDia1 are 
colored as yellow and marked with red asterisk. The alignment was 
performed in Clustal Omega and the image was created by BOXSHADE 
server to highlight the sequence conservation among the FH2 domains. 
The conserved amino acids are highlighted in black.  
 
5.3 EFFECT OF PHOSPHORYLATION ON mDia1 ACTIVITY 
 It is known that the formin mDia1 is a multidomain protein that performs de novo 
nucleation and assembles unbranched actin filaments. The effect of phosphorylation on 
mDia1 activity was studied using in vitro phosphorylated mDia1 where mDia1 was 
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phosphorylated in the presence of YopO, profilin and Sf9 actin as described in section 
2.8.1.  
 
5.3.1  Phosphorylated mDial shows reduced nucleation activity 
 YopO phosphorylated mDia1 was tested for its efficiency to nucleate actin 
filaments in comparison to wild type mDia1 in a pyrene-actin assay. As a control, mDia1 
was subjected to the same phosphorylation conditions with the YopO kinase dead mutant 
(YopO KD – D267A/K269A), which has been shown to have no kinase activity due to 
the mutations at its catalytic cleft. Phosphorylated mDia1 was observed to have 
attenuated ability to nucleate the actin filaments, as compared to the unphosphorylated 









Figure 5.4 Effect of YopO-phosphorylated mDia1 on actin filament 
nucleation. 50 nM of phosphorylated mDia1 was incubated with 2 µM of 
actin in Buffer A and polymerization was initiated with the addition of 
KMEI buffer. mDia1 phosphorylated by YopO is shown to have 
attenuated ability to nucleate the filaments as compared to the 
unphosphorylated mDia1/WT.  
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5.3.2  Phosphorylation at the C-terminal region does not affect mDia1’s
 nucleation activity 
 Formin mDia1 contains a diaphanous inhibitory domain (DID) at the N-terminus, 
which interacts with the DAD domain at the C-terminus to maintain the formin in its 
autoinhibited form (Fig. 1.12). The autoinhibited state of formins is relieved by the 
binding of Rho proteins, which disrupt the interaction between DAD and DID.  
 The mass spectrometry analysis of the phosphorylated mDia1 by YopO identified 
five phosphorylation sites that are close to the DAD region near the C-terminal end of 
mDia1. I set out to determine if phosphorylation at the C-terminal end disrupts the auto-
inhibitory mechanism of formin mDia1. Li et al. showed that the nucleation of actin 
filaments by mDia1 (FH1-FH2-DAD) can be abolished in the presence of recombinantly 
expressed DID domain [273]. Thus, the ability of the phosphorylated mDia1 (FH1-FH2-
DAD) to undergo inhibition by DID was tested using pyrene-actin nucleation assays. The 
DID-DD (FH3) region of mDia1 (residues 1-463) was recombinantly expressed with an 
N-terminal His-tag in E. coli and purified via Ni2+ affinity resin with on-column tag 
cleavage by 3C protease, followed by size exclusion chromatography. 
 In agreement with the literature, the pyrene-actin assay results show that the 
nucleation activity of WT mDia1 was inhibited efficiently by DID (Fig. 5.5). The 
nucleation efficiency of the phosphorylated mDia1 is reduced by DID to a similar extent 
as the WT control suggesting that the DID-DAD interactions of mDia1 were not affected 
by phosphorylation by YopO. The difference in nucleation activity observed between the 
mDia1 phosphorylated by YopO WT and KD is attributed to attenuation of nucleation 
activity of the phosphorylated mDia1 as described earlier in section 5.3.1. In conclusion, 
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the phosphorylation sites identified at the region C-terminal to DAD did not effect the 










Figure 5.5 Effect of YopO-phosphorylated mDia1 on actin filament 
nucleation in the presence of the DID-DD (FH3) domain. 50 nM of 
phosphorylated/unphosphorylated mDia1 and mDia1 WT were incubated 
with 2 µM of actin and 60 nM of DID-DD (FH3) in Buffer A and 
polymerization was initiated with the addition of KMEI buffer. mDia1 
phosphorylated by YopO undergoes inhibition by DID to nucleate the 
filaments to the same extent as the WT control.  
 
5.4  DISCUSSION 
 Formin mDia1 is an actin nucleator that performs de novo nucleation of actin 
monomers to assemble unbranched filaments. Formin mDia1 has been identified as a 
novel substrate of YopO both in the presence and absence of profilin by Lee et al. as 
shown in the figure 1.23. It was also hypothesized that phosphorylation of mDia1 by 
YopO from Yersinia could lead to misregulation of the actin cytoskeleton which would 
affect the phagocytic mechanism of host macrophages.  
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 Thus, in an attempt to unravel the mechanism of misregulation of the actin 
dynamics by YopO phosphorylated mDia1, the phosphorylated protein was analyzed by 
MS to identify the potential phosphorylation sites. The effect of the phosphorylated 
mDia1 on actin dynamics was studied by pyrene actin assays to understand the 
mechanism of action of the phosphorylated mDia1. Mass spectrometry identified seven 
phosphorylation sites in phosphopeptides with spectral counts greater than 1. In vitro 
mutational validation was not performed and hence the natively in vitro phosphorylated 
protein was used to test the effect of the protein on actin dynamics. The phosphorylation 
sites identified fall in the FH2 region and in the region C-terminal to the diaphanous auto-
regulatory domain (DAD), a domain that is predicted to be disordered in all formin 
family members. The FH2 region of mDia1 plays a central role in the nucleation process, 
recruiting actin monomers to form the nucleus and acting as the barbed-end capper to 
prevent the loss of actin monomers from the barbed end, thereby stabilizing the filaments. 
Formin mDia1 is regulated by the auto-inhibitory mechanism in which interactions 
between the DAD and DID domains secure mDia1 in its inactivated state. Upon binding 
of RhoGTPases, the interactions between the DID and DAD regions are released and the 
formin becomes functionally active. Thus, the phosphorylation sites identified on mDia1 
correspond to the regions that are vital for the regulatory mechanism and nucleation 
activity of formins.  
 Therefore, I set out to investigate the effect of phosphorylation on mDia1 with 
respect to actin dynamics in the context of nucleation and auto-inhibition. The nucleation 
assay was performed to test the efficiency of the phosphorylated mDia1 to nucleate the 
filaments compared to the unphosphorylated form. The results showed that the 
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phosphorylated mDia1 had weaker nucleation effect on the actin filaments compared to 
the WT and the unphosphorylated form in the presence of YopO KD, which has been 
shown to have no kinase activity. The auto-inhibitory effect was examined through the 
nucleation assays by employing the recombinant DID-DD (FH3) domain which has been 
shown to have inhibitory effect on the nucleation activity of FH1-FH2-DAD [273]. 
However, DID and DAD interactions were not affected by phosphorylation of mDia1 by 
YopO, suggesting that the phosphorylation sites identified at the region C-terminal to 
DAD does not affect the auto-inhibitory mechanism of mDia1.  
 Based on the results obtained from these biochemical assays, it will be interesting 
to understand the involvement of the identified phosphorylation sites in the interaction 
between mDia1and actin. Although the individual domains of mDia1 have been well 
studied by X-ray crystallography, the interactions of mDia1 with actin remain unknown 
till date. However, the crystal structures of the FH2 domain of its close homologues 
Bni1p and FMNL3 in complex with actin are available in the PDB database.  
 The phosphorylation sites identified at the FH2 region of mDia1 were mapped 
onto the crystal structures of the core FH2 domain of mDia1 (PDB:1V9D [107]) and then 
superimposed on structures of the FMNL3(FH2)-actin complex (PDB: 4EAH [114]) and 
the Bni1p(FH2)-actin complex (PDB: 1Y64 [109]). The superimposed models reveal that 
the identified phosphorylation site S844 on mDia1 lie close to the barbed end of actin 
(subdomain 1) and could be involved in stabilizing mDia1-actin interactions (Fig. 5.6 & 
5.7). As shown by the biochemical assays, the phosphorylated formin mDia1 displayed 
reduced nucleation activity as compared to the WT. This result agrees with the modeled 
structure of the FH2 domain of the phosphorylated mDia1 where the phosphorylation at 
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S844 would lead to destabilization of mDia1-actin interactions due to steric clashes of the 
phosphate groups with the interacting residues on actin. However the phosphorylation 
event did not completely abolish the nucleation property of mDia1, possibly a result of 
residual activity of any unphosphorylated mDia1 due to incomplete phosphorylation by 
YopO as excess substrate was employed in the phosphorylation reaction (YopO:mDia1 
1:5). Another plausible explanation could be that the phosphorylation event on mDia1 
leads to destabilization of its FH2 domain but not complete abolishment of its interaction 
with actin. The quantification of the amount of mDia1 phosphorylated by YopO would 




























Figure 5.6 Superimposition of the crystal structure of the core FH2 
domain of mDia1 (PDB: 1V9D [107]) with FH2 region of human FMNL3 
in complex with actin (PDB:4EAH [114]). The phosphorylation site S844 
identified on mDia1 lies close to the subdomain 1 of actin and is indicated 
as black sphere. Actin and FH2 regions of FMNL3 and mDia1 are labeled 






















Figure 5.7 Superimposition of the crystal structure of the core FH2 
domain of mDia1 (PDB: 1V9D [107]) with FH2 region of yeast Bni1p in 
complex with actin (PDB:1Y64 [109]). The phosphorylation site S844 
identified on mDia1 lies close to the subdomain 1 of actin and is indicated 
as black spheres. Actin and FH2 regions of Bni1p and mDia1 are labeled 
in their respective colors.  
 
 The models also show that the identified phosphorylation site S844 on mDia1 lies 
close to the region where Bni1p and FMNL3 bind to the barbed of actin, further 
indicating the importance of these residues in the interactions with actin. The second 
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phosphorylation site identified on FH2 domain, S942 did not seem to be involved in 
interactions with actin and hence was not included in the discussion here.  
 The rest of the phosphorylation sites identified at the region C-terminal to DAD 
were not mapped onto the crystal structures of mDia1 or any other formin as no structural 
data is available for this region and this region is predicted to be disordered by DisEMBL 
[274]. These phosphorylation sites may be non-functional or may regulate mDia1’s 
interactions with other proteins. 
 The results obtained for the effect of the phosphorylated formin mDia1 on actin 
dynamics, suggest that the YopO phosphorylated mDia1 has reduced nucleation effect 
compared to the WT, which correlates with the reduction of F-actin filament formation. 
Formin mDia1 not only nucleates actin filaments but also stabilizes F-actin by acting as a 
barbed end capper to produce stable F-actin rich structures like filopodia. These 
structures help macrophages to extend and engulf foreign particles for clearance in the 
process of phagocytosis. Thus, the phosphorylation sites identified on mDia1 could 
potentially affect the binding of mDia1’s FH2 with the barbed end of actin resulting in 
poor nucleation and elongation leading to a reduction in F-actin population.  
 
5.5 CONCLUSION 
 In summary, we can conclude that the YopO phosphorylated formin mDia1 
misregulates the actin cytoskeleton possibly by impinging on the F-actin population by a 
reduction in nucleation activity. However, in vitro validation of the phosphorylated sites 
identified on the FH2 domain is still required to draw concrete conclusions on the effect 




PHOSPHORYLATION OF VASP, EVL AND WASP BY YopO 
 
6.1 PREPARATION OF PHOSPHORYLATED VASP, EVL AND WASP FOR 
 MASS SPECTROMETRY 
 Lee et al. [210] reported VASP, EVL and WASP as novel substrates of YopO. 
The phosphorylated proteins were analyzed by mass spectrometry for identification of 
phosphorylation sites. Full length human VASP and EVL were recombinantly expressed 
with an N-terminal His-tag and purified via sequential via Ni2+-affinity and size exclusion 
chromatographies. Subsequent gel filtration profiles of the full-length human VASP (1-
380) and EVL (1-416) show that VASP and EVL elute as tetramers corresponding to 
molecular weights of ~160 kDa and ~180 kDa, respectively (Fig. 6.1A,B). Human WASP 
PWA (160-502), encompassing the GBD, PR and VCA domains, was recombinantly 
expressed with an N-terminal GST-tag and a C-terminal His-tag and purified via 
sequential GST and Ni2+ affinity chromatographies (Fig. 6.1C). The protein yield was too 



























































Figure 6.1 Preparation of phosphorylated VASP, EVL and WASP for 
mass spectrometry. The elution profile (A280) from size exclusion 
chromatography using Superdex 200pg of (A) the full length human 
VASP and (B) full length human EVL. In both A and B, the peaks 
corresponding to our protein of interest are marked with arrows. Other 






elution profile (A280) from HIS affinity chromatography of PWA WASP. 
(D) SDS-PAGE gel of the phosphorylated mixture containing the 
recombinantly purified substrates of YopO, YopO kinase, Sf9 actin and 
profilin. Note PWA WASP and YopO co-migrate. The band 
corresponding to the proteins are marked with black box and were excised 
from SDS-PAGE for MS analysis. 
 
 In order to identify the phosphorylated sites on these substrates of YopO, the 
individual proteins were phosphorylated in separate reactions in vitro in the presence of 
YopO, Sf9 actin and profilin. The phosphorylated mixture was separated by SDS-PAGE 
and the bands marked with rectangular boxes (Fig. 6.1D) were analyzed by MS. 
 
6.2 IDENTIFICATION OF THE PHOSPHORYLATED SITES BY MASS 
 SPECTROMETRY 
 The phosphorylated VASP, EVL and WASP were analyzed using mass 
spectrometry by the Quantitative Proteomics Facility at IMCB, Singapore. Briefly, the 
VASP, EVL and WASP bands marked with a rectangular box in Fig. 6.1D were excised 
from SDS-PAGE followed by procedures mentioned in the section 2.5. Phosphopeptides 
that were identified more than once (i.e. spectral count greater than one) were considered 
to be more confidently identified, and so, only phosphopeptides with spectral counts 
greater than one are indicated in the domain structures of VASP and EVL (Fig. 6.2) and 
WASP (Fig. 6.3).  
 A detailed tabulation of all the identified phosphopeptides for VASP, EVL and 
WASP, with their spectral counts and phosphorylation sites are given in Table 6.1, 6.2 




6.2.1 Analysis of the mass spectrometry data of the phosphorylated VASP and 
EVL 
 VASP and EVL, both members of the Ena/VASP family of proteins, were proven 
to be substrates of YopO by Lee et al. (Fig. 1.23). Both proteins share high sequence 
homology and possess similar functional characteristics with respect to actin dynamics. 
Therefore, the identified phosphorylation sites on each protein were indicated in the 
sequence alignment of VASP and EVL to have better understanding of the common 
domains that were phosphorylated (Fig. 6.2). Analysis of the phosphorylated proteins by 
mass spectrometry identified phosphorylation sites at the C-terminal region of both 
VASP and EVL, the majority of which fall between the G-actin binding domain and the 
tetramerization domain. The residues of VASP S128, S258, S289, S322/S323/S324/S325 
and S314; and the residues S252/253/255, S298, S304, S320/321, S331 and S339 of EVL 
were shown to have been phosphorylated by YopO. Mass spectrometry analysis could 
not differentiate between the phosphorylated and unphosphorylated serine 
phosphopeptides that contains two or more serines in tandem (serines that are separated 
by “/” symbol in Fig. 6.2 and in Tables 6.1 & 6.2). Thus, an equal probability of 
phosphorylation was assigned to the serines that lie next to each other. Among the 
phosphorylation sites identified on VASP, S258 and S289 lie close to the F-actin binding 
region marked with green (Fig. 6.2). Therefore I set out to study the effect of 






Table 6.1 Phosphopeptides identified by mass spectrometry for the YopO 









S34 1 1 WLPAGTGPQAFSR 
T43 or 
S46 
1 1 VQIYHNPTANSFR 







S149 1 1 QQPGPSEHIER 
S245 1 1 VSKQEEASGGPTAPK 
S258 6 1 SGGGGLMEEMNAMLAR 




S303 1 1 VPAQSESVR 
S305 1 1 VPAQSESVR 
S314 5 1 NSTTLPR 


















1 1 SSSSVTTSETQPCTPSSSDYSDLQR 
 
The peptides shown in grey correspond to those identified only once in the MS scan.  





Table 6.2 Phosphopeptides identified by mass spectrometry for the YopO 






















2 1 VQRPEDASGGSSPSGTSKSDANR 
S255 1 1 VQRPEDASGGSSPSGTSKSDANR 
S261 1 1 ASSGGGGGGLMEEMNK 
S298 9 1 KEDESQMEDPSTSPSPGTR 




2 1 AASQPPNSSEAGR 
S331 3 2 SNSVEKPVSSILSR 
S339 4 1 
SNSVEKPVSSILSR 
PVSSILSR 
S360 1 1 SPLQSQPHSR 
S364 1 1 SPLQSQPHSR 
 
The peptides shown in grey correspond to those identified only once in the MS scan.  





























Figure 6.2 Domain architecture of full length human VASP and EVL with 
phosphorylation sites highlighted. The domain nomenclature denotes 
Ena/VASP homology domain 1 (EVH1), proline-rich region (PR) and an 
Ena/VASP homology domain 2 (EVH2) that contains a G-actin-binding 
site (G), an F-actin-binding site (F) and a tetramerization (TET) domain. 
Sequence alignment of VASP and EVL showing the high degree of 
153 
 
similarity between G- (highlighted in blue) and F-actin (highlighted in 
green) binding regions and tetramerization domain (highlighted in red). 
The identified phosphorylation sites on VASP are indicated with red dots 
and on EVL with green dots, placed above and below the sequences of 
VASP and EVL, respectively. 
 
6.2.2 Analysis of the mass spectrometry data obtained for YopO phosphorylated 
WASP 
 Mass spectrometry analysis of the YopO phosphorylated WASP identified 
phosphopeptides corresponding to the regions of GBD at the N-terminus and VCA at the 
C-terminal region (Fig. 6.3). The WASP construct used in this study comprises of the 
residues 160-502 (GBD-PR-V-C-A) and does not include the WH1 domain. The residues 
S453/S454, which lie in the linker region between the verprolin homology (V) and 
central region (C) of the VCA region were identified to be phosphorylated by YopO. The 
VCA domain of WASP is involved in ARP2/3 activation, where it binds ARP2/3 and 
delivers the G-actin bound to its V region to the ARP2/3 nucleation site resulting in a 
trimeric actin-like template for the formation of filaments. Thus, the sites that were 
identified to be phosphorylated by YopO at the C-terminal region could have potential 
effects on ARP2/3 activation by WASP.  
 The majority of the phosphorylation sites identified on WASP fall in the N-
terminal region, within the GBD domain and its vicinity. S248 lies in the CRIB motif, the 
motif that interacts with RhoGTPase Cdc42 to bring about activation of WASP, was 
shown to be phosphorylated. Other sites that were identified in the GBD domain include 
S269, S277 and S287. Two sites were also found N- and C-terminal to the GBD, 
S208/S209/S210 and S339, respectively. Phosphorylation at the GBD domain could have 




Table 6.3 Phosphopeptides identified by mass spectrometry for the YopO 




















S248 3 1 HVSHVGWDPQNGFDVNNLDPDLR 










S287 2 1 
AGISEAQLTDAETSK 
 






































Figure 6.3 Domain architecture of WASP with the identified 
phosphorylation sites indicated by red dots. The domain nomenclature 
denotes WASP homology domain 1 (WH1), GBD (GTPase binding 




verprolin homology (V), the central region (C) and an acidic region (A). 
Most of the phosphorylation sites identified fall within the N-terminal 
region of WASP in the vicinity of GBD. The serines that are identified to 
be phosphorylated in the CRIB motif and in the linker region between V 
and C regions are indicated with red dots in the sequence alignment of 
human (h) and mouse (m) WASP, which share high similarity.  
 
6.3  EFFECT OF THE PHOSPHORYLATED VASP AND WASP ON 
 ACTIN DYNAMICS 
6.3.1  Effect of the phosphorylated VASP on actin dynamics 
 VASP and EVL are both members of the Ena/VASP family of proteins, and share 
similar domain structures and functional characteristics with respect to actin dynamics. 
Therefore functional studies to determine the effect of phosphorylation by YopO were 
only performed for VASP. Like mDia1, the natively phosphorylated VASP was 
employed in the functional assays. Previously, Lee et al. [210] had reported that VASP 
phosphorylated by YopO had attenuated ability to accelerate actin polymerization 
compared to the unphosphorylated controls. In this study, the effect of phosphorylated 
VASP on F-actin binding was analyzed by co-sedimentation assay.  
 VASP was phosphorylated in the presence of YopO, Sf9 actin and profilin. VASP 
was preincubated with Sf9 actin and YopO to allow the phosphorylation of VASP by 
YopO. This YopO-phosphorylated VASP was then added to pre-polymerized F-actin and 
subjected to high-speed centrifugation, which separates F-actin (and its interactors) from 
G-actin. The pellet and supernatant fractions were analyzed using SDS-PAGE. The SDS-
PAGE gel was later stained with Pro-Q solution (an alternative to radioactive [γ-32P] 
phosphorylation assay). Phosphorylated VASP showed up as two bands upon ProQ 
staining, one with the same electrophoretic mobility as the unphosphorylated version and 
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other with an altered electrophoretic mobility (Fig. 6.4). The phosphorylation effect on 
VASP was also directly proportional to concentration of YopO WT added. A difference 
in migration was not detected on SDS-PAGE, and bands corresponding to VASP were 
not detected in the Pro-Q stained gel for VASP incubated with YopO KD, which has 
been shown to have no kinase activity.  
 Analyses of the pellet and supernatant fractions reveal that, both phosphorylated 
and unphosphorylated VASP co-sediment with F-actin to the same extent suggesting that 








Figure 6.4 Co-sedimentation assays to test the biding of phosphorylated 
VASP to F-actin. 4 µM F-actin was incubated with 1 µM of VASP 
(phosphorylated/unphosphorylated) for 1 h at room temperature and 
subjected to ultracentrifugation (352,000 × g, 1 h), and the supernatants 
(S) and the pellets (P) were analyzed by SDS-PAGE (top panel). The 
SDS-PAGE gel was stained with ProQ solution and visualized under 
Typhoon FLA7000 imaging system (bottom panel). 1-4: Individual 
protein controls; 5-6: YopO WT/KD with VASP; 7: VASP with actin; 8: 
0.5 µM YopO WT with actin; 9: 0.25 µM YopO WT with actin; 10: 0.5 
µM of YopO KD with actin; 11: 0.25 µM of YopO KD with actin. Both 
the phosphorylated and unphosphorylated forms of VASP appear to bind 
F-actin with the similar extents, suggesting that the phosphorylation of 






 6.3.2  Effect of the phosphorylated WASP on ARP2/3 activation  
 WASP is known be an activator of ARP2/3, the protein complex that performs 
nucleation and formation of Y-branched actin filaments [275]. Thus, in order to identify 
the effect of phosphorylation of WASP on ARP2/3 activation, the pyrene-actin nucleation 
assay was performed using phosphorylated WASP in vitro in the presence of YopO, actin 
and profilin. ARP2/3 on its own does not nucleate actin polymerization. Addition of 
PWA eliminated the lag phase and resulted in increase in polymerization of the filaments. 
Polymerization kinetics of PWA phosphorylated by YopO WT (active) and YopO KD 
(inactive) appear similar, suggesting that phosphorylation at the VCA region does not 









Figure 6.5 ARP2/3 nucleation assay to test the effects of the 
phosphorylated WASP on ARP2/3 activation. G-actin (1 µM) was 
incubated with phosphorylated/unphosphorylated WASP (400 nM), 
profilin (1.4 µM) and ARP2/3 (10 nM) for 1 hour followed by 
polymerization with Buffer F. Both phosphorylated and unphosphorylated 
forms of WASP have identical polymerization kinetics, indicating that the 






6.4  DISCUSSION 
6.4.1  Phosphorylation of VASP by YopO affects binding to G-actin but not F-
 actin 
 A comparative analysis of the mass spectrometry data of VASP and EVL, 
suggests that YopO phosphorylation occurs at the C-terminal region of these proteins 
comprising of the G- and F-actin binding regions and tetramerization domain. Since 
VASP and EVL act through similar mechanisms on actin, the biochemical assays were 
performed only on one of the proteins, VASP, to understand the effect of the 
phosphorylation on actin dynamics.  
 It was previously reported by Lee et al. [210] that the phosphorylated VASP had 
attenuated ability to promote the actin polymerization. However, the reason for such an 
attenuated ability was not described. Coincidently, in this study, the identified 
phosphorylation sites were mapped into the C-terminal region of VASP close to the G-
actin binding domain. Hence, the phosphorylation sites identified close to the G-actin 
binding region i.e. S258 could play an important role in the VASP-G-actin interaction. 
Unfortunately, no structural data is available for the region of VASP, which contains the 
identified phosphorylation sites.  
 Phosphorylation sites were also identified in the vicinity of the F-actin binding 
region. This prompted further investigation on the ability of the phosphorylated VASP to 
bind F-actin by co-sedimentation assays. VASP is found to be localized with the barbed 
end of the filaments at the filopodial tips, where it acts as an anti-capping protein by 
protecting the filament ends from other capping proteins [223,224]. Thus, interaction of 
VASP with F-actin is essential for filament elongation in filopodia formation.  
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 The co-sedimentation assay results, however, show that the ability of 
phosphorylated VASP to bind the sides of F-actin is not affected. This suggests that the 
attenuation in activity of VASP works by a mechanism other than affecting its affinity to 
F-actin. Thus YopO deregulates the cytoskeletal machinery through phosphorylation of 
VASP potentially by perturbing its ability to bind G-actin, yet F-actin binding appears not 
to be affected.  
6.4.2 Phosphorylation of WASP by YopO does not affect its ability to 
 activate ARP2/3 but may interfere on its own activation mechanism  
 Most of the phosphorylation sites identified on WASP lie at the N-terminal 
region. A couple of sites were identified at the C-terminal part of the VCA domain, in the 
linker connecting V and C regions. The effect of the phosphorylation sites that are 
identified in the VCA region of WASP on actin dynamics was analyzed by an ARP2/3 
activation assay using phosphorylated WASP (PWA), and as a control, unphosphorylated 
WASP. The result showed that phosphorylation of WASP by YopO had no effect on its 
ability to activate ARP2/3.  
  WASP can exist in an auto-inhibited form, which gets activated by RhoGTPases. 
RhoGTPase Cdc42 binds the GBD region (CRIB motif) of WASP to relieve the auto-
inhibition. As most of the phosphorylation sites identified exist in the GBD region, it can 
be hypothesized that the phosphorylation of WASP by YopO may affect the activation 
mechanism of WASP by disrupting its interaction with Cdc42 (Fig. 6.6). RhoGTPases 
are upstream regulators of a number of actin polymerization machineries. Particularly, 
the RhoGTPase Cdc42 activates WASP, which in turn acts as an activator for ARP2/3. 
Interestingly, analysis of the available solution structure of the complex of GBD-Cdc42 
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(PDB:1CEE [162]) revealed that the phosphorylation site S248 identified on the CRIB 
motif of the GBD region of WASP forms a hydrogen bond with N39 and makes non-
bonding contacts with D38 of Cdc42 [162] (Fig. 6.7). Phosphorylation by YopO at S248 
of WASP could potentially affect the binding of Cdc42 with GBD domain, interfering 
with the activation of WASP and consequently, the activation of ARP2/3. Ultimately, the 
phosphorylation event on the CRIB motif of WASP could affect the nucleation by 
ARP2/3, resulting in the reduction of branched filament formation at the lamellipodia. 
Therefore, phosphorylation of WASP by YopO could indirectly affect filamentous actin 
population, by compromising its own activation mechanism. WASP is a key factor in 
transducing signals from the cell surface to the actin cytoskeleton, and a lack of WASP 
results in cytoskeletal defects due to perturbation of cellular activities like proliferation, 










Figure 6.6 Schematic of the activation mechanism of WASP. 
Autoinhibited WASP gets activated upon Cdc42 binding to GBD, 
releasing VCA domain. VCA interacts with ARP2/3 followed by actin 




 Alternatively, phosphorylation of WASP at the GBD region could also disrupt the 
interactions of the VCA domain with the GBD region, this interaction of which secures 
WASP in its auto-inhibited state. As a result, phosphorylated WASP might become 
constitutively active leading to unregulated ARP2/3 activation. There is some precedent 
for this since phosphorylation of WASP by Btk kinase at Tyr291 that lies in the vicinity 







































Figure 6.7 The interaction between Cdc42 and GBD of WASP. A. The 
interacting residues between Cdc42 and GBD-WASP. The solid blue lines 
represent the hydrogen bonds and dashed orange lines indicate non-
bonding contacts. Ser248 of the GBD region of WASP (Ser19) is 
indicated with a red asterisk. The figure was generated in PDBSUM. B. 
Solution structure of Cdc42:GBD-WASP (PDB:1CEE [162]) (top panel). 
An enlarged view of the complex showing the interactions of S248 of 





6.5  CONCLUSION 
 To summarize, YopO phosphorylates the actin elongators VASP/EVL and affects 
the actin polymerization machinery by a mechanism other than affecting affinity for F-
actin. Actin remodeling is vital to the process of phagocytosis and YopO hijacks the actin 
regulators VASP/EVL of the host system, which are important in the remodeling process. 
The ability of the substrate WASP to activate ARP2/3 was not affected upon 
phosphorylation by YopO. However, phosphorylation of WASP could result in negative 
or positive regulation of its own activation mechanism, indirectly affecting the ARP2/3 
activation. The misregulation of activation of ARP2/3 could lead to poor filament 
formation during phagocytosis at the site of particle engulfment. Taken together, YopO 
resists phagocytosis by host macrophages by modifying their cytoskeletal organization 
hampering development of actin-rich structures that are essential for phagosome 
formation.  
 In the next chapter, a comprehensive model of how YopO misregulates the actin 
cytoskeleton by phosphorylating the various actin regulators (gelsolin, mDia1, VASP, 











MODEL FOR YopO MEDIATED MISREGULATION OF THE 
ACTIN CYTOSKELETON 
 
 In the previous chapters, phosphorylation events on the various substrates were 
described – with identification of the phosphorylation sites, in vitro validation of the 
identified sites, and determination of the effect of phosphorylation on actin dynamics.  
 In this chapter, the collective effect of the phosphorylation of substrates by YopO 
on the misregulation of the actin cytoskeleton and phagocytosis will be discussed. The 
kinase substrate specificity of YopO will also be considered. 
 
7.1 MODEL OF BINDING OF THE SUBSTRATES OF YopO FOR 
 PHOSPHORYLATION  
 Prior to this work, it has been reported by Lee et al. [210] that YopO, an inactive 
kinase, gets activated upon binding to subdomain 4 of G-actin, via its kinase domain 
leaving the binding pocket between subdomain 1 and 3 of actin free to bind other actin 
binding proteins for phosphorylation. The actin regulators that were identified as 
substrates of YopO include gelsolin, mDia1, VASP, EVL and WASP. However the 
phosphorylation sites on the phosphorylated substrates of YopO were not reported.  
 In the work described in this thesis, mass spectrometry on phosphorylated 
substrates of YopO was carried out to identify the phosphorylation sites. Models of 
modes of binding of the substrates to the YopO-actin complex were derived based on the 
obtained mass spectrometry results. These models will allow the prediction of where 
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putative substrates will be phosphorylated. A schematic representation of the model of 
binding of these substrates to the YopO-actin complex is shown in the figure 7.1.  
 Gelsolin, an actin severing protein, consists of six domains (G1-G6). YopO 
phosphorylates gelsolin in the linker region between domains G3 and G4 on residues 
S381, S384 and S385. Gelsolin adopts an open confirmation upon Ca2+ activation that 
promotes the extension of the linker between the two halves of gelsolin G1-G3 and G4-
G6 to bind the barbed end of the actin filaments. Based on the available X-ray structures 
of active and inactive conformations of gelsolin, we hypothesize that the extended linker 
region in active gelsolin is capable of reaching the catalytic cleft between the kinase and 
GDI domains of YopO for phosphorylation, in agreement with the identified 
phosphorylation data (Fig. 7.1A). The binding of G1 at the barbed end and G2 on the side 
of actin between domains 1 and 2 allows the linker and the C-terminal region of gelsolin 
to reach the catalytic cleft of YopO kinase.  
 mDia1, an actin nucleator, has been shown to be phosphorylated by YopO at the 
FH2 domain and in the region C-terminal to DAD in the presence of profilin. Profilin 
serves as an adaptor, binding the barbed end of actin and the FH1 domain of mDia1, and 
positions the FH2-DAD region towards the catalytic cleft for phosphorylation by YopO 
(Fig 7.1B). In total seven phosphorylation sites have been identified, two of which (S844 
and S942) fall in the FH2 domain whereas the rest were in the region C-terminal to the 
DAD domain (T1213, S1214, S1218, S1237 and T1242). The region C-terminal to DAD 
is structurally predicted to be disordered and flexible could easily be phosphorylated by 
YopO as it reaches into the catalytic cleft of the kinase domain. However, only two sites 
have been identified in the FH2 domain that lie N-terminal to the DAD region, perhaps 
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due to the fact that the FH2 homodimer can only insert into the catalytic cleft at a certain 
angle and thus has a lower frequency of phosphorylation. All these observations suggest 
the importance of the ability of the substrates to access the catalytic cleft of the kinase for 
phosphorylation.  
 Actin elongators VASP and EVL are also substrates of YopO. A profilin-bound 
actin monomer binds to the proline-rich region of VASP, directing the F-actin binding 
and tetramerization domain towards the catalytic cleft of the kinase (Fig 7.1C). No 
phosphorylation was detected in the G-actin binding domain, as it is bound to actin and 
cannot reach into the catalytic cleft. These models agree with the mass spectrometry 
results of VASP and EVL, for which phosphorylation sites were identified in the 
proximity of the F-actin binding region and the tetramerization domain.   
 YopO phosphorylates WASP, an activator of the actin nucleating protein ARP2/3, 
in the presence of profilin. The proline-rich region (PR) of WASP positions the protein 
for phosphorylation via binding profilin at the barbed end of actin (Fig 7.1D). The VCA 
(WH2-C-A) region C-terminal of PR was shown to have been phosphorylated only at a 
few sites, in contrast to the N-terminal region near the GBD domain that contains many 
phosphorylation sites. This perhaps results from the repulsion between the largely 
negative acidic domain (A) of VCA with the catalytic cleft of the kinase that bears 
negatively charged residues surrounding the cleft (Fig. 3.11). In contrast, the N-terminal 
GBD domain would be able to access the active site of the kinase with the help of the 
linker region between the GBD and the PR domains. 
 Taken together, the substrate preference of the YopO kinase relies upon the 
ability of the substrates to access the catalytic cleft. This agrees well with the regions of 
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Figure 7.1 Schematics of the models of binding of the various substrates 
of YopO into the catalytic cleft of YopO for phosphorylation. YopO-actin 
complex is shown as a surface representation using PyMOL. The GDI 
domain of YopO (G) is shown in magenta; the kinase domain of YopO 
(K) in white; actin (A) in marine. Profilin (P) as a solid circle in red. The 
actin domains 1-4 are labeled. The catalytic cleft of the kinase domain of 
YopO is indicated with a red star. A. The full length human cytoplasmic 
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gelsolin bound to the YopO-actin complex extending its linker between 
G3 and G4 across the catalytic cleft of the kinase domain of YopO (G1-
G6: gelsolin domains 1-6) B. Model of binding of the formin mDia1 
(FH1-FH2-DAD) to the YopO-actin-profilin complex, extending its C-
terminal region towards the catalytic cleft of the kinase domain of YopO 
(FH1/FH2 - Formin homology domains 1/2; DAD-Diaphanous 
autoinhibitory domain). Formin exists as homodimer, however only one 
chain is shown here for simplicity. C. Model of the full length human 
VASP/EVL bound to the YopO-actin-profilin complex with its C-terminal 
end oriented towards the active site of kinase (EVH1-Ena/VASP 
homology domain 1; PR-proline rich region; G- G-actin binding region; F-
F-actin binding region; TET- tetramerization domain). VASP/EVL is not 
indicated as a tetramer for simplicity. D. Model of the full length human 
WASP bound to the YopO-actin-profilin complex with its VCA and GBD 
domain directed towards the kinase domain of YopO (WH1-WASP 
homology domain 1; GBD-GTPase binding domain; V- verprolin 
homology; C- central region; A- acidic region).  
 
 
7.2 MODEL OF THE EFFECT OF PHOSPHORYLATED   SUBSTRATES ON 
 PHAGOCYTOSIS 
  In this study, the phosphorylation sites identified on YopO’s substrates, gelsolin, 
mDia1, VASP, EVL and WASP and the effect of phosphorylation of these substrates on 
actin dynamics have been described. A model for the mechanism of action of the 
phosphorylated substrates on the cytoskeletal disruption leading to the compromised 
phagocytosis of macrophages has been derived (Fig 7.2). The model was drawn based on 
the phosphorylation data identified by mass spectrometry on the phosphorylated 
substrates, coupled with the results obtained from various biochemical assays performed 
using the phosphomimetic/in vitro phosphorylated substrates. The model illustrates the 
downstream effects of the phosphorylated substrates on the actin cytoskeletal 
organization coupled with its effect on phagocytosis. The molecular activities of the 
substrates of YopO in the formation of actin-rich filopodial protrusions involved in 
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phagocytosis were described earlier (Fig. 1.24). Gelsolin phosphorylated by YopO has 
been shown to exhibit increased depolymerization activity on actin filaments. This 
characteristic property gained upon phosphorylation would negatively regulate filopodial 
formation by enhancing actin disassembly, perhaps increasing filopodia retraction and 
impairing filopodia formation. Likewise, the reduced nucleation ability of the 
phosphorylated mDia1 would hamper the formation of the filopodial tip in the initiation 
phase, where mDia1 is involved in de novo nucleation. YopO phosphorylated VASP has 
attenuated actin polymerization activity (Lee et al. [210]) which would result in the 
reduction of F-actin formation during the elongation phase. For the substrate WASP, 
although the effect of the phosphorylated protein on ARP2/3 activation remains 
unaffected, the phosphorylation event might affect its self-activation mechanism leading 
to a reduction in the availability of the active WASP. The binding of the VCA region of 
the activated WASP to ARP2/3 is essential for the nucleation activity of ARP2/3. 
 Jointly, the phosphorylated actin regulators potentially perturb cytoskeletal 
remodeling either directly or indirectly by reducing F-actin formation or increasing F-
actin disassembly. This may lead to attenuated development of actin-rich protrusions, 
which are essential for motility and phagocytosis by macrophages. This is in agreement 
with in vivo studies that showed that over expression of the YopO homologue, YpkA 
leads to extensive actin cytoskeletal disruption with cell rounding and retraction of fibres 
[185,208]. Thus, YopO resists phagocytosis by misregulating filamentous actin formation 

























Figure 7.2 A comprehensive model for the mode of action of YopO. A 
comprehensive model for the mode of action of YopO on actin 
cytoskeletal regulation and the process of phagocytosis through 





7.3 YopO - A HIGHLY PROMISCUOUS KINASE  
 The substrate selectivity of kinases is conferred by various factors, which include 
the local determinants near the active site, charge and hydrophobicity of the surface 
residues and subcellular localization. The consensus sequence for a particular kinase is 
derived based on the phosphorylation sites identified on its various substrates. Based on 
the analysis of various crystal structures of kinase-substrate complexes, the residues that 
lie in the positions +/- 5 to the N- and C-terminus of the phosphorylation site (P-site) of 
the substrates are involved in potential interactions with the activation segment of the 
kinase, between DFG and APE motifs [277,278,279,280]. The activation segment is 
highly variable among the kinases that help to differentiate specific substrates (Fig. 7.3). 







Figure 7.3 Sequence alignments of the catalytic and active sites of YopO 
kinase with related eukaryotic kinases. The activation segment demarcated 
by DFG and APE motifs is highly variable. The catalytic aspartate and 
lysine are shown in red and cyan respectively. The DFG motif is in 
magenta; APE in green; activation segment of YopO is highlighted in 
yellow. Alignment was performed using Clustal Omega.  
 
 Mass spectrometry on the substrates phosphorylated by YopO yielded 
phosphopeptides with different phosphorylation sites. A comparative analysis of the 
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phosphorylated region of these peptides did not yield any consensus sequence around the 
P-site. The amino acids present N- and C-terminal to the P-site varies greatly and do not 
cluster into any particular group (Fig. 7.4). There is perhaps a tendency for hydrophobic 








Figure 7.4 Consensus sequence analysis of YopO. Consensus sequence 
analysis of YopO kinase based on the phosphopeptides identified on its 
substrates gelsolin, mDia1, VASP, EVL and WASP. Ser at the residue 
position 0 represents the P-site. The residues N- and C-terminal of the P-
site are highly random and variable. The logo was created using the 
program PhosphoLogo [281].  
 
 This leads to a conclusion that YopO phosphorylates a wide range of substrates of 
which consensus site specificity plays only a minor role. This promiscuous action of 
YopO kinase could potentially phosphorylate a range of substrates involved in the host 
signaling pathways, using actin as a docking surface. YopO is likely to be mimicking 
human kinases in phosphorylating host proteins due to its promiscuous nature and its 






CONCLUSIONS AND FUTURE RESEARCH 
 
8.1  CONCLUSIONS  
 Studies on Yersinia’s YpkA/YopO over the past 15 years have led us to an 
understanding that these effector proteins resists phagocytosis via disrupting the actin 
cytoskeletal organization of the host [185,193,200]. Although the effect of YpkA/YopO 
on cytoskeletal disruption is proven by various in vivo studies, the mechanism of action 
remained unclear. The crystal structure of the effector protein YopO (encompassing the 
GDI and kinase domains) in complex with actin was solved by Lee et al. [210] along 
with th identification of various actin regulators as substrates of YopO. The work 
suggested that YopO interferes with the actin cytoskeleton by sequestration of 
RhoGTPases, stalling of actin polymerization by steric hindrance and misregulation of a 
number of actin cytoskeleton regulators by phosphorylation. However, the effects of 
phosphorylation by YopO on the function of these actin cytoskeleton regulators were not 
determined. 
 Thus, the work in this thesis was aimed at understanding the effects of 
phosphorylation by YopO on the activity and function of a number of actin cytoskeleton 
regulators. This work also aims to shed light on how YopO, through phosphorylation of 
these substrates, can contribute to disabling phagocytosis. The phosphorylation sites on 
the substrates gelsolin, mDia1, VASP, EVL and WASP by YopO were identified via 
proteomics approach, with in vitro validation of the phosphorylation sites performed for 
gelsolin. Various biochemical assays were designed and performed on each substrate to 
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understand the effect of phosphorylation on G- and F-actin dynamics. Gelsolin 
phosphorylated by YopO was shown to exhibit increased depolymerizing activity on 
actin filaments. Reduced nucleation activity was observed for phosphorylated mDia1; 
VASP phosphorylated by YopO has attenuated actin polymerization activity (Lee et al. 
[210]). For the substrate WASP no direct effect on polymerization was observed, 
however phosphorylatio by YopO might effect WASP self-activation mechanism leading 
to misregulated ARP2/3 nucleation activity. All these findings lead to the conclusion that 
the net filamentous actin population was effected by the effect of phosphorylation on 
these substrates. Finally, a comprehensive model was established based on these results. 
In the model, phosphorylated actin regulators are hypothesized to disable phagocytosis of 
the host macrophages via reduction of formation of F-actin rich filopodial protrusions. In 
another part of this work, the structure of YopO in complex with actin and ligands 
MgADP has been elucidated. The structure provides a deeper understanding of the 
catalytic mechanism of the kinase domain of YopO.  
 Analysis of the phosphorylated regions of the various substrates of YopO did not 
yield a particular consensus phosphorylation sequence for YopO. This suggests that 
peptide specificity may not play a major role in substrate selection but rather, YopO can 
aberrantly phosphorylate any substrate that is recruited by the actin it is bound to, 
provided it meets the requirement of being able to reach the catalytic cleft while 
interacting with the actin-bound YopO. Given that there are more than 300 actin-binding 
proteins discovered so far, the ability to aberrantly phosphorylate any substrate that 
YopO can recruit using actin as a scaffold should have more far-reaching consequences. 
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 In vitro phosphorylation of the actin regulators by YopO, however, did not result 
in complete upregulation/downregulation of the individual protein’s activity. This 
suggests that phosphorylation of the actin regulators by YopO may not be the only way 
by which Yersinia exerts its anti-phagocytic activity towards macrophages. In 
physiological conditions, YopO co-ordinates with the other anti-phagocytic factors Psa, 
F1, other Yops (YopH, T and E) to block phagocytosis in the host cells [214]. The 
combined effect of all these virulence factors renders Yersinia resistant to phagocytosis 
by macrophages.  
 YpkA/YopO is an essential virulence factor of Yersinia that contributed to the 
deaths of hundreds of millions of people in the past and cases are still observed in the 
present. Upon infection, YopO disables the immune system via ensuring the survival of 
the pathogen inside the host [214]. In conclusion, YopO can act as a potential negative 
regulator of the host defense mechanism that impairs the phagocytic process of 
macrophages by cytoskeletal disruption via phosphorylation of the actin regulators.  
 
8.2  FUTURE WORK 
8.2.1 In vitro mutation validation of the identified phosphorylation sites for mDia1, 
VASP, EVL and WASP 
 The phosphorylation sites identified on substrates mDia1, VASP, EVL and 
WASP have yet to be validated in vitro mutation in the work described in this thesis. In 
vitro mutation validation of phosphorylation sites on these substrates are technically 
tedious due to the large number of phosphorylation sites identified via MS. However, it 
would be interesting to validate the sites that are identified on the various domains of 
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these proteins, say FH2 domain on mDia1 and VCA on WASP by preparing phospho-
deletion mutants followed by [γ-32P] phosphorylation assays. This would allow mapping 
of the effect of phosphorylation to the precise phosphorylation site on the protein. 
 
8.2.2 Quantification of the percentage of protein phosphorylated by YopO  
 The effect of the phosphorylated actin regulators mDia1, VASP and WASP on 
actin dynamics were studied using the proteins that were phosphorylated in vitro. 
Phosphorylation reactions carried out in vitro may not always result in a complete 
phosphorylation of the substrate depending on many factors such as the substrate 
concentration, kinase activity or the local environment under which the reaction was 
carried out. Thus, it will be useful to quantitate the percentage of protein that is 
phosphorylated by YopO to draw concrete conclusions on the extent to which the 
phosphorylated protein affects the actin dynamics. Various methods have been developed 
recently, that include     Phos Tag™- SDS PAGE and Pro-Q® Diamond phosphoprotein 
gel stain which allows the quantification of the percentage of proteins that are 
phosphorylated [282,283]. Alternatively, the phosphorylated protein can be purified from 
the phosphorylation mixture via phosphoprotein purification techniques [284,285] for use 
in biochemical assays.  
 
8.2.3 Data collection and structure determination of the gelsolin phosphomimetic 
mutants 
 As described in section 4.5, the crystals obtained for phosphomimetic mutants of 
gelsolin were relatively small compared to WT crystals and diffracted poorly in in-house 
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X-ray facility at DBS, NUS. Optimization of the crystal growth via micro or 
macroseeding [270] to obtain larger crystals might result in better diffraction data.  
 Based on the biochemical assays, the mutations present in the phosphomimetic 
mutants of gelsolin leads to its calcium-independent activation. Therefore, it is 
anticipated to obtain the structure corresponding to the active form of gelsolin from these 
mutants. However, the linker region between G3 and G4 that adopts an extended 
conformation in the activated form is prone to proteolysis as described in the literature 
[95]. This would either result in no electron density for the linker or the phosphomimetic 
mutations could stabilize the linker against proteolysis. Either of these results would 
support the activation mechanism of the phosphomimetic mutants as hypothesized in 
chapter 4. 
 
8.2.4 To determine if the phosphorylated mDia1 by YopO affects filament 
elongation  
 Formin mDia1 acts as a nucleator as well as elongator of the actin filaments. Only 
the nucleation activity of phosphorylated mDia1 was assessed in this work. Formins 
perform filament elongation as they processively move along the actin filaments [219]. 
They constitute the major part of the filopodial tip complexes where they perform 
filament elongation to increase the filament lengths during filopodial growth. Thus, 
performing barbed end filament elongation assays as described [286] on the 
phosphorylated protein will provide clues on the effect of phosphorylation of mDia1 by 




8.2.5 To test the effect of phosphorylation of WASP on its activation mechanism 
 Majority of phosphorylation sites identified on WASP were located at the GBD 
domain which leads to a hypothesis that the phosphorylated WASP can either be 
constitutively active or incapable of being activated by Cdc42 binding. The ability of 
Cdc42 to bind the phosphorylated form of WASP can be validated through Isothermal 
titration calorimetry (ITC) [287] / Surface Plasma Resonance (SPR) [288] techniques. An 
ARP2/3 activation assay involving the auto-inhibited WASP construct and 
phosphorylated WASP will help to understand WASP’s activation mechanism.  
 
8.2.6 Validation of the substrate length to reach the catalytic cleft of YopO kinase 
for phosphorylation 
 Based on the work by Lee et al. [210] and the phosphorylation sites identified on 
the various substrates of YopO in the work described in this thesis, it was hypothesized 
that not all proteins that bind the barbed end of YopO-bound actin are phosphorylated by 
YopO. Only the proteins of particular length and size that are accessible to the catalytic 
cleft of the kinase that is approx. 31.5 Å wide are phosphorylated. To validate this 
hypothesis, substrates of different lengths that bind barbed end of YopO-bound actin can 
be tested for their ability to be phosphorylated. Among the substrates identified for 
YopO, gelsolin is well studied and is capable of being expressed in different lengths i.e. 
G1/G1-G2/G1-G2-G3/G1-G2-G3-linker etc. Therefore, the substrate length requirement 





8.2.7   In vivo studies to understand the effect of the phosphorylated  substrates of 
 YopO on actin cytoskeletal disruption 
 To further validate the in vitro effects of the phosphorylated substrates of YopO 
on actin dynamics, in vivo studies can be performed using macrophage cell lines 
transfected with phosphomimetic mutants of the substrates. In vitro assays suggest that 
phosphorylation of the actin regulators by YopO leads to reduction in net F-actin 
formation. In vivo, the cells transfected with phosphomimetic mutants of the substrate of 
YopO may perhaps show defects in the lamellipodia/filopodia formation that can be 
visualized by phalloidin stabilized F-actin filaments. In vivo experiments involving 
fluorescence microscopy would allow the study of the localization of the phosphorylated 
















1. Kabsch W, Mannherz HG, Suck D, Pai EF, Holmes KC (1990) Atomic structure of the 
actin: DNase I complex. Nature 347: 37-44. 
 
2. Dong Y, Asch H, Medina D, Guzman R, Asch B (1999) Concurrent deregulation of 
gelsolin and cyclin D1 in the majority of human and rodent breast cancers. Int. J. 
Cancer 81: 930-938. 
 
3. Nakata T, Nishina Y, Yorifuji H (2001) Cytoplasmic γ Actin as a Z-Disc Protein. 
Biochem. Biophys. Res. Commun. 286: 156-163. 
 
4. Vandekerckhove J, Weber K (1978) At least six different actins are expressed in a 
higher mammal: An analysis based on the amino acid sequence of the amino-
terminal tryptic peptide. J. Mol. Biol. 126: 783-802. 
 
5. Selden L, Gershman L, Estes J (1986) A kinetic comparison between Mg-actin and Ca-
actin. J. Muscle Res. Cell. Motil. 7: 215-224. 
 
6. Page R, Lindberg U, Schutt CE (1998) Domain motions in actin. J. Mol. Biol. 280: 
463-474. 
 
7. Chik JK, Lindberg U, Schutt CE (1996) The Structure of an Open State of β-Actin at 
2.65 Å Resolution. J. Mol. Biol. 263: 607-623. 
 
8. Oda T, Iwasa M, Aihara T, Maeda Y, Narita A (2009) The nature of the globular- to 
fibrous-actin transition. Nature 457: 441-445. 
 
9. Wang H, Robinson RC, Burtnick LD (2010) The structure of native G-actin. 
Cytoskeleton 67: 456-465. 
 
10. Yarmola EG, Somasundaram T, Boring TA, Spector I, Bubb MR (2000) Actin-
Latrunculin A Structure and Function: differential modulation of actin-binding 
protein function by latrunculin A. J. Biol. Chem. 275: 28120-28127. 
 
11. Otterbein LR, Graceffa P, Dominguez R (2001) The Crystal Structure of 
Uncomplexed Actin in the ADP State. Science 293: 708-711. 
 
12. Holmes KC, Popp D, Gebhard W, Kabsch W (1990) Atomic model of the actin 
filament. Nature 347: 44-49. 
 
13. Arata T (1986) Structure of the actin-myosin complex produced by crosslinking in the 
presence of ATP. J. Mol. Biol. 191: 107-116. 
 
14.  Chhabra ES, Higgs HN (2007) The many faces of actin: matching assembly factors 




15.  Svitkina TM, Verkhovsky Ab Fau - McQuade KM, McQuade Km Fau - Borisy GG, 
Borisy GG (1997) Analysis of the actin-myosin II system in fish epidermal 
keratocytes: mechanism of cell body translocation. J. Cell. Biol. 139: 397-415. 
 
16. Svitkina TM, Borisy GG (1999) Arp2/3 complex and actin depolymerizing 
factor/cofilin in dendritic organization and treadmilling of actin filament array in 
lamellipodia. J. Cell. Biol. 145: 1009-1026. 
 
17. Ponti A, Machacek M Fau - Gupton SL, Gupton Sl Fau - Waterman-Storer CM, 
Waterman-Storer Cm Fau - Danuser G, Danuser G (2004) Two distinct actin 
networks drive the protrusion of migrating cells. Science 305: 1782-1786. 
 
18. Borm B, Requardt Rp Fau - Herzog V, Herzog V Fau - Kirfel G, Kirfel G (2005) 
Membrane ruffles in cell migration: indicators of inefficient lamellipodia 
adhesion and compartments of actin filament reorganization. Exp. Cell. Res. 302: 
83-95. 
 
19.  Patel PC, Harrison RE (2008) Membrane ruffles capture C3bi-opsonized particles in 
activated macrophages. Mol. Biol. Cell. 19: 4628-4639. 
 
20.  Faix J, Rottner K (2006) The making of filopodia. Curr. Opin. Cell. Biol. 18: 18-25. 
 
21.  Vasioukhin V, Bauer C, Yin M, Fuchs E (2000) Directed Actin Polymerization Is the 
Driving Force for Epithelial Cell–Cell Adhesion. Cell 100: 209-219. 
 
22. Oldenbourg R, Katoh K, Danuser G (2000) Mechanism of Lateral Movement of 
Filopodia and Radial Actin Bundles across Neuronal Growth Cones. Biophys. J. 
78: 1176-1182. 
 
23. Lebrand C, Dent Ew Fau - Strasser GA, Strasser Ga Fau - Lanier LM, Lanier Lm Fau 
- Krause M, Krause M Fau - Svitkina TM, et al. (2004) Critical role of Ena/VASP 
proteins for filopodia formation in neurons and in function downstream of netrin-
1. Neuron 42: 37-49. 
 
24. Schirenbeck A, Bretschneider T, Arasada R, Schleicher M, Faix J (2005) The 
Diaphanous-related formin dDia2 is required for the formation and maintenance 
of filopodia. Nat. Cell. Biol. 7: 619-625. 
 
25.  Frieden C (1985) Actin and Tubulin Polymerization: The Use of Kinetic Methods to 
Determine Mechanism. Annu. Rev. Biophys. Biophys. Chem. 14: 189-210. 
 
26. Asakura S, Kasai M, Oosawa F (1960) The effect of temperature on the equilibrium 




27. Zimmerle Ct Fau - Frieden C, Frieden C (1986) Effect of temperature on the 
mechanism of actin polymerization. Biochemistry 25: 6432-6438. 
 
28. Wegner A (1976) Head to tail polymerization of actin. J. Mol. Biol.108: 139-150. 
 
29. Kasai M, Asakura S, Oosawa F (1962) The cooperative nature of G-F transformation 
of actin. Biochimica. et. Biophysica. Acta. 57: 22-31. 
 
30. Wegner A, Isenberg G (1983) 12-fold difference between the critical monomer 
concentrations of the two ends of actin filaments in physiological salt conditions. 
Proc. Natl. Acad. Sci. U.S.A. 80: 4922-4925. 
 
31. Carlier MF, Pantaloni D (1986) Direct evidence for ADP-inorganic phosphate-F-actin 
as the major intermediate in ATP-actin polymerization. Rate of dissociation of 
inorganic phosphate from actin filaments. Biochemistry 25: 7789-7792. 
 
32. Dos Remedios, D. CGC, Dedova KM, Tsubakihara IV, A. MBD, et al. (2003) Actin 
Binding Proteins: Regulation of Cytoskeletal Microfilaments. Physiol. Rev. 83: 
433-473. 
 
33. Goldsehmidt-Clermont PJ, Machesky LM, Doberstein SK, Pollard TD (1991) 
Mechanism of the interaction of human platelet profilin with actin. J. Cell. Biol. 
113: 1081-1089. 
 
34. Chika JK, Lindbergb U, Schutt CE (1996) The structure of an open state of beta-actin 
at 2.65 Å resolution. J. Mol. Biol. 263: 607-623. 
 
35. Perelroizen I, Didry D, Christensen H, Chua N-H, Carlier M-F (1996) Role of 
nucleotide exchange and hydrolysis in the function of profilin in action assembly. 
J. Biol. Chem. 271: 12302-12309. 
 
36. Goldschmidt-Clermont P, Machesky L, Baldassare J, Pollard T (1990) The actin-
binding protein profilin binds to PIP2 and inhibits its hydrolysis by phospholipase 
C. Science 247: 1575-1578. 
 
37. Sun H, Kwiatkowska K, Yin H (1996) beta-Thymosins are not simple actin monomer 
buffering proteins. Insights from overexpression studies. J. Biol. Chem. 271: 
9223-9230. 
 
38. Low T, Hu S, Goldstein A (1981) Complete amino acid sequence of bovine thymosin 
beta 4: a thymic hormone that induces terminal deoxynucleotidyl transferase 
activity in thymocyte populations. Proc. Natl. Acad. Sci. U. S. A. 78: 1162-1166. 
 
39. Goldschmidt-Clermont P, Furman M, Wachsstock D, Safer D, Nachmias V, et al. 
(1992) The control of actin nucleotide exchange by thymosin beta 4 and profilin. 
184 
 
A potential regulatory mechanism for actin polymerization in cells. Mol. Biol. 
Cell. 3: 1015-1024. 
 
40. Irobi E, Aguda A, Larsson M, Guerin C, Yin H, et al. (2004) Structural basis of actin 
sequestration by thymosin-beta4: implications for WH2 proteins. EMBO. J. 23: 
3599-3608. 
 
41. Carter L, Christopherson R, dos Remedios C (1997) Analysis of the binding of 
deoxyribonuclease I to G-actin by capillary electrophoresis. Electrophoresis 18: 
1054-1058. 
 
42. Mannherz H, Goody R, Konrad M, Nowak E (1980) The interaction of bovine 
pancreatic deoxyribonuclease I and skeletal muscle actin. Eur. J. Biochem. 104: 
367-379. 
 
43. Weber A, Pennise C, Pring M (1994) DNase I increases the rate constant of 
depolymerization at the pointed (-) end of actin filaments. Biochemistry 33: 4780-
4786. 
 
44. Xue B, Leyrat C, Grimes JM, Robinson RC (2014) Structural basis of thymosin-
β4/profilin exchange leading to actin filament polymerization. Proc. Natl. Acad. 
Sci. U. S. A. 111: E4596-E4605. 
 
45. Eulitz D, Mannherz H (2007) Inhibition of deoxyribonuclease I by actin is to protect 
cells from premature cell death. Apoptosis 12: 1511-1521. 
 
46. Menna E, Fossati G, Scita G, Matteoli M (2011) From filopodia to synapses: the role 
of actin-capping and anti-capping proteins. Eur. J. Neurosci. 34: 1655-1662. 
 
47. Casella Jf Fau - Craig SW, Craig Sw Fau - Maack DJ, Maack Dj Fau - Brown AE, 
Brown AE (1987) Cap Z(36/32), a barbed end actin-capping protein, is a 
component of the Z-line of skeletal muscle. J. Cell. Biol. 105: 371-379. 
 
48. Nag S, Larsson M, Robinson RC, Burtnick LD (2013) Gelsolin: The tail of a 
molecular gymnast. Cytoskeleton 70: 360-384. 
 
49. Zigmond SH, Evangelista M, Boone C, Yang C, Dar AC, et al. (2003) Formin Leaky 
Cap Allows Elongation in the Presence of Tight Capping Proteins. Curr. Biol. 13: 
1820-1823. 
 
50. Kovar DR, Wu J-Q, Pollard TD (2005) Profilin-mediated Competition between 
Capping Protein and Formin Cdc12p during Cytokinesis in Fission Yeast. Mol. 




51. Weber A, Pennise Cr Fau - Babcock GG, Babcock Gg Fau - Fowler VM, Fowler VM 
(1994) Tropomodulin caps the pointed ends of actin filaments. J. Cell. Biol. 127: 
1627-1635. 
 
52. Weber A, Pennise CR, Fowler VM (1999) Tropomodulin Increases the Critical 
Concentration of Barbed End-capped Actin Filaments by Converting ADP·Pi-
actin to ADP-actin at All Pointed Filament Ends. J. Biol. Chem. 274: 34637-
34645. 
 
53. Uribe R, Jay D (2009) A review of actin binding proteins: new perspectives. Mol. 
Biol. Rep. 36: 121-125. 
 
54. Mogilner A, Rubinstein B (2005) The Physics of Filopodial Protrusion. Biophys. J. 
89: 782-795. 
 
55. Mogilner A, Oster G (1996) Cell motility driven by actin polymerization. Biophys. J.  
71: 3030-3045. 
 
56. Ross R, Jonuleit H, Bros M, Ross X-L, Yamashiro S, et al. (2000) Expression of the 
Actin-Bundling Protein Fascin in Cultured Human Dendritic Cells Correlates with 
Dendritic Morphology and Cell Differentiation. J. Invest. Dermatol. 115: 658-
663. 
 
57. Vignjevic D, Kojima S-i, Aratyn Y, Danciu O, Svitkina T, et al. (2006) Role of fascin 
in filopodial protrusion. J. Cell. Biol. 174: 863-875. 
 
58. Yamashiro S, Yamakita Y, Ono S, Matsumura F (1998) Fascin, an Actin-bundling 
Protein, Induces Membrane Protrusions and Increases Cell Motility of Epithelial 
Cells. Mol. Biol. Cell, 9: 993-1006. 
 
59. Ylänne J, Scheffzek K, Young P, Saraste M (2001) Crystal Structure of the α-Actinin 
Rod Reveals an Extensive Torsional Twist. Structure 9: 597-604. 
 
60. Djinović-Carugo K, Young P, Gautel M, Saraste M (1999) Molecular Basis for 
Cross-Linking of Actin Filaments: Structure of the α-Actinin Rod. Cell 98: 537-
546. 
 
61. Otey CA, Carpen O (2004) α-actinin revisited: A fresh look at an old player. 
Cytoskeleton 58: 104-111. 
 
62. Fraley TS, Pereira CB, Tran TC, Singleton C, Greenwood JA (2005) 
Phosphoinositide Binding Regulates α-Actinin Dynamics: mechanism for 




63. Gardel ML, Nakamura F, Hartwig JH, Crocker JC, Stossel TP, et al. (2006) 
Prestressed F-actin networks cross-linked by hinged filamins replicate mechanical 
properties of cells. Proc. Natl. Acad. Sci. U. S. A. 103: 1762-1767. 
 
64. Kim H, Sengupta A, Glogauer M, McCulloch CA (2008) Filamin A regulates cell 
spreading and survival via β1 integrins. Exp. Cell. Res. 314: 834-846. 
 
65. Van der Flier A, Sonnenberg A (2001) Structural and functional aspects of filamins. 
Biochimica et Biophysica Acta (BBA) - Mol. Cell. Res. 1538: 99-117. 
 
66.  Nakagawa H, Miki H, Nozumi M, Takenawa T, Miyamoto S, et al. (2003) IRSp53 is 
colocalised with WAVE2 at the tips of protruding lamellipodia and filopodia 
independently of Mena. J. Cell. Sci. 116: 2577-2583. 
 
67.  Burtnick LD, Koepf EK, Grimes J, Jones EY, Stuart DI, et al. (1997) The Crystal 
Structure of Plasma Gelsolin: Implications for Actin Severing, Capping, and 
Nucleation. Cell 90: 661-670. 
 
68. Robinson RC, Mejillano M, Le VP, Burtnick LD, Yin HL, et al. (1999) Domain 
Movement in Gelsolin: A Calcium-Activated Switch. Science 286: 1939-1942. 
 
69. Sakurai T, Kurokawa H, Nonomura Y (1991) Comparison between the gelsolin and 
adseverin domain structure. J. Biol. Chem. 266: 15979-15983. 
 
70. Rodríguez Del Castillo A, Vitale ML, Trifaró JM (1992) Ca2+ and pH determine the 
interaction of chromaffin cell scinderin with phosphatidylserine and 
phosphatidylinositol 4,5,-biphosphate and its cellular distribution during 
nicotinic-receptor stimulation and protein kinase C activation. J. cell. Biol. 119: 
797-810. 
 
71. Rodriguez Del Castillo A, Lemaire S Fau - Tchakarov L, Tchakarov L Fau - 
Jeyapragasan M, Jeyapragasan M Fau - Doucet JP, Doucet Jp Fau - Vitale ML, et 
al. (1990) Chromaffin cell scinderin, a novel calcium-dependent actin filament-
severing protein. EMBO. J. 9: 43-52. 
 
72. Northrop J, Weber A, Mooseker MS, Franzini-Armstrong C, Bishop MF, et al. (1986) 
Different calcium dependence of the capping and cutting activities of villin. J. 
Biol. Chem. 261: 9274-9281. 
 
73. Walsh TP, Weber A, Davis K, Bonder E, Mooseker M (1984) Calcium dependence of 
villin-induced actin depolymerization. Biochemistry 23: 6099-6102. 
 
74. Chen Q, Pollard Thomas D (2013) Actin Filament Severing by Cofilin Dismantles 




75. Elam WA, Kang H, De La Cruz EM (2013) Biophysics of actin filament severing by 
cofilin. FEBS Lett. 587: 1215-1219. 
 
76. Pollard TD, Cooper JA (2009) Actin, a Central Player in Cell Shape and Movement. 
Science 326: 1208-1212. 
 
77. Yin HL, Stossel TP (1979) Control of cytoplasmic actin gel-sol transformation by 
gelsolin, a calcium-dependent regulatory protein. Nature 281: 583-586. 
 
78. Arora PD, Chan MWC, Anderson RA, Janmey PA, McCulloch CA (2005) Separate 
Functions of Gelsolin Mediate Sequential Steps of Collagen Phagocytosis. Mol. 
Biol. Cell, 16: 5175-5190. 
 
79. Janmey PA, Chaponnier C, Lind SE, Zaner KS, Stossel TP, et al. (1985) Interactions 
of gelsolin and gelsolin-actin complexes with actin. Effects of calcium on actin 
nucleation, filament severing, and end blocking. Biochemistry 24: 3714-3723. 
 
80. Lagarrigue E, Ternent D, Maciver SK, Fattoum A, Benyamin Y, et al. (2003) The 
activation of gelsolin by low pH. FEBS J. 270: 4105-4112. 
 
81. Janmey PA, Stossel TP (1987) Modulation of gelsolin function by 
phosphatidylinositol 4,5-bisphosphate. Nature 325: 362-364. 
 
82. Kwiatkowski DJ, Stossel TP, Orkin SH, Mole JE, Coltens HR, et al. (1986) Plasma 
and cytoplasmic gelsolins are encoded by a single gene and contain a duplicated 
actin-binding domain. Nature 323: 455-458. 
 
83. Sun HQ, Yamamoto M, Mejillano M, Yin HL (1999) Gelsolin, a Multifunctional 
Actin Regulatory Protein. J. Biol. Chem. 274: 33179-33182. 
 
84. Choe H, Burtnick LD, Mejillano M, Yin HL, Robinson RC, et al. (2002) The Calcium 
Activation of Gelsolin: Insights from the 3Å Structure of the G4–G6/Actin 
Complex. J. Mol. Biol. 324: 691-702. 
 
85. Kwiatkowski DJ (1999) Functions of gelsolin: motility, signaling, apoptosis, cancer. 
Curr. Opin. Cell Biol. 11: 103-108. 
 
86. Silacci P, Mazzolai L, Gauci C, Stergiopulos N, Yin HL, et al. (2004) Gelsolin 
superfamily proteins: key regulators of cellular functions. Cell. Mol. Life Sci. 61: 
2614-2623. 
 
87. Witke W, Sharpe AH, Hartwig JH, Azuma T, Stossel TP, et al. (1995) Hemostatic, 




88. Serrander L, Skarman P, Rasmussen B, Witke W, Lew DP, et al. (2000) Selective 
Inhibition of IgG-Mediated Phagocytosis in Gelsolin-Deficient Murine 
Neutrophils. J. Immunol. 165: 2451-2457. 
 
89. Kamada S, Kusano H, Fujita H, Ohtsu M, Koya R, et al. (1998) A cloning method for 
caspase substrates that uses the yeast two-hybrid system: cloning of the 
antiapoptotic gene gelsolin. Proc. Natl. Acad. Sci. U. S. A. 95: 8532-8537. 
 
90. Burtnick LD, Urosev D, Irobi  E, Narayan K, Robinson RC (2004) Structure of the N-
terminal half of gelsolin bound to actin: roles in severing, apoptosis and FAF. 
EMBO. J. 23: 2713-2722. 
 
91. Kothakota S, Azuma T, Reinhard C, Klippel A, Tang J, et al. (1997) Caspase-3-
Generated Fragment of Gelsolin: Effector of Morphological Change in Apoptosis. 
Science 278: 294-298. 
 
92. Asch H, Head K, Dong Y, Natoli F, Winston J, et al. (1996) Widespread loss of 
gelsolin in breast cancers of humans, mice, and rats. Cancer. Res. 56: 4841-4845. 
 
93. Azuma T, Koths K, Flanagan L, Kwiatkowski D (2000) Gelsolin in Complex with 
Phosphatidylinositol 4,5-Bisphosphate Inhibits Caspase-3 and -9 to Retard 
Apoptotic Progression. J. Biol. Chem. 275: 3761-3766. 
 
94. Koya RC, Fujita H, Shimizu S, Ohtsu M, Takimoto M, et al. (2000) Gelsolin Inhibits 
Apoptosis by Blocking Mitochondrial Membrane Potential Loss and Cytochrome 
c Release. J. Biol. Chem. 275: 15343-15349. 
 
95. Nag S, Ma Q, Wang H, Chumnarnsilpa S, Lee WL, et al. (2009) Ca(2+) binding by 
domain 2 plays a critical role in the activation and stabilization of gelsolin. Proc. 
Natl. Acad. Sci. U. S. A.106: 13713-13718. 
 
96. Burtnick LD, Urosev D, Irobi E, Narayan K, Robinson RC (2004) Structure of the N-
terminal half of gelsolin bound to actin: roles in severing, apoptosis and FAF. 
EMBO. J. 23: 2713-2722. 
 
97. Ressad F, Didry D, Xia G-X, Hong Y, Chua N-H, et al. (1998) Kinetic Analysis of 
the Interaction of Actin-depolymerizing Factor (ADF)/Cofilin with G- and F-
Actins: comparison of plant and human ADFs and effect of phosphorylation J. 
Biol. Chem. 273: 20894-20902. 
 
98. Ditsch A, Wegner A (1994) Nucleation of Actin Polymerization by Gelsolin. Eur. J. 
Biochem. 224: 223-227. 
 
99. Corte VD, Demol H, Goethals M, Damme JV, Gettemans J, et al. (1999) 
Identification of Tyr438 as the major in vitro c-Src phosphorylation site in human 
gelsolin: A mass spectrometric approach. Protein Sci. 8: 234-241. 
189 
 
100. De Corte V, Gettemans J, Vandekerckhove J (1997) Phosphatidylinositol 4,5-
bisphosphate specifically stimulates PP60c-src catalyzed phosphorylation of 
gelsolin and related actin-binding proteins. FEBS Lett. 401: 191-196. 
 
101. Takiguchi K, Yamashiro-Matsumura S Fau - Matsumura F, Matsumura F Artificial 
phosphorylation removes Gelsolin's dependence on calcium. 
 
102. Wang Q, Xie Y, Du Q-S, Wu X-J, Feng X, et al. (2003) Regulation of the formation 
of osteoclastic actin rings by proline-rich tyrosine kinase 2 interacting with 
gelsolin. J. Cell. Biol. 160: 565-575. 
 
103. Chesarone MA, DuPage AG, Goode BL (2010) Unleashing formins to remodel the 
actin and microtubule cytoskeletons. Nat. Rev. Mol. Cell. Biol. 11: 62-74. 
 
104. Otomo T, Otomo C, Tomchick DR, Machius M, Rosen MK (2005) Structural Basis 
of Rho GTPase-Mediated Activation of the Formin mDia1. Mol. Cell, 18: 273-
281. 
 
105. Romero S, Le Clainche C, Didry D, Egile C, Pantaloni D, et al. (2004) Formin Is a 
Processive Motor that Requires Profilin to Accelerate Actin Assembly and 
Associated ATP Hydrolysis. Cell 119: 419-429. 
 
106. Schonichen A, Geyer M (2010) Fifteen formins for an actin filament: a molecular 
view on the regulation of human formins. Biochem. Biophys. Acta. 1803: 152-
163. 
 
107. Shimada A, Nyitrai M, Vetter IR, Kühlmann D, Bugyi B, et al. (2004) The Core 
FH2 Domain of Diaphanous-Related Formins Is an Elongated Actin Binding 
Protein that Inhibits Polymerization. Mol. Cell 13: 511-522. 
 
108. Liu W, Sato A, Khadka D, Bharti R, Diaz H, et al. (2008) Mechanism of activation 
of the Formin protein Daam1. Proc. Natl. Acad. Sci. U. S. A. 105: 210-215. 
 
109. Otomo T, Tomchick DR, Otomo C, Panchal SC, Machius M, et al. (2005) Structural 
basis of actin filament nucleation and processive capping by a formin homology 2 
domain. Nature 433: 488-494. 
 
110. Rose R, Weyand M, Lammers M, Ishizaki T, Ahmadian MR, et al. (2005) Structural 
and mechanistic insights into the interaction between Rho and mammalian Dia. 
Nature 435: 513-518. 
 
111. Nezami A, Poy F Fau - Toms A, Toms A Fau - Zheng W, Zheng W Fau - Eck MJ, 
Eck MJ (2010) Crystal structure of a complex between amino and carboxy 
terminal fragments of mDia1: insights into autoinhibition of diaphanous-related 




112. Faix J, Grosse R (2006) Staying in Shape with Formins. Dev. Cell 10: 693-706. 
 
113. Otomo T, Tomchick DR, Otomo C, Machius M, Rosen MK (2010) Crystal Structure 
of the Formin mDia1 in Autoinhibited Conformation. PLoS ONE 5: e12896. 
 
114. Thompson ME, Heimsath EG, Gauvin TJ, Higgs HN, Kull FJ (2013) FMNL3 FH2–
actin structure gives insight into formin-mediated actin nucleation and elongation. 
Nat. Struct. Mol. Biol. 20: 111-118. 
 
115. Watanabe N, Kato T Fau - Fujita A, Fujita A Fau - Ishizaki T, Ishizaki T Fau - 
Narumiya S, Narumiya S (1999) Cooperation between mDia1 and ROCK in Rho-
induced actin reorganization. Nat. Cell. Biol. 1: 136-143. 
 
116. Tuxworth RI, Weber I, Wessels D, Addicks GC, Soll DR, et al. (2001) A role for 
myosin VII in dynamic cell adhesion. Curr. Biol. 11: 318-329. 
 
117. Salazar-Fontana LI, Barr V, Samelson LE, Bierer BE (2003) CD28 Engagement 
Promotes Actin Polymerization Through the Activation of the Small Rho GTPase 
Cdc42 in Human T Cells. J. Immunol. 171: 2225-2232. 
 
118. Hogg N, Laschinger M, Giles K, McDowall A (2003) T-cell integrins: more than 
just sticking points. J. Cell. Sci. 116: 4695-4705. 
 
119. Colucci-Guyon E, Niedergang F, Wallar BJ, Peng J, Alberts AS, et al. (2005) A 
Role for Mammalian Diaphanous-Related Formins in Complement Receptor 
(CR3)-Mediated Phagocytosis in Macrophages. Curr. Biol. 15: 2007-2012. 
 
120. Lewkowicz E, Herit F, Le Clainche C, Bourdoncle P, Perez F, et al. (2008) The 
microtubule-binding protein CLIP-170 coordinates mDia1 and actin 
reorganization during CR3-mediated phagocytosis. J. Cell. Biol. 183: 1287-1298. 
 
121. Brandt DT, Marion S, Griffiths G, Watanabe T, Kaibuchi K, et al. (2007) Dia1 and 
IQGAP1 interact in cell migration and phagocytic cup formation. J. Cell. Biol.  
178: 193-200. 
 
122. Watanabe N, Madaule P, Reid T, Ishizaki T, Watanabe G, et al. (1997) p140mDia, a 
mammalian homolog of Drosophila diaphanous,is a target protein for Rho small 
GTPase and is a ligand for profilin. EMBO J. 16: 3044-3056. 
 
123. Goulimari P, Kitzing TM, Knieling H, Brandt DT, Offermanns S, et al. (2005) 
Gα12/13 Is Essential for Directed Cell Migration and Localized Rho-Dia1 
Function. J. Biol. Chem. 280: 42242-42251. 
 
124. Wen Y, Eng CH, Schmoranzer J, Cabrera-Poch N, Morris EJS, et al. (2004) EB1 
and APC bind to mDia to stabilize microtubules downstream of Rho and promote 




125. Li D, Dammer EB, Lucki NC, Sewer MB (2013) cAMP-stimulated phosphorylation 
of diaphanous 1 regulates protein stability and interaction with binding partners in 
adrenocortical cells. Mol. Biol. Cell 24: 848-857. 
 
126. Staus DP, Taylor JM, Mack CP (2011) Enhancement of mDia2 activity by Rho-
kinase-dependent phosphorylation of the diaphanous autoregulatory domain. 
Biochem. J. 439: 57-65. 
 
127. Cheng L, Zhang J, Ahmad S, Rozier L, Yu H, et al. (2011) Aurora B Regulates 
Formin mDia3 in Achieving Metaphase Chromosome Alignment. Dev. Cell 20: 
342-352. 
 
128. Applewhite DA, Barzik M, Kojima S-i, Svitkina TM, Gertler FB, et al. (2007) 
Ena/VASP Proteins Have an Anti-Capping Independent Function in Filopodia 
Formation. Mol. Biol. Cell 18: 2579-2591. 
 
129. Bear JE, Svitkina TM, Krause M, Schafer DA, Loureiro JJ, et al. (2002) Antagonism 
between Ena/VASP Proteins and Actin Filament Capping Regulates Fibroblast 
Motility. Cell 109: 509-521. 
 
130. Carl UD, Pollmann M Fau - Orr E, Orr E Fau - Gertlere FB, Gertlere Fb Fau - 
Chakraborty T, Chakraborty T Fau - Wehland J, et al. (1999) Aromatic and basic 
residues within the EVH1 domain of VASP specify its interaction with proline-
rich ligands. Curr. Biol. 9: 715-718. 
 
131. Krause M, Leslie JD, Stewart M, Lafuente EM, Valderrama F, et al. (2004) 
Lamellipodin, an Ena/VASP Ligand, Is Implicated in the Regulation of 
Lamellipodial Dynamics. Dev. Cell 7: 571-583. 
 
132. Bashaw GJ, Kidd T, Murray D, Pawson T, Goodman CS (2000) Repulsive Axon 
Guidance. Cell 101: 703-715. 
 
133. Klostermann A, Lutz B Fau - Gertler F, Gertler F Fau - Behl C, Behl C (2000) The 
orthologous human and murine semaphorin 6A-1 proteins (SEMA6A-1/Sema6A-
1) bind to the enabled/vasodilator-stimulated phosphoprotein-like protein (EVL) 
via a novel carboxyl-terminal zyxin-like domain. J. Biol. Chem. 275: 39647-
39653. 
 
134. Niebuhr K, Ebel F Fau - Frank R, Frank R Fau - Reinhard M, Reinhard M Fau - 
Domann E, Domann E Fau - Carl UD, et al. (1997) A novel proline-rich motif 
present in ActA of Listeria monocytogenes and cytoskeletal proteins is the ligand 
for the EVH1 domain, a protein module present in the Ena/VASP family. 
 
135. Lambrechts A, Kwiatkowski AV, Lanier LM, Bear JE, Vandekerckhove J, et al. 
(2000) cAMP-dependent Protein Kinase Phosphorylation of EVL, a Mena/VASP 
192 
 
Relative, Regulates Its Interaction with Actin and SH3 Domains. J. Biol. Chem. 
275: 36143-36151. 
 
136. Gertler FB, Comer Ar Fau - Juang JL, Juang Jl Fau - Ahern SM, Ahern Sm Fau - 
Clark MJ, Clark Mj Fau - Liebl EC, et al. (1995) Enabled, a dosage-sensitive 
suppressor of mutations in the Drosophila Abl tyrosine kinase, encodes an Abl 
substrate with SH3 domain-binding properties. Genes. Dev. 9: 521-533. 
 
137. Walders-Harbeck B, Khaitlina SY, Hinssen H, Jockusch BM, Illenberger S (2002) 
The vasodilator-stimulated phosphoprotein promotes actin polymerisation through 
direct binding to monomeric actin. FEBS Lett. 529: 275-280. 
 
138. Bachmann C, Fischer L Fau - Walter U, Walter U Fau - Reinhard M, Reinhard M 
(1999) The EVH2 domain of the vasodilator-stimulated phosphoprotein mediates 
tetramerization, F-actin binding, and actin bundle formation. J. Biol. Chem. 274: 
23549-23557. 
 
139. Harbeck B, Huttelmaier S Fau - Schluter K, Schluter K Fau - Jockusch BM, 
Jockusch Bm Fau - Illenberger S, Illenberger S (2000) Phosphorylation of the 
vasodilator-stimulated phosphoprotein regulates its interaction with actin. J. Biol. 
Chem. 275: 30817-30825. 
 
140. Ahern-Djamali SM, Comer Ar Fau - Bachmann C, Bachmann C Fau - Kastenmeier 
AS, Kastenmeier As Fau - Reddy SK, Reddy Sk Fau - Beckerle MC, et al. (1998) 
Mutations in Drosophila enabled and rescue by human vasodilator-stimulated 
phosphoprotein (VASP) indicate important functional roles for Ena/VASP 
homology domain 1 (EVH1) and EVH2 domains. Mol. Biol. Cell. 9: 2157-2171. 
 
141. Fedorov AA, Fedorov E, Gertler F, Almo SC (1999) Structure of EVH1, a novel 
proline-rich ligand-binding module involved in cytoskeletal dynamics and neural 
function. Nat. Struct. Mol. Biol. 6: 661-665. 
 
142. Ferron F, Rebowski G Fau - Lee SH, Lee Sh Fau - Dominguez R, Dominguez R 
(2007) Structural basis for the recruitment of profilin-actin complexes during 
filament elongation by Ena/VASP. EMBO. J. 26: 4597-4606. 
 
143. Kuhnel K, Jarchau T Fau - Wolf E, Wolf E Fau - Schlichting I, Schlichting I Fau - 
Walter U, Walter U Fau - Wittinghofer A, et al. (2004) The VASP tetramerization 
domain is a right-handed coiled coil based on a 15-residue repeat. Proc. Natl. 
Acad. Sci. U. S. A. 101: 17027-17032. 
 
144. Krause M, Sechi AS, Konradt M, Monner D, Gertler FB, et al. (2000) Fyn-Binding 
Protein (Fyb)/Slp-76–Associated Protein (Slap), Ena/Vasodilator-Stimulated 
Phosphoprotein (Vasp) Proteins and the Arp2/3 Complex Link T Cell Receptor 




145. Grevengoed EE, Loureiro JJ, Jesse TL, Peifer M (2001) Abelson kinase regulates 
epithelial morphogenesis in Drosophila. J. Cell. Biol.  155: 1185-1198. 
 
146. Coppolino MG, Krause M, Hagendorff P, Monner DA, Trimble W, et al. (2001) 
Evidence for a molecular complex consisting of Fyb/SLAP, SLP-76, Nck, VASP 
and WASP that links the actin cytoskeleton to Fcγ receptor signalling during 
phagocytosis. J. Cell. Sci. 114: 4307-4318. 
 
147. Anderson SI, Behrendt B, Machesky LM, Insall RH, Nash GB (2003) Linked 
regulation of motility and integrin function in activated migrating neutrophils 
revealed by interference in remodelling of the cytoskeleton. Cell Motility and the 
Cytoskeleton 54: 135-146. 
 
148. Halbrügge M, Friedrich C, Eigenthaler M, Schanzenbächer P, Walter U (1990) 
Stoichiometric and reversible phosphorylation of a 46-kDa protein in human 
platelets in response to cGMP- and cAMP-elevating vasodilators. J. Biol. Chem. 
265: 3088-3093. 
 
149. HalbrÜgge M, Walter U (1989) Purification of a vasodilator-regulated 
phosphoprotein from human platelets. Eur. J. Biochem. 185: 41-50. 
 
150. Gambaryan S, Hauser W, Kobsar A, Glazova M, Walter U (2001) Distribution, 
cellular localization, and postnatal development of VASP and Mena expression in 
mouse tissues. Histochem. Cell Biol. 116: 535-543. 
 
151. Lanier LM, Gates MA, Witke W, Menzies AS, Wehman AM, et al. (1999) Mena Is 
Required for Neurulation and Commissure Formation. Neuron 22: 313-325. 
 
152. Aszodi A, Pfeifer A Fau - Ahmad M, Ahmad M Fau - Glauner M, Glauner M Fau - 
Zhou XH, Zhou Xh Fau - Ny L, et al. (1999) The vasodilator-stimulated 
phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of 
agonist-induced platelet aggregation, but is dispensable for smooth muscle 
function. EMBO. J. 18: 37-48. 
 
153. Bear JE, Loureiro JJ, Libova I, Fässler R, Wehland J, et al. (2000) Negative 
Regulation of Fibroblast Motility by Ena/VASP Proteins. Cell 101: 717-728. 
 
154. Butt E, Abel K Fau - Krieger M, Krieger M Fau - Palm D, Palm D Fau - Hoppe V, 
Hoppe V Fau - Hoppe J, et al. (1994) cAMP- and cGMP-dependent protein kinase 
phosphorylation sites of the focal adhesion vasodilator-stimulated phosphoprotein 
(VASP) in vitro and in intact human platelets. J. Biol. Chem. 269: 14509-14517. 
 
155. Gertler FB, Niebuhr K Fau - Reinhard M, Reinhard M Fau - Wehland J, Wehland J 
Fau - Soriano P, Soriano P (1996) Mena, a relative of VASP and Drosophila 





156. Blume C, Benz PM, Walter U, Ha J, Kemp BE, et al. (2007) AMP-activated Protein 
Kinase Impairs Endothelial Actin Cytoskeleton Assembly by Phosphorylating 
Vasodilator-stimulated Phosphoprotein. J. Biol. Chem.  282: 4601-4612. 
 
157. Wentworth JK, Pula G Fau - Poole AW, Poole AW (2006) Vasodilator-stimulated 
phosphoprotein (VASP) is phosphorylated on Ser157 by protein kinase C-
dependent and -independent mechanisms in thrombin-stimulated human platelets. 
Biochem. J. 393: 1470-8728. 
 
158. Doppler HR, Bastea Li Fau - Lewis-Tuffin LJ, Lewis-Tuffin Lj Fau - Anastasiadis 
PZ, Anastasiadis Pz Fau - Storz P, Storz P (2013) Protein kinase D1-mediated 
phosphorylations regulate vasodilator-stimulated phosphoprotein (VASP) 
localization and cell migration.  J. Biol. Chem. 288: 24382-24393. 
 
159. Thrasher AJ, Burns SO (2010) WASP: a key immunological multitasker. Nat. Rev. 
Immunol. 10: 182-192. 
 
160. Snapper SB, Rosen FS (1999) The Wiskott Aldrich syndrome protein (WASP): 
Roles in Signaling and Cytoskeletal Organization. Annu. Rev. Immunol. 17: 905-
929. 
 
161. Kim AS, Kakalis LT, Abdul-Manan N, Liu GA, Rosen MK (2000) Autoinhibition 
and activation mechanisms of the Wiskott-Aldrich syndrome protein. Nature 404: 
151-158. 
 
162. Abdul-Manan N, Aghazadeh B, Liu GA, Majumdar A, Ouerfelli O, et al. (1999) 
Structure of Cdc42 in complex with the GTPase-binding domain of the Wiskott-
Aldrich syndrome protein. Nature 399: 379-383. 
 
163. Volkman BF, Prehoda KE, Scott JA, Peterson FC, Lim WA (2002) Structure of the 
N-WASP EVH1 Domain-WIP Complex: Insight into the Molecular Basis of 
Wiskott-Aldrich Syndrome. Cell 111: 565-576. 
 
164. Carlier M-F, Nioche P, Broutin-L'Hermite I, Boujemaa R, Le Clainche C, et al. 
(2000) GRB2 Links Signaling to Actin Assembly by Enhancing Interaction of 
Neural Wiskott-Aldrich Syndrome Protein (N-WASp) with Actin-related Protein 
(ARP2/3) Complex. J. Biol. Chem. 275: 21946-21952. 
 
165. Rohatgi R, Nollau P, Ho H-YH, Kirschner MW, Mayer BJ (2001) Nck and 
Phosphatidylinositol 4,5-Bisphosphate Synergistically Activate Actin 





166. Tsuboi S, Meerloo J (2007) Wiskott-Aldrich Syndrome Protein Is a Key Regulator 
of the Phagocytic Cup Formation in Macrophages. J. Biol. Chem. 282: 34194-
34203. 
 
167. Leverrier Y, Lorenzi R, Blundell MP, Brickell P, Kinnon C, et al. (2001) Cutting 
Edge: The Wiskott-Aldrich Syndrome Protein Is Required for Efficient 
Phagocytosis of Apoptotic Cells. J. Immunol. 166: 4831-4834. 
 
168. Zicha, Allen, Brickell, Kinnon, Dunn, et al. (1998) Chemotaxis of macrophages is 
abolished in the Wiskott-Aldrich syndrome. Br. J. Haematol. 101: 659-665. 
 
169. Burns S, Thrasher AJ, Blundell MP, Machesky L, Jones GE (2001) Configuration of 
human dendritic cell cytoskeleton by Rho GTPases, the WAS protein, and 
differentiation. Blood 98: 1142-1149. 
 
170. Badour K, Zhang J Fau - Shi F, Shi F Fau - McGavin MKH, McGavin Mk Fau - 
Rampersad V, Rampersad V Fau - Hardy LA, et al. (2003) The Wiskott-Aldrich 
syndrome protein acts downstream of CD2 and the CD2AP and PSTPIP1 
adaptors to promote formation of the immunological synapse. Immunity 18: 
1074-7613. 
 
171. Sasahara Y, Rachid R Fau - Byrne MJ, Byrne Mj Fau - de la Fuente MA, de la 
Fuente Ma Fau - Abraham RT, Abraham Rt Fau - Ramesh N, et al. (2002) 
Mechanism of recruitment of WASP to the immunological synapse and of its 
activation following TCR ligation. Mol. Cell. 10: 1097-2765. 
 
172. Lorenzi R, Brickell PM, Katz DR, Kinnon C, Thrasher AJ (2000) Wiskott-Aldrich 
syndrome protein is necessary for efficient IgG-mediated phagocytosis. Blood 95: 
2943-2946. 
 
173. Chereau D, Kerff F, Graceffa P, Grabarek Z, Langsetmo K, et al. (2005) Actin-
bound structures of Wiskott–Aldrich syndrome protein (WASP)-homology 
domain 2 and the implications for filament assembly. Proc. Natl. Acad. Sci. 
U.S.A. 102: 16644-16649. 
 
174. Lutskiy MI, Shcherbina A, Bachli ET, Cooley J, Remold-O'Donnell E (2007) 
WASP localizes to the membrane skeleton of platelets. Br. J. Haematol. 139: 98-
105. 
 
175. Wu X, Suetsugu S, Cooper LA, Takenawa T, Guan J-L (2004) Focal Adhesion 
Kinase Regulation of N-WASP Subcellular Localization and Function. J. Biol. 
Chem. 279: 9565-9576. 
 
176. Baba Y, Nonoyama S, Matsushita M, Yamadori T, Hashimoto S, et al. (1999) 
Involvement of Wiskott-Aldrich Syndrome Protein in B-Cell Cytoplasmic 




177. Torres E, Rosen MK (2006) Protein-tyrosine Kinase and GTPase Signals Cooperate 
to Phosphorylate and Activate Wiskott-Aldrich Syndrome Protein 
(WASP)/Neuronal WASP. J. Biol. Chem. 281: 3513-3520. 
 
178. Cory GOC, Cramer R, Blanchoin L, Ridley AJ (2003) Phosphorylation of the 
WASP-VCA Domain Increases Its Affinity for the Arp2/3 Complex and 
Enhances Actin Polymerization by WASP. Mol. Cell 11: 1229-1239. 
 
179. Yokoyama N, Lougheed J, Miller WT (2005) Phosphorylation of WASP by the 
Cdc42-associated Kinase ACK1: dual hydroxyamino acid specificity in a tyrosine 
kinase. J. Biol. Chem.  280: 42219-42226. 
 
180. Cornelis GR (2006) The type III secretion injectisome. Nat. Rev. Micro. 4: 811-825. 
 
181. Cornelis GR, Wolf-Watz H (1997) The Yersinia Yop virulon: a bacterial system for 
subverting eukaryotic cells. Mol. Micro. 23: 861-867. 
 
182. Cornelis GR, Boland A, Boyd AP, Geuijen C, Iriarte M, et al. (1998) The Virulence 
Plasmid of Yersinia, an Antihost Genome. Microbiol. Mol. Biol. Rev. 62: 1315-
1352. 
 
183. Viboud GI, Bliska JB (2005) Yersinia outer proteins: Role in Modulation of Host 
Cell Signaling Responses and Pathogenesis. Annu. Rev. Microbiol. 59: 69-89. 
 
184. Juris SJ, Shao F, Dixon JE (2002) Yersinia effectors target mammalian signalling 
pathways. Cell. Micro. 4: 201-211. 
 
185. Juris SJ, Rudolph AE, Huddler D, Orth K, Dixon JE (2000) A distinctive role for the 
Yersinia protein kinase: Actin binding, kinase activation, and cytoskeleton 
disruption. Proc. Natl. Acad. Sci. U. S. A. 97: 9431-9436. 
 
186. Aepfelbacher M, Trasak C, Ruckdeschel K (2007) Effector functions of pathogenic 
Yersinia species. Thromb. Haemostasis 98. 
 
187. Grosdent N, Maridonneau-Parini I, Sory M-P, Cornelis GR (2002) Role of Yops and 
Adhesins in Resistance of Yersinia enterocolitica to Phagocytosis. Infection and 
Immunity 70: 4165-4176. 
 
188. Ruckdeschel K, Harb S, Roggenkamp A, Hornef M, Zumbihl R, et al. (1998) 
Yersinia enterocolitica Impairs Activation of Transcription Factor NF-κB: 
Involvement in the Induction of Programmed Cell Death and in the Suppression 





189. Ruckdeschel K, Machold J, Roggenkamp A, Schubert S, Pierre J, et al. (1997) 
Yersinia enterocolitica Promotes Deactivation of Macrophage Mitogen-activated 
Protein Kinases Extracellular Signal-regulated Kinase-1/2, p38, and c-Jun NH2-
terminal Kinase: correlation with its inhibitory effect on tumor necrosis factor-α 
production. J. Biol. Chem. 272: 15920-15927. 
 
190. Shao F, Vacratsis PO, Bao Z, Bowers KE, Fierke CA, et al. (2003) Biochemical 
characterization of the Yersinia YopT protease: Cleavage site and recognition 
elements in Rho GTPases. Proc. Natl. Acad. Sci. U. S. A.  100: 904-909. 
 
191. Bliska JB, Black DS (1995) Inhibition of the Fc receptor-mediated oxidative burst in 
macrophages by the Yersinia pseudotuberculosis tyrosine phosphatase. Infect. 
Immun. 63: 681-685. 
 
192. Galyov EE, Hakansson S, Forsberg A, Wolf-Watz H (1993) A secreted protein 
kinase of Yersinia pseudotuberculosis is an indispensable virulence determinant. 
Nature 361: 730-732. 
 
193. Prehna G, Ivanov MI, Bliska JB, Stebbins CE (2006) Yersinia Virulence Depends 
on Mimicry of Host Rho-Family Nucleotide Dissociation Inhibitors. Cell 126: 
869-880. 
 
194. Black DS, Marie-Cardine A, Schraven B, Bliska JB (2000) The Yersinia tyrosine 
phosphatase YopH targets a novel adhesion-regulated signalling complex in 
macrophages. Cell. Micro. 2: 401-414. 
 
195. Viboud GI, Bliska JB Yersinia outer proteins: role in modulation of host cell 
signaling responses and pathogenesis. 
 
196. xE, llman M, Persson C, Wolf-Watz H (1997) Yersinia proteins that target host cell 
signaling pathways. J. Clin. Invest. 99: 1153-1157. 
 
197. Trasak C, Zenner G, Vogel A, Yüksekdag G, Rost R, et al. (2007) Yersinia Protein 
Kinase YopO Is Activated by A Novel G-actin Binding Process. J. Biol. Chem. 
282: 2268-2277. 
 
198. Heasman SJ, Ridley AJ (2008) Mammalian Rho GTPases: new insights into their 
functions from in vivo studies. Nat. Rev. Mol. Cell. Biol. 9: 690-701. 
 
199. Barz C, Abahji TN, Trülzsch K, Heesemann J (2000) The Yersinia Ser/Thr protein 
kinase YpkA/YopO directly interacts with the small GTPases RhoA and Rac-1. 
FEBS Lett. 482: 139-143. 
 
200. Groves E, Rittinger K, Amstutz M, Berry S, Holden DW, et al. (2010) Sequestering 
of Rac by the Yersinia Effector YopO Blocks Fcγ Receptor-mediated 




201. Dukuzumuremyi J-M, Rosqvist R, Hallberg B, Åkerström B, Wolf-Watz H, et al. 
(2000) The Yersinia Protein Kinase A Is a Host Factor Inducible RhoA/Rac-
binding Virulence Factor. J. Biol. Chem. 275: 35281-35290. 
 
202. Aderem A, Underhill DM (1999) Mechanisms of phagocytosis in macrophages. 
Annu. Rev. Immunol. 17: 593-623. 
 
203. Caron E, Hall A (1998) Identification of Two Distinct Mechanisms of Phagocytosis 
Controlled by Different Rho GTPases. Science 282: 1717-1721. 
 
204. Tzircotis G, Braga VMM, Caron E (2011) RhoG is required for both FcγR- and 
CR3-mediated phagocytosis. J. Cell. Sci. 124: 2897-2902. 
 
205. Cox D, Chang P, Zhang Q, Reddy PG, Bokoch GM, et al. (1997) Requirements for 
Both Rac1 and Cdc42 in Membrane Ruffling and Phagocytosis in Leukocytes. J. 
Exp. Med. 186: 1487-1494. 
 
206. Stevens JM, Galyov EE, Stevens MP (2006) Actin-dependent movement of bacterial 
pathogens. Nat. Rev. Micro. 4: 91-101. 
 
207. Wiley DJ, Nordfeldth R, Rosenzweig J, DaFonseca CJ, Gustin R, et al. (2006) The 
Ser/Thr kinase activity of the Yersinia protein kinase A (YpkA) is necessary for 
full virulence in the mouse, mollifying phagocytes, and disrupting the eukaryotic 
cytoskeleton. Microb. Pathog. 40: 234-243. 
 
208. Håkansson S, Galyov EE, Rosqvist R, Wolf-Watz H (1996) The Yersinia YpkA 
Ser/Thr kinase is translocated and subsequently targeted to the inner surface of the 
HeLa cell plasma membrane. Mol. Micro. 20: 593-603. 
 
209. Straley SC, Bowmer WS (1986) Virulence genes regulated at the transcriptional 
level by Ca2+ in Yersinia pestis include structural genes for outer membrane 
proteins. Infect. Immun. 51: 445-454. 
 
210. Lee WL, Grimes JM, Robinson RC (2015) Yersinia effector YopO uses actin as bait 
to phosphorylate proteins that regulate actin polymerization. Nat. Struct. Mol. 
Biol. 22: 248-255. 
 
211. Dominguez R (2004) Actin-binding proteins – a unifying hypothesis. Trends 
Biochem. Sci. 29: 572-578. 
 
212. Juris SJ, Shah K, Shokat K, Dixon JE, Vacratsis PO (2006) Identification of otubain 
1 as a novel substrate for the Yersinia protein kinase using chemical genetics and 




213. Rosenberger CM, Finlay BB (2003) Phagocyte sabotage: disruption of macrophage 
signalling by bacterial pathogens. Nat. Rev. Mol. Cell. Biol. 4: 385-396. 
 
214. Ke Y, Chen Z, Yang R (2013) Yersinia pestis: mechanisms of entry into and 
resistance to the host cell. Front Cell Infect Microbiol 3: 106. 
 
215. Navarro L, Koller A, Nordfelth R, Wolf-Watz H, Taylor S, et al. (2007) 
Identification of a Molecular Target for the Yersinia Protein Kinase A. Mol. Cell 
26: 465-477. 
 
216. May RC, Machesky LM (2001) Phagocytosis and the actin cytoskeleton. J. Cell. Sci. 
114: 1061-1077. 
 
217. Pollard TD, Blanchoin L, Mullins RD (2000) Molecular Mechanisms Controlling 
Actin Filament Dynamics In Nonmuscle Cells. Annu. Rev. Biophys. Biomol. 
Struct. 29: 545-576. 
 
218. Kress H, Stelzer EHK, Holzer D, Buss F, Griffiths G, et al. (2007) Filopodia act as 
phagocytic tentacles and pull with discrete steps and a load-dependent velocity. 
Proc. Natl. Acad. Sci. U. S. A. 104: 11633-11638. 
 
219. Mellor H (2010) The role of formins in filopodia formation. Biochimica et 
Biophysica Acta (BBA) - Mol. Cell. Res. 1803: 191-200. 
 
220. Pruyne D, Evangelista M, Yang C, Bi E, Zigmond S, et al. (2002) Role of Formins 
in Actin Assembly: Nucleation and Barbed-End Association. Science 297: 612-
615. 
 
221. Kovar DR, Pollard TD (2004) Insertional assembly of actin filament barbed ends in 
association with formins produces piconewton forces. Proc. Natl. Acad. Sci. U. S. 
A. 101: 14725-14730. 
 
222. Lu M, Witke W, Kwiatkowski DJ, Kosik KS (1997) Delayed Retraction of 
Filopodia in Gelsolin Null Mice. J. Cell. Biol. 138: 1279-1287. 
 
223. Barzik M, Kotova TI, Higgs HN, Hazelwood L, Hanein D, et al. (2005) Ena/VASP 
Proteins Enhance Actin Polymerization in the Presence of Barbed End Capping 
Proteins. J. Biol. Chem. 280: 28653-28662. 
 
224. Pasic L, Kotova T, Schafer DA (2008) Ena/VASP Proteins Capture Actin Filament 
Barbed Ends. J. Biol. Chem. 283: 9814-9819. 
 
225. Dent EW, Kwiatkowski AV, Mebane LM, Philippar U, Barzik M, et al. (2007) 




226. Mattila PK, Lappalainen P (2008) Filopodia: molecular architecture and cellular 
functions. Nat. Rev. Mol. Cell. Biol. 9: 446-454. 
 
227. Krause M, Bear JE, Loureiro JJ, Gertler FB (2002) The Ena/VASP enigma. J. Cell. 
Sci. 115: 4721-4726. 
 
228. Bononi A, Agnoletto C Fau - De Marchi E, De Marchi E Fau - Marchi S, Marchi S 
Fau - Patergnani S, Patergnani S Fau - Bonora M, et al. (2011) Protein kinases 
and phosphatases in the control of cell fate. Enzyme. Res. 2011: 2090-0414. 
 
229. Endicott JA, Noble Me Fau - Johnson LN, Johnson LN (2012) The structural basis 
for control of eukaryotic protein kinases. Annu. Rev. Biochem. 81: 1545-4509. 
 
230. Hanks SK, Hunter T (1995) Protein kinases 6. The eukaryotic protein kinase 
superfamily: kinase (catalytic) domain structure and classification. FASEB J. 9: 
576-596. 
 
231. Pereira SFF, Goss L, Dworkin J (2011) Eukaryote-Like Serine/Threonine Kinases 
and Phosphatases in Bacteria. Microbiol. Mol. Biol. Rev. 75: 192-212. 
 
232. Young TA, Delagoutte B, Endrizzi JA, Falick AM, Alber T (2003) Structure of 
Mycobacterium tuberculosis PknB supports a universal activation mechanism for 
Ser/Thr protein kinases. Nat. Struct. Mol. Biol. 10: 168-174. 
 
233. Huse M, Kuriyan J (2002) The Conformational Plasticity of Protein Kinases. Cell 
109: 275-282. 
 
234. Sharrocks AD, Yang S-H, Galanis A (2000) Docking domains and substrate-
specificity determination for MAP kinases. Trends in Biochem. Sci. 25: 448-453. 
 
235. Ubersax JA, Ferrell Jr JE (2007) Mechanisms of specificity in protein 
phosphorylation. Nat. Rev. Mol. Cell. Biol. 8: 530-541. 
 
236. Bayliss R, Sardon T, Vernos I, Conti E (2003) Structural Basis of Aurora-A 
Activation by TPX2 at the Mitotic Spindle. Mol. Cell 12: 851-862. 
 
237. Pike AC, Rellos P Fau - Niesen FH, Niesen Fh Fau - Turnbull A, Turnbull A Fau - 
Oliver AW, Oliver Aw Fau - Parker SA, et al. (2008) Activation segment 
dimerization: a mechanism for kinase autophosphorylation of non-consensus 
sites. EMBO J. 20: 704-714. 
 
238. Kornev AP, Haste NM, Taylor SS, Ten Eyck LF (2006) Surface comparison of 
active and inactive protein kinases identifies a conserved activation mechanism. 




239. Eswaran J, Soundararajan M, Kumar R, Knapp S (2008) UnPAKing the class 
differences among p21-activated kinases. Trends in Biochem. Sci. 33: 394-403. 
 
240. Zhu G, Liu Y Fau - Shaw S, Shaw S (2005) Protein kinase specificity. A strategic 
collaboration between kinase peptide specificity and substrate recruitment. Cell 
Cycle 4: 52-56. 
 
241. Adams JA (2001) Kinetic and Catalytic Mechanisms of Protein Kinases. Chem. 
Rev. 101: 2271-2290. 
 
242. Knighton DR, Zheng Jh Fau - Ten Eyck LF, Ten Eyck Lf Fau - Ashford VA, 
Ashford Va Fau - Xuong NH, Xuong Nh Fau - Taylor SS, et al. (1991) Crystal 
structure of the catalytic subunit of cyclic adenosine monophosphate-dependent 
protein kinase. Science 253: 407-414. 
 
243. Good MC, Zalatan JG, Lim WA (2011) Scaffold Proteins: Hubs for Controlling the 
Flow of Cellular Information. Science 332: 680-686. 
 
244. Reményi A, Good MC, Lim WA (2006) Docking interactions in protein kinase and 
phosphatase networks. Curr. Opin. Struct. Biol. 16: 676-685. 
 
245. Canova MJ, Molle V (2014) Bacterial Serine/Threonine Protein Kinases in Host-
Pathogen Interactions. J. Biol. Chem. 289: 9473-9479. 
 
246. Ko TP, Jeng Wy Fau - Liu C-I, Liu Ci Fau - Lai M-D, Lai Md Fau - Wu C-L, Wu Cl 
Fau - Chang W-J, et al. (2010) Structures of human MST3 kinase in complex with 
adenine, ADP and Mn2+. Acta. Crystallogr. D Biol. Crystallogr. 66: 145-154. 
 
247. Narayan K, Chumnarnsilpa S Fau - Choe H, Choe H Fau - Irobi E, Irobi E Fau - 
Urosev D, Urosev D Fau - Lindberg U, et al. (2003) Activation in isolation: 
exposure of the actin-binding site in the C-terminal half of gelsolin does not 
require actin. FEBS Lett. 552: 82-85. 
 
248. Nag S, Ma Q Fau - Wang H, Wang H Fau - Chumnarnsilpa S, Chumnarnsilpa S Fau 
- Lee WL, Lee Wl Fau - Larsson M, et al. Ca2+ binding by domain 2 plays a 
critical role in the activation and stabilization of gelsolin. 
 
249. Otwinowski Z, Minor W (1997) Processing of X-ray diffraction data collected in 
oscillation mode. Elsevier. pp. 307-326. 
 
250. Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, et al. (2011) Overview 
of the CCP4 suite and current developments. Acta. Crystallogr. D Biol. 




251. Zwart P, Afonine P, Grosse-Kunstleve R, Hung L-W, Ioerger T, et al. (2008) 
Automated Structure Solution with the PHENIX Suite. In: Kobe B, Guss M, 
Huber T, editors. Structural Proteomics: Humana Press. pp. 419-435. 
 
252. Emsley P, Lohkamp B, Scott WG, Cowtan K (2010) Features and development of 
Coot. Acta. Crystallogr. D Biol. Crystallogr.  66: 486-501. 
 
253. Afonine PV, Grosse-Kunstleve RW, Echols N, Headd JJ, Moriarty NW, et al. (2012) 
Towards automated crystallographic structure refinement with phenix.refine. 
Acta. Crystallogr. D Biol. Crystallogr.  68: 352-367. 
 
254. Terwilliger TC, Grosse-Kunstleve RW, Afonine PV, Moriarty NW, Zwart PH, et al. 
(2008) Iterative model building, structure refinement and density modification 
with the PHENIX AutoBuild wizard. Acta. Crystallogr. D Biol. Crystallogr.  64: 
61-69. 
 
255. Zheng H, Chordia MD, Cooper DR, Chruszcz M, Müller P, et al. (2014) Validation 
of metal-binding sites in macromolecular structures with the CheckMyMetal web 
server. Nat. Protocols 9: 156-170. 
 
256. McCoy AJ (2007) Solving structures of protein complexes by molecular 
replacement with Phaser. Acta. Crystallogr. D Biol. Crystallogr.  63: 32-41. 
 
257. Pronk S, Páll S, Schulz R, Larsson P, Bjelkmar P, et al. (2013) GROMACS 4.5: a 
high-throughput and highly parallel open source molecular simulation toolkit. 
Bioinformatics 29: 845-854. 
 
258. Best RB, Zhu X, Shim J, Lopes PEM, Mittal J, et al. (2012) Optimization of the 
Additive CHARMM All-Atom Protein Force Field Targeting Improved Sampling 
of the Backbone ϕ, ψ and Side-Chain χ1 and χ2 Dihedral Angles. J. Chem. 
Theory. Comput. 8: 3257-3273. 
 
259. Bussi G, Donadio D, Parrinello M (2007) Canonical sampling through velocity 
rescaling. J. Chem. Phys. 126: 014101. 
 
260. Parrinello M, Rahman A (1981) Polymorphic transitions in single crystals: A new 
molecular dynamics method. J. Appl. Phys. 52: 7182-7190. 
 
261. Essmann U, Perera L, Berkowitz ML, Darden T, Lee H, et al. (1995) A smooth 
particle mesh Ewald method. J. Chem. Phys. 103: 8577-8593. 
 
262. Hess B (2008) P-LINCS:  A Parallel Linear Constraint Solver for Molecular 
Simulation. J. Chem. Theory. Comput. 4: 116-122. 
 
263. Miyamoto S, Kollman PA (1992) Settle: An analytical version of the SHAKE and 




264. Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J. 
Mol. Graph 14: 33-38, 27-38. 
 
265. Ohki T, Ohno C, Oyama K, Mikhailenko SV, Ishiwata Si (2009) Purification of 
cytoplasmic actin by affinity chromatography using the C-terminal half of 
gelsolin. Biochem. Biophys. Res. Commun. 383: 146-150. 
 
266. Benvenuti M, Mangani S (2007) Crystallization of soluble proteins in vapor 
diffusion for x-ray crystallography. Nat. Protocols 2: 1633-1651. 
 
267. Wang J, Wu Jw Fau - Wang Z-X, Wang ZX (2011) Structural insights into the 
autoactivation mechanism of p21-activated protein kinase. Structure 19: 1752-
1761. 
 
268. Record CJ, Chaikuad A, Rellos P, Das S, Pike ACW, et al. (2010) Structural 
Comparison of Human Mammalian Ste20-Like Kinases. PLoS ONE 5: e11905. 
 
269. Shaw Stewart PD, Kolek SA, Briggs RA, Chayen NE, Baldock PFM (2011) 
Random Microseeding: A Theoretical and Practical Exploration of Seed Stability 
and Seeding Techniques for Successful Protein Crystallization. Cryst. Growth 
Des. 11: 3432-3441. 
 
270. Bergfors TM (1999) Macroseeding: a real-life success story. Protein Crystallization: 
Techniques, Strategies, and Tips, International University Line, La Jolla, CA  
 
271. Brandon C, and J. Tooze (1991) Introduction to Protein Structure. Garland 
Publishing, New York/London. 
 
272. Xue B, Robinson RC (2013) Guardians of the actin monomer. Eur. J. Cell Biol. 92: 
316-332. 
 
273. Li F, Higgs HN (2005) Dissecting Requirements for Auto-inhibition of Actin 
Nucleation by the Formin, mDia1. J. Biol. Chem. 280: 6986-6992. 
 
274. Linding R, Jensen LJ, Diella F, Bork P, Gibson TJ, et al. (2003) Protein Disorder 
Prediction. Structure 11: 1453-1459. 
 
275. Smith BA, Daugherty-Clarke K, Goode BL, Gelles J (2013) Pathway of actin 
filament branch formation by Arp2/3 complex revealed by single-molecule 
imaging. Proc. Natl. Acad. Sci. U. S. A. 110: 1285-1290. 
 
276. Blundell MP, Worth A, Bouma G, Thrasher AJ (2010) The Wiskott-Aldrich 





277. Davis TL, Walker JR, Allali-Hassani A, Parker SA, Turk BE, et al. (2009) Structural 
Recognition of an Optimized Substrate for the Ephrin family of Receptor 
Tyrosine Kinases. FEBS J. 276: 4395-4404. 
 
278. Lowe ED, Noble ME, Skamnaki VT, Oikonomakos NG, Owen DJ, et al. (1997) The 
crystal structure of a phosphorylase kinase peptide substrate complex: kinase 
substrate recognition. EMBO J. 16: 6646-6658. 
 
279. Hubbard SR (1997) Crystal structure of the activated insulin receptor tyrosine kinase 
in complex with peptide substrate and ATP analog. EMBO J. 16: 5572-5581. 
 
280. Cook A, Lowe ED, Chrysina ED, Skamnaki VT, Oikonomakos NG, et al. (2002) 
Structural Studies on Phospho-CDK2/Cyclin A Bound to Nitrate, a Transition 
State Analogue:  Implications for the Protein Kinase Mechanism. Biochemistry 
41: 7301-7311. 
 
281. Douglass J, Gunaratne R, Bradford D, Saeed F, Hoffert JD, et al. (2012) Identifying 
protein kinase target preferences using mass spectrometry. Am. J. Physiol. 303: 
C715-C727. 
 
282. Kinoshita E, Kinoshita-Kikuta E, Koike T (2009) Separation and detection of large 
phosphoproteins using Phos-tag SDS-PAGE. Nat. Protocols 4: 1513-1521. 
 
283. Jacob A, Turck C (2008) Detection of Post-translational Modifications by 
Fluorescent Staining of Two-Dimensional Gels. In: Kannicht C, editor. Post-
translational Modifications of Proteins: Humana Press. pp. 21-32. 
 
284. Machida M, Kosako H, Shirakabe K, Kobayashi M, Ushiyama M, et al. (2007) 
Purification of phosphoproteins by immobilized metal affinity chromatography 
and its application to phosphoproteome analysis. FEBS J. 274: 1576-1587. 
 
285. Kinoshita E, Yamada A, Takeda H, Kinoshita-Kikuta E, Koike T (2005) Novel 
immobilized zinc(II) affinity chromatography for phosphopeptides and 
phosphorylated proteins. Journal of Separation Science 28: 155-162. 
 
286. Heimsath EG, Higgs HN (2012) The C Terminus of Formin FMNL3 Accelerates 
Actin Polymerization and Contains a WH2 Domain-like Sequence That Binds 
Both Monomers and Filament Barbed Ends. J. Biol. Chem. 287: 3087-3098. 
 
287. Velazquez-Campoy A, Freire E (2006) Isothermal titration calorimetry to determine 
association constants for high-affinity ligands. Nat. Protocols 1: 186-191. 
 
288. Stahelin RV (2013) Surface plasmon resonance: a useful technique for cell 
biologists to characterize biomolecular interactions. Mol. Biol. Cell 24: 883-886. 
 
 
